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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a 5-year survival 
rate of less than 8 %. Hallmarks of pancreatic cancer are extensive desmoplasia and strong 
resistance to standard chemotherapeutic agents, e.g. gemcitabine. In this context, impaired 
drug delivery and drug metabolism pathways might play a crucial role in mediating this 
pronounced chemoresistance.  
In this study, I investigated tumor cell intrinsic and extrinsic mechanisms of 
chemotherapeutic resistance in PDAC.  
Pharmacokinetic characteristics of gemcitabine (dFdC) were analyzed in the widely used 
LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mouse model by liquid chromatography 
tandem mass-spectrometry (LC-MS/MS). Surprisingly, the levels of gemcitabine were 
elevated in the primary, stroma-rich and hypovascular tumor samples compared with 
matched normal liver samples and samples from liver metastases. A more detailed analysis 
by our group revealed an increased ratio of cancer-associated fibroblasts (CAFs) in primary 
tumors compared to liver metastases. Notably, gemcitabine metabolizing enzymes were 
highly expressed in epithelial but not stromal cells. The inactivating enzymes cytidine 
deaminase (CDA), deoxycytidylate deaminase (DCTD), and cytosolic 5’-nucleotidase 1A 
(NT5C1A) were hardly expressed in the stromal compartment of murine and human PDAC 
samples in vivo. In contrast, these enzymes were robustly expressed in the epithelial 
compartment. Consequently, the cytotoxic gemcitabine metabolite dFdCTP accumulated in 
murine CAFs, as the phosphorylated metabolites are unable to cross the cell membrane. 
Drug scavenging of CAFs was confirmed in conditioned medium (CM) assays. Incubation 
of tumor cells with CM of gemcitabine treated CAFs reduced the available amount of 
gemcitabine for tumor cells in vitro. Due to the low proliferation rate of CAFs in vivo, these 
cells might have exhibited intrinsic resistance to the increased amounts of dFdCTP.  
Further experiments were aimed to characterize NT5C1A, a previously unrecognized 
gemcitabine inactivating enzyme in pancreatic cancer that reverses the initial 
phosphorylation step of gemcitabine. Immunohistochemical staining of tissue microarrays 
(TMAs) with more than 400 tumor samples, from two independent cohorts of resected 
PDAC patients, were used to study the expression pattern of NT5C1A in PDAC. We found 
robust protein expression in the epithelial compartment of 64-70 % of PDAC patients, 
whereas robust stromal expression of NT5C1A was detectable in less than 20 % of these 
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Recombinant expression of this enzyme was used to elucidate its impact on 
chemotherapeutic resistance. Re-expression of NT5C1A in pancreatic stellate cells (PSCs) 
reduced the intracellular levels of the active gemcitabine metabolite dFdCTP, suggesting 
NT5C1A as novel target for stromal reprogramming.   
Gemcitabine response in tumor cells overexpressing NT5C1A was investigated using 
standard biochemical assays and orthotopic transplantation of the modified tumor cells into 
mice. Indeed, cells overexpressing NT5C1A showed higher resistance towards gemcitabine 
and had decreased levels of intracellular dFdCTP and of cleaved caspase 3 (CC3) levels 
following treatment with gemcitabine. Tumor weights were increased in mice that were 
transplanted with NT5C1A expressing cells compared to control cells upon gemcitabine 
treatment, showing the relevance of this enzyme in therapeutic effectiveness. Given its role 
in dephosphorylation of nucleoside monophosphates, NT5C1A overexpression in 
pancreatic cancer cells did not reduce chemosensitivity towards paclitaxel, a standard 
chemotherapeutic agent that acts independently of intracellular phosphorylation.  
In conclusion, our study gave new insight into the impact of drug metabolizing enzymes on 
chemotherapeutic resistance in PDAC. We demonstrated that alterations in drug 
metabolism and not impaired drug delivery mainly determine the response to gemcitabine 
in PDAC. Our results further demonstrated NT5C1A as target for stromal reprogramming. 
Most importantly, our findings pave the way for a more detailed stratification of patients for 
treatments and suggest NT5C1A to be considered as a possible predictor of treatment 
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1. Introduction 
1.1 Pancreas anatomy and physiological function  
The pancreas plays an important role as a key regulator of glucose homeostasis and 
protein, lipid, as well as carbohydrate digestion (Hezel et al., 2006; Prinz, 2012). The 
pancreatic gland is anatomically divided into three parts, namely the pancreas head, the 
pancreas body, and the pancreas tail (Prinz, 2012).  
Physiologically, the pancreas has important endocrine and exocrine functions. The 
endocrine function is accomplished by the islets of Langerhans, as depicted in Figure 1, 
and results in the production of insulin and its antagonist glucagon (Prinz, 2012).  
The exocrine part of the pancreas is responsible for the production of digestive enzymes 
and their delivery into the gastrointestinal tract (Prinz, 2012). This part of the pancreas is an 
organized network of acinar and duct cells and makes up around 80 % of the total tissue 
mass (Figure 1) (Hezel et al., 2006). The main cell types of the exocrine pancreas are the 
acinar cells, centro-acinar cells, and bicarbonate-secreting duct cells (Kleeff et al., 2016). 
Acinar cells are organized along the ductal cells and act in response to signals from the 
stomach and duodenum. The secretion of enzymes into the ductal lumen is achieved by 
centro-acinar cells (Hezel et al., 2006; Kleeff et al., 2016). The produced pancreatic juice 
mainly consists of water, bicarbonate, and digestive enzymes. Lipase and α-amylase are 
secreted in their active forms, whereas trypsinogen, chymotrypsinogen, and 
phospholipase A are proenzymes (Renz-Polster & Krautzig, 2013). Following secretion into 
the duodenum, the proenzymes become activated through enzymes of the intestinal 
mucosa. The active enzymes are able to digest carbohydrates (amylase), proteins (trypsin, 
chymotrypsin), and fats (lipase) (Hall, 2016; Renz-Polster & Krautzig, 2013).   
Figure 1: Pancreas anatomy. The main cell types of the exocrine pancreas are ductal cells (black 
arrow) and acinar cell networks (orange circle). Islets of Langerhans (red dotted circle) belong to the 
endocrine part of the pancreas. Representative image of hematoxylin and eosin (H&E) staining of 
human PDAC tissue is shown. Scale bar 100 µm.   
Pancreatic ducts 
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1.2 Pancreatic cancer  
Management of cancer is a major challenge regarding public health. The various cancer 
types differ strongly in their characteristics, aggressiveness, and response to treatment. 
Cancer is the second most common cause of death, only cardiovascular diseases lead to 
a higher number of deaths in the United States (U.S.) (Kochanek et al., 2016). However, 
within Europe cancer became already the number one among the causes of death in 
13 countries (Townsend et al., 2015).   
One of the most aggressive solid tumor entities is pancreatic cancer, which is currently the 
fourth leading cause of cancer-associated death (U.S. cancer statistic 2015) (Nielsen et al., 
2016; Siegel et al., 2018) due to late diagnosis, strong heterogeneity and plasticity, and 
consequently strong resistance to chemotherapy (Adamska et al., 2017; Siegel et al., 2018) 
The most common type of pancreatic cancer is PDAC, which accounts for more than 90 % 
of pancreatic tumor cases (Hezel et al., 2006; Prinz, 2012). Further categories of pancreatic 
neoplasms are neuroendocrine tumors, cystic pancreatic tumors, and acinar cell 
carcinomas. Rare types of pancreatic tumors include colloid carcinomas, 




1.3 Pancreatic ductal adenocarcinoma   
As previously mentioned, adenocarcinomas are the most common type of pancreatic 
cancer, with a low survival rate, highlighted by a mortality to incidence ratio of 0.98 
(GLOBOCAN 2012) (Ferlay et al., 2015). Pancreatic cancer is projected to become the 
second most common cause of cancer-related death by 2030 not only in the U.S., but also 
in Germany (Quante et al., 2016; Rahib et al., 2014).  
The relative 5-year survival rate for all stages is only 8 %, which increases to 32 % if the 
tumor is still localized at the time of diagnosis (Siegel et al., 2018). The one-year survival 
rate is less than 20 % and median overall survival is 6-9 months for locally advanced PDAC 
and 3 months if the disease is diagnosed at a metastatic stage (Adamska et al., 2017; Kleeff 
et al., 2016). Most PDAC cases are diagnosed at locally advanced or distant stages (e.g. 
80 % of cases in the U.S. between 2007 and 2013) (Siegel et al., 2018) due to a lack of 
biomarkers and screening methods for early detection (Cid-Arregui & Juarez, 2015). 
Additionally, PDAC initially exerts no or unspecific symptoms, like abdominal pain or weight 
loss (Kleeff et al., 2016; Oberstein & Olive, 2013). Symptoms in a progressed state of PDAC 
are bile duct or duodenal obstruction, consequently leading to jaundice, anorexia, vomiting, 
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and nausea. In later stages the tumor can cause severe pain by the infiltration of mesenteric 
and retroperitoneal nerves (Drewes et al., 2018; Kleeff et al., 2016).  
Moreover, pancreatic cancer (in the further course of the text used as synonym for PDAC) 
is one of the most aggressive tumor entities among solid neoplasms with perineural invasion 
and early distant metastases (Kleeff et al., 2016). Most commonly, PDAC metastasizes to 
the liver, lung, and/ or peritoneum (Makohon-Moore & Iacobuzio-Donahue, 2016). 
Therefore, less than 20 % of PDAC patients are eligible for surgery with curative intention 
(Kleeff et al., 2016). Additionally, even if surgery is possible and no lymph-node or distant 
metastases are detected, recurrence of the tumor is a major problem (Erkan, Hausmann, 
et al., 2012). Moreover, a major challenge for the treatment of PDAC patients is the fact that 
PDAC is highly refractory to systemic therapies (Kleeff et al., 2016).  
In contrast to other cancer types, histological hallmark features of PDAC are 
hypovascularity and an extensive desmoplastic reaction (tumor microenvironment) leading 
to local hypoxia and low nutrient availability (Ying et al., 2016). The desmoplastic reaction 
will be discussed in detail in a separate chapter. The main characteristics of PDAC are 














Figure 2: Schematic overview of pancreatic cancer characteristics. As described in this chapter, 
PDAC is marked by low survival rates, late diagnosis, and an extensive desmoplastic reaction. Due 
to these hallmark features PDAC treatment is extremely challenging.   
 
1.3.1 Risk factors  
Pancreatic cancer is a disease that commonly occurs in the elderly, thereby defining age 
as a risk factor. Moreover, an approximately two-fold increased risk is associated with 
long-term diabetes mellitus type 2 (Batabyal et al., 2014; Kleeff et al., 2016). Preventable 
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risk factors for pancreatic cancer are tobacco smoking and heavy alcohol consumption 
(Bosetti et al., 2012; Duell, 2012; Genkinger et al., 2009; Iodice et al., 2008). The latter can 
result in chronic pancreatitis, which also occurs independently of alcohol consumption, and 
increases the risk for pancreatic cancer by more than tenfold (Kleeff et al., 2016; Raimondi 
et al., 2010). Altogether, smoking, diabetes type 2, and chronic pancreatitis account for 
25-30 % of all cases of PDAC (Kleeff et al., 2016). Furthermore, the risk for pancreatic 
cancer was reported to be increased with obesity, low physical activity, and nutritional 
aspects like high intake of saturated fats (Becker et al., 2014; Kleeff et al., 2016).  
A further important point to mention is genetic factors, which increase the risk for pancreatic 
cancer. Although, sporadic pancreatic cancer accounts for approximately 90 % of PDAC 
cases, 10 % of PDAC patients have a family history of pancreatic cancer or inherited cancer 
syndromes (Becker et al., 2014; Chari et al., 2015). Most commonly, a specific genetic 
component leading to PDAC cannot be found in patients with familial pancreatic cancer. 
However, hereditary breast and ovarian cancer syndrome (HBOC), familial adenomatous 
polyposis, familial atypical multiple mole melanoma, Lynch syndrome, Peutz-Jeghers 
syndrome, and Li-Fraumeni syndrome were identified to increase the risk for pancreatic 
cancer development (Carrera et al., 2017; Grover & Syngal, 2010). For instance, mutations 
in the tumor suppressors BRCA1 and BRCA2, which have relevant functions in DNA repair, 
are the genetic basis of HBOC syndrome, and BRCA2 mutations have been associated 
with an at least 3.5-fold increased risk to develop PDAC (Becker et al., 2014; The Breast 
Cancer Linkage Consortium, 1999). Consequently, the detection of genetic risk factors 
might help for early tumor detection and gives the possibility for gene-specific therapies 
(Becker et al., 2014).  
 
1.3.2 Precursor lesions 
PDAC develops through acinar-to-ductal metaplasia (ADM) and neoplastic precursor 
lesions (Eser et al., 2014). Three types of precursor lesions are known, explicitly 
microscopic pancreatic intraepithelial neoplasia (PanIN), which are the most important 
precursors for PDAC, intraductal papillary mucinous neoplasms (IPMN), and mucinous 
cystic neoplasms (MCN) (Ying et al., 2016). The definition of PanIN lesions is based on the 
observation that patients presented intraductal lesions years before they developed 
invasive adenocarcinoma and also on the finding that patients with fully resected tumors 
but ductal lesions in the remaining tissue developed adenocarcinomas. Furthermore, 
genetic mutations like KRAS mutations were described in these lesions (Brat et al., 1998; 
Klimstra & Longnecker, 1994). Based on this, Hruban et al. described a progression model 
for PDAC referring to the different stages of PanIN lesions and their association with a 
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distinctive pattern of genetic alterations (Hruban et al., 2000). PanIN lesions can be 
classified into three grades according to the extent of histopathological alterations. The 
lowest grades of lesions are PanIN-1A with flat lesions and PanIN-1B presenting low-grade 
dysplasia with papillary architecture. PanIN-2 already shows loss of polarity, nuclear 
crowding, and cell enlargement. Advanced PanIN-3 lesions, which are crucial for the 
progression into invasive carcinomas, exhibit severe nuclear atypia with nuclear 
enlargement and poor orientation of the nuclei. Furthermore, these lesions demonstrate 
with luminal necrosis and epithelial cell budding into the ductal lumen occurs (Hruban et al., 
2008; Ying et al., 2016). An overview of the PanIN stages is given in Figure 3. PanIN-1 and 
PanIN-2 lesions can also be found in older people and in pancreatitis patients, but do not 
necessarily progress to PDAC (Hruban et al., 2008). Furthermore, PanIN lesion progression 
was found to be associated with an increase in extracellular matrix (ECM) deposition 
(Erkan, Hausmann, et al., 2012).  
Figure 3: Precursor lesions of pancreatic cancer. Representative H&E images for the different 
progression stages from normal pancreatic tissue to invasive PDAC are shown in human tissue. 
From left to right, normal acinar tissue with a normal duct (arrow), early PanIN-1, PanIN-2, and finally 
PanIN-3 lesions and invasive PDAC are presented. The most common genetic mutations in 
oncogenes and tumor suppressor genes are indicated in the order they usually occur during PDAC 
progression. Scale bars 20 µm. Own illustration, content based on (Hruban et al., 2008). 
 
1.3.3 Mutations in PDAC 
Genetically, PDAC harbors oncogenic KRAS mutations that are present in 88 % to 100 % 
of all PDAC patients and are thus seen as driver mutations for invasive PDAC. KRAS 
mutations are the earliest genetic alteration in human PDAC development, which are 
already present in PanIN-1 lesions, and are most commonly G12D and G12V 
KRAS-activating mutations (Almoguera et al., 1988; Eser et al., 2014; Hruban et al., 2008; 
Ying et al., 2016). Telomere shortening is another event that occurs during the early phase 
of carcinogenesis (Van Heek et al., 2002). The tumor suppressor gene CDKN2A (p16) 
commonly gets inactivated in early carcinogenesis and is therefore commonly present in 
PanIN-2 lesions. Mutations in the TP53 (p53) tumor suppressor gene occur at high 
Normal duct PanIN-1 PanIN-2 PanIN-3 PDAC 
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frequencies in PDAC patients in later stages of PDAC development (PanIN-3 lesions). 
Further tumor suppressor genes are mutated at lower frequencies, as there are 
DPC4/SMAD4 and BRCA2 genetic mutations, which are also described to occur later in 
PDAC progression (Figure 3) (Hruban et al., 2008; Jaffee et al., 2002; Neesse et al., 2015).  
 
1.3.4 The tumor microenvironment  
The tumor microenvironment (TME) in PDAC, also termed pancreatic cancer stroma is 
significantly involved in PDAC initiation, progression, and invasion. Furthermore, the tumor 
stroma has been strongly implicated in mediating chemoresistance in PDAC. The stromal 
components can make up as much as 90 % of the total tumor mass (Ying et al., 2016). 
The tumor stroma was proposed to exert a biophysical barrier to chemotherapeutic drug 
delivery due to its hypovascularity and high interstitial fluid pressure and subsequent vessel 
compression (Lunardi et al., 2014). Recently, the stroma was described to have tumor-
promoting as well as tumor-restraining properties. Stromal depletion approaches were 
consequently discussed in detail in the current literature (Gore & Korc, 2014; Jacobetz et 
al., 2013; Oezdemir et al., 2014; Olive et al., 2009; Provenzano et al., 2012; Rhim et al., 
2014). However, the detailed contribution of the various stromal components remains 
largely unknown. Thus, it is necessary to elucidate the key players in the desmoplastic 
reaction and to understand the underlying mechanisms in more detail.  
Major cellular components of the tumor stroma are CAFs and myofibroblasts, inflammatory 
cells, blood and lymphatic vessels that differ from normal vessel architecture, as well as 
immune cells, such as myeloid-derived suppressor cells (MDSCs), regulatory T cells, and 
tumor-associated macrophages (Neesse et al., 2011; Ying et al., 2016). Further 
components of the ECM in PDAC are collagen, glycosaminoglycans like hyaluronic acid, 
cytokines, soluble growth factors, matrix metalloproteinases, and secreted protein acidic 
and rich in cysteine (SPARC) (Lunardi et al., 2014; Neesse et al., 2011; Ying et al., 2016).    
As the desmoplastic reaction leads to a complex network of cellular and acellular 
components, complex signaling cues between tumor cells and the various stromal 
components occur. This tumor-stroma crosstalk results in transcriptional alterations of 
stromal cells, alterations in tumor cell biology, and consequently, leads to cancer cell 
motility, stromal neovascularization, and resistance to hypoxia and systemic therapies 
(Adamska et al., 2017; Neesse et al., 2011). For instance, Bachem et al. demonstrated that 
pancreatic cancer cells induced stromal cell proliferation and synthesis of ECM components 
by stromal cells, like collagen type I and type III, as well as fibronectin (Bachem et al., 2005).    
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1.3.4.1 Cancer-associated fibroblasts 
CAFs are key components in the stromal reaction and are mainly derived from PSCs (Apte 
et al., 2004). In a quiescent state PSCs are located in the periacinar space, have a stellate 
morphology, and store vitamin A droplets in the cytoplasm (Erkan, Adler, et al., 2012; 
Nielsen et al., 2016). Characteristic markers are vimentin, desmin, and nestin, however, 
these cells do not express α-smooth muscle actin (α-SMA) (Omary et al., 2007).  
Quiescent PSCs become activated in response to tissue injury or during carcinogenesis. 
Activation is mediated by oxidant stress, platelet-derived growth factor, transforming growth 
factor-β (TGF-β), tumor necrosis factor-α (TNF-α), and by several interleukins and cytokines 
as well as toxins (Erkan, Adler, et al., 2012; Nielsen et al., 2016). Activated PSCs acquire 
a spindle-shape myofibroblast-like phenotype, lose their vitamin A lipid droplets, and can 
be characterized by expression of α-SMA as a typical marker (Nielsen et al., 2016). Further 
markers of activated fibroblasts are fibroblast activation protein (FAP), platelet-derived 
growth factor receptor-α (PDGFα) and PDGFβ, and desmin. In contrast, fibroblast-specific 
protein 1 (FSP1) is a marker of quiescent fibroblasts (Kalluri, 2016). Of note, none of these 
markers are specific for fibroblasts and activated fibroblasts do not express all markers to 
the same extent, thus, illustrating the heterogeneity of this cell type (Kalluri, 2016). 
Moreover, in 2017, Öhlund et al. presented data regarding subpopulations of CAFs in 
pancreatic cancer, which significantly differ in their characteristics (Öhlund et al., 2017). The 
authors described one group of CAFs, the so-called myCAFs, being located in direct 
proximity to the tumor cells and expressing high levels of α-SMA. The second subgroup is 
involved in the immune reaction by expression of high levels of interleukin-6 (IL-6), 
therefore, termed iCAFs. These cells are located more distantly from tumor cells and 
express α-SMA at lower levels (Öhlund et al., 2017). 
Additionally, CAFs are proliferative, develop migratory and phagocytic properties, produce 
excessive amounts of ECM components, like collagen I and III as well as fibronectin, and 
furthermore, secrete a variety of proteins associated with proliferation, cell motility, invasion, 
and inflammation (Nielsen et al., 2016; Omary et al., 2007). Moreover, PSCs were shown 
to have the ability to produce matrix metalloproteinases (MMPs), enzymes that are 
responsible for ECM protein degradation and thus, were suggested to be critically involved 
in ECM turnover (Phillips et al., 2003). Consequently, activated PSCs are key components 
of the tumor-stroma crosstalk and thus, are strongly involved in tumor growth and 
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1.3.5 Heterogeneity of pancreatic cancer 
The strong variability in the composition of the tumor stroma leads to another characteristic 
feature of pancreatic cancer, the heterogeneity. PDAC is a very heterogeneous disease in 
terms of genetic mutations, stromal composition, and tumor cell metabolic profiles 
(Adamska et al., 2017; Carr & Fernandez-Zapico, 2016; Ying et al., 2016). Consequently, 
various subtypes of PDAC were defined aiming at patient stratification for more effective 
treatments according to the individual tumor characteristics.    
Collisson et al., Bailey et al., and Moffitt et al. presented relevant data regarding genetic 
heterogeneity of PDAC (Bailey et al., 2016; Collisson et al., 2011; Moffitt et al., 2015). In 
2011, Collisson and colleagues defined the classical, quasi-mesenchymal, and 
exocrine-like subtypes of PDAC, dependent on global gene expression data from resected 
PDAC patients. The classical subtype was associated with better survival and higher gene 
expression levels of GATA6 and enhanced dependency on KRAS. However, cell lines with 
the quasi-mesenchymal subtype showed better sensitivity towards gemcitabine treatment 
than cells with the classical subtype (Collisson et al., 2011). 
Dependent on transcription factor expression and the respective downstream targets, the 
subtypes defined by Bailey et al. were the squamous, the pancreatic progenitor, the 
immunogenic, and the aberrantly differentiated endocrine exocrine subtypes (Bailey et al., 
2016).   
Interestingly, Moffitt et al. defined normal and activated stromal subtypes. SPARC, WNT 
family members, and MMPs were associated with the activated stroma subtype. The FAP 
gene that encodes for the fibroblast activation protein was furthermore detected in the 
activated subtype. Taken together, these characteristics resulted in lower median survival 
times in the activated stroma subtype (Moffitt et al., 2015).  
 
1.3.6 Mouse models of PDAC 
In order to find model systems that represent the heterogeneity of PDAC as well as the 
pronounced desmoplastic reaction, great effort was taken to translate the knowledge about 
genetic factors involved in PDAC progression into suitable in vivo models.  
Most importantly to mention are the genetically engineered mouse models (GEMM). In 
2003, Hingorani et al. presented promising data from PDX-1-Cre;LSL-KRASG12D and 
P48+/Cre;LSL-KRASG12D (KC) mice that harbor a heterozygous activating KRASG12D mutation 
(Hingorani et al., 2003). A Lox-STOP-Lox (LSL) construct was inserted into the KRAS locus 
of the mouse genome, which leads to inhibition of transcription and translation. The modified 
exon 1 was engineered to contain a glycine to aspartic acid transition in codon 12, which is 
the most common mutation in human PDAC (Hingorani et al., 2003). Consequently, this 
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results in GTPase activity and thus, constitutively active downstream signaling pathways of 
Ras. These mice require interbreeding with mice that express Cre-recombinase from 
pancreas-specific promotors, like PDX-1 or P48 promoters. Excision of the silencing 
cassette with subsequent recombination results in conditional expression of the mutant 
allele in the pancreas (Hingorani et al., 2003). Pancreata of these KC mice are larger and 
have nodular parenchyma. Histologically, all stages of PanIN lesions were found with 100 % 
penetrance and after 7-10 months there were more neoplastic ducts found than normal 
ducts. Moreover, in a few animals the disease progressed to invasive and metastatic PDAC. 
Therefore, this mouse model recapitulates a wide range of histopathological features of 
human PDAC (Figure 4) (Hingorani et al., 2003).   
 
Figure 4: Pancreatic cancer progression in KC mice. As described by Hingorani et al. in 2003, 
the KC model closely resembles the histological features of human PDAC with the typical precursor 
lesions (PanIN-1, PanIN-2, and PanIN-3). The normal duct is indicated by an arrow. Representative 
images of H&E stainings, scale bars 20 µm.   
 
LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mice additionally harbor an inactivating 
point mutant allele of Trp53R172H, also silenced by the Lox-STOP-Lox cassette (Hingorani 
et al., 2005). These mice have a median survival of only 5 months and nearly all mice 
showed invasive carcinomas at time of necropsy (Hingorani et al., 2005). A large, firm, and 
fibrotic pancreas tumor can be found in nearly all of these mice. Usually mice develop 
cachexia, abdominal distension, and frequently hemorrhagic ascites. Moreover, biliary and 
small bowel obstructions are also present in these animals, which are also typical symptoms 
in PDAC patients (Hingorani et al., 2005). Both models are commonly used GEMMs, which 
recapitulate a wide spectrum of the human disease. 
Additionally, xenograft and syngeneic models of PDAC are used, which can be based on 
murine or human cell lines or tissue fragments. In these models it is important to distinguish 
between heterotopic (subcutaneous) and orthotopic transplantation (into the mouse 
pancreas) (Ponz-Sarvise et al., 2015). Orthotopically transplanted mice resemble the 
clinical situation much better than heterotopically transplanted mice, develop metastases, 
and hence, allow conclusive studies of chemotherapeutic responses (Herreros-Villanueva 
et al., 2012). Moreover, several modifications of the tumor cells are possible prior to 
transplantation.  
 
Normal duct PanIN-1 PanIN-2 PanIN-3 PDAC 
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1.3.7 Therapeutic strategies 
Available treatment options are limited in pancreatic cancer due to its fast progression, early 
metastatic spread, and the high refractoriness to chemotherapeutics. Consequently, the 
disease status at time of diagnosis is crucial for the decision of the most suitable therapy 
(Adamska et al., 2017; Stathis & Moore, 2010).  
 
1.3.7.1 Resectable pancreatic cancer  
Surgery remains the only potential curative strategy for PDAC but is limited to early disease 
stages (Adamska et al., 2017). Surgery is usually combined with adjuvant chemotherapeutic 
treatment to reduce the risk for recurrence (Garrido-Laguna & Hidalgo, 2015). In the 
adjuvant setting 5-fluorouracil (5-FU) with folinic acid or gemcitabine, respectively, were 
shown in important clinical trials (European Study Group for Pancreatic Cancer (ESPAC)-1 
and ESPAC-3, as well as Charité-Onkologie (CONKO)-001) to be superior in regards to 
median survival compared to observation groups (Neoptolemos et al., 2009; Oettle et al., 
2013). Furthermore, gemcitabine with capecitabine was demonstrated in the ESPAC-4 
phase III clinical trial to increase median overall survival in resected PDAC patients, 
compared to the gemcitabine group (Neoptolemos et al., 2017).  
Neoadjuvant chemotherapy should be considered in borderline resectable pancreatic 
tumors to increase the chance for R0 resection (Adamska et al., 2017). Furthermore, 
neoadjuvant therapeutic regimens are used in clinical trials (Assifi et al., 2011; Philip et al., 
2009). 
 
1.3.7.2 Unresectable pancreatic cancer   
5-FU alone or the combination with other cytotoxic drugs was used as first-line treatment 
for unresectable pancreatic cancer patients in earlier decades (Adamska et al., 2017). In 
1997, gemcitabine monotherapy was described to be superior to 5-FU with regards to 
overall survival (1.2 months increase), performance status of patients, as well as pain 
intensity and reduction of analgesic treatment (Burris et al., 1997), thus becoming the 
standard treatment for metastatic pancreatic cancer (Ellenrieder et al., 2016). 
Chemotherapy with gemcitabine is usually well tolerated and rarely severe side-effects 
occur, e.g. hematotoxicity, vomiting, and increased liver enzymes (Ellenrieder et al., 2016). 
Several clinical trials failed to identify partner drugs for gemcitabine-based therapy in locally 
advanced PDAC to further improve patient outcome. Thus, gemcitabine monotherapy 
remained the standard treatment at this stage of the disease (Ellenrieder et al., 2016).  
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Nevertheless, two novel treatment strategies were found to improve patient survival in the 
palliative setting. The treatment regimen FOLFIRINOX, which is a combination of 
oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil, as first-line therapy in metastatic 
PDAC increased survival rates compared to gemcitabine (11.1 vs. 6.8 months) (Conroy et 
al., 2011). Progression-free survival times and response rates were also improved in the 
FOLFIRINOX group. However, severe side-effects like febrile neutropenia limit the use of 
this therapy regimen to patients with good performance status (Conroy et al., 2011).  
The second combination therapy is nano-formulated albumin bound (nab)-paclitaxel plus 
gemcitabine (Von Hoff et al., 2013). Albumin is known as a natural carrier of endogenous 
hydrophobic molecules. Consequently, an albumin-bound formulation of paclitaxel, a water-
insoluble chemotherapeutic drug, was designed. In this formulation, albumin binds to 
paclitaxel in a reversible non-covalent manner to improve the pharmacokinetic profile of the 
drug (Miele et al., 2009). Von Hoff et al. reported the results of a clinical phase III study of 
metastatic pancreatic cancer patients treated either with nanoparticle albumin bound 
(nab)-paclitaxel plus gemcitabine or gemcitabine monotherapy. The trial clearly 
demonstrated that the combination therapy is superior over monotherapy in regards to 
median overall survival (8.5 vs. 6.7 months), survival and response rates, and progression 
free survival. Similar to the FOLFIRINOX regimen, the adverse effects increased in the 
combination therapy (Von Hoff et al., 2013).   
The identification of molecular targets for novel treatment opportunities are subject to 
intensive research. Subgroup analysis is a promising strategy for personalized treatment 
and is required for novel PDAC treatment approaches due to the high heterogeneity of 
mutations in these tumors (Adamska et al., 2017).  
In case of tumor progression during chemotherapy, second-line treatment might be 
beneficial for those patients. The choice of appropriate treatment protocols depends on the 
first-line therapeutics and the patient performance status. Most protocols are based on 
gemcitabine or 5-FU (Ellenrieder et al., 2016). 
 
 
1.4 Gemcitabine  
1.4.1 Cellular uptake of gemcitabine 
Gemcitabine is a cytidine analogue that has potent antitumor activity and is routinely used 
in chemotherapeutic treatment regimens in varying cancer types. It is administered as the 
prodrug 2’,2’-difluoro 2’-deoxycytidine (dFdC), the native form of gemcitabine (Mini et al., 
2006). It requires cellular uptake and subsequent sequential intracellular phosphorylation 
to exert its cytotoxic activity (Mini et al., 2006), as visualized in Figure 5.  
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Cellular uptake is achieved by specific nucleoside transporters on the cell plasma 
membrane. Two different types of these transporters exist. SLC28 human concentrative 
nucleoside transporters (hCNTs) are sodium-dependent carriers, whereas SLC29 
transporters, the human equilibrative nucleoside transporters (hENTs) work sodium-
independently (Mini et al., 2006; Wong et al., 2009). The most important transporter is 
hENT1, but also hENT2, hCNT1, and hCNT3 were demonstrated to play important roles in 
gemcitabine transport through the plasma cell membrane (De Sousa Cavalcante & 
Monteiro, 2014) (Figure 5). Consequently, the expression levels of nucleoside transporters 
are intensively investigated for its impact on gemcitabine effectiveness as anticancer drug. 
For instance, Greenhalf et al. presented data from the ESPAC-3 clinical trial showing high 
hENT1 expression being correlated with increased overall survival in gemcitabine-treated 
resected PDAC patients (Greenhalf et al., 2014).    
 
1.4.2 Activation of gemcitabine  
Intracellularly, gemcitabine is phosphorylated to 2’,2’-difluoro 2’-deoxycytidine 
monophosphate (dFdCMP) by deoxycytidine kinase (dCK), which is considered to be the 
rate-limiting step in gemcitabine activation. Nucleoside kinases are required for further 
gemcitabine phosphorylation. These are the pyrimidine nucleoside monophosphate kinase 
(UMP-CMP), which was described to catalyze the second phosphorylation step to dFdCDP, 
and the nucleoside diphosphate kinase, which is involved in the final phosphorylation step 
(De Sousa Cavalcante & Monteiro, 2014; Wong et al., 2009) (Figure 5). Other kinases, like 
the mitochondrial enzyme thymidine kinase 2, are also involved in gemcitabine 
phosphorylation to its cytotoxic form, but their impact is comparably low (Mini et al., 2006; 
Wang et al., 1999).    
 
1.4.3 Inactivation of gemcitabine  
The main inactive form of gemcitabine is 2’,2’-difluoro 2’-deoxyuridine (dFdU). Several 
enzymes are involved in the inactivation of gemcitabine, but the most important one is CDA, 
which is responsible for deamination of the majority of intracellular native gemcitabine to 
dFdU. Additionally, the monophosphate form of gemcitabine dFdCMP is deaminated by 
deoxycytidine deaminase (DCTD) (Alvarellos et al., 2014). Reversion of the initial 
phosphorylation step is catalyzed by an enzyme group so called cytosolic 5’-nucleotidases 
(NT5Cs) and is therefore another inactivation pathway for intracellular gemcitabine. These 
enzymes do not produce inactive dFdU metabolites but generate native dFdC (Alvarellos 
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Figure 5: Schematic illustration of gemcitabine uptake and metabolism. Gemcitabine is a 
prodrug which requires cellular uptake by specific transporters and intracellular phosphorylation to 
become cytotoxically active. Cellular uptake of the gemcitabine prodrug (dFdC) is mainly achieved 
by the hENT1, hENT2, hCNT1, and hCNT3 transporters. Intracellular gemcitabine is phosphorylated 
by deoxycytidine kinase (dCK) and other kinases to the cytotoxic triphosphate metabolite (dFdCTP), 
which is the active form and thus, is finally incorporated into DNA. Gemcitabine is rapidly inactivated 
to 2’,2’-difluoro 2’-deoxyuridine (dFdU) through deamination by key inactivating enzymes, like CDA 
and DCTD. Gemcitabine is further inactivated through dephosphorylation to dFdC by cytosolic 
5’-nucleotidases (NT5Cs). Own illustration, based on (De Sousa Cavalcante & Monteiro, 2014; Mini 
et al., 2006).  
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1.4.4 Mechanisms of action of gemcitabine 
Gemcitabine in its active form inhibits DNA synthesis by incorporation into DNA and 
subsequent termination of chain elongation (De Sousa Cavalcante & Monteiro, 2014). 
Interestingly, following dFdCTP incorporation into DNA, another single deoxynucleotide will 
still be incorporated before chain elongation stops. Given this non-terminal position of 
gemcitabine, DNA polymerases are unable to proceed with chain elongation. Accordingly, 
this is known as ‘masked chain-termination’. Furthermore, exactly the same fact also 
prevents DNA repair enzymes to remove gemcitabine from the DNA (De Sousa Cavalcante 
& Monteiro, 2014). Additionally, the cytotoxic effect of gemcitabine is increased by ‘self-
potentiating’ mechanisms. This refers to enzyme inhibition by gemcitabine metabolites, thus 
reducing the intracellular levels of competing natural DNA precursors (Mini et al., 2006). 
 
 
1.5 Chemotherapeutic resistance in pancreatic cancer 
Broad resistance towards chemotherapeutics is a major challenge in the treatment of 
pancreatic cancer. Chemotherapeutic resistance can be divided into innate and acquired 
resistance. Pancreatic cancer is characterized by innate resistance to most therapies. 
Furthermore, it is distinguished between cell-autonomous and non-cell-autonomous 
mechanisms of resistance (Oberstein & Olive, 2013). Notably, important signaling pathways 
involved in growth regulation, proliferation, differentiation, apoptosis, invasion, and 
angiogenesis might contribute to chemotherapeutic resistance via both routes (Amrutkar & 
Gladhaug, 2017).  
The high degree of genetic alterations plays an important role in cell-autonomous 
chemoresistance. Moreover, epigenetic mechanisms and post-transcriptional gene 
regulation are involved in cell intrinsic chemotherapeutic resistance (Chand et al., 2016; 
Oberstein & Olive, 2013). For instance, Ras mutations promote the desmoplastic reaction 
by paracrine signals, which is in turn a major contributor to non-cell-autonomous 
chemotherapeutic resistance (Oberstein & Olive, 2013). In contrast to the driver mutations, 
genetic changes that occur in the advanced state of the disease rather contribute to 
acquired resistance (Oberstein & Olive, 2013).  
The main extrinsic factor of chemotherapeutic resistance is the TME. It is subject of 
intensive research to reveal the mechanisms underlying the complex interplay between 
tumor cells and stromal components (Chand et al., 2016). The desmoplastic reaction in 
PDAC is significantly influenced by this tumor-stroma crosstalk, thus providing a non-cell-
autonomous barrier for drug delivery and response (Oberstein & Olive, 2013). Hypoxia and 
hypovascularization are the main characteristics of PDAC and create a nutrient and 
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oxygen poor environment for the tumor cells. Consequently, only the most aggressive tumor 
cells will survive. They adapt to this challenging environment by acute cellular 
reprogramming, e.g. by activation of hypoxia inducible factor-1α (HIF-1α) and its 
downstream pathways, thereby enhancing chemoresistance (Chand et al., 2016).  
CAFs drive ECM remodeling and secrete stromal components like collagen type I and 
MMPs and are the major fibrosis-producing cells. The resulting dense fibrous stroma 
causes vessel compression and was described as a biophysical barrier for efficient drug 
delivery (Amrutkar & Gladhaug, 2017).  
 
1.5.1 Chemotherapeutic resistance towards gemcitabine 
The clinical response to gemcitabine is low and various reasons have been proposed, like 
alterations in drug metabolism, a reduction in cellular uptake of the gemcitabine prodrug, 
as well as rapid enzymatic inactivation (Frese et al., 2012; Greenhalf et al., 2014; Maréchal 
et al., 2012; Weizman et al., 2014) 
Gemcitabine drug delivery is subject to the described challenges during drug delivery to the 
tumor. Additional mechanisms need to be considered that are specific to gemcitabine 
transport, cellular uptake, and activation. Gemcitabine transport through the plasma cell 
membrane is mainly mediated by the hENT1 nucleoside transporter. Thus, low expression 
of this transporter was assumed to be associated with gemcitabine resistance (Oberstein & 
Olive, 2013). Maréchal et al. (2012) demonstrated a direct correlation of hENT1 expression 
in human tumor samples with survival of patients who underwent adjuvant gemcitabine 
therapy following surgery. 
Moreover, gemcitabine metabolizing enzymes are involved in resistance. The rate-limiting 
activation step for gemcitabine is phosphorylation by dCK, hence the expression level of 
dCK is crucial for gemcitabine efficacy (Maréchal et al., 2012). CDA as main inactivating 
enzyme is intensively studied for its impact on gemcitabine resistance, and expression was 
already described to be correlated with overall survival of PDAC patients (Amrutkar & 
Gladhaug, 2017). Moreover, enhanced activity of NT5C1A, a mammalian 5’-nucleotidase, 
prevents intracellular dFdCTP formation, thus making it an interesting subject for further 
investigation on its role in gemcitabine resistance (Amrutkar & Gladhaug, 2017). Enhanced 
activity was described in the context of gemcitabine-resistant leukemia cell lines (Dumontet 
et al., 1999), but not in solid tumors so far. 
Ribonucleotide reductase (RR) is crucial in DNA synthesis by converting ribonucleotides 
into dNTPs, where subunit M1 (RRM1) is important for enzyme regulation and subunit 2 
(RRM2) for enzyme activity (Amrutkar & Gladhaug, 2017). RR inhibition is achieved by 
dFdCDP and leads to reduced levels of dNTPs, thus facilitating dFdCTP incorporation into 
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DNA (Heinemann et al., 1990). Furthermore, increased pyrimidine biosynthesis, leading to 
high levels of deoxycytidine triphosphate, was suggested to reduce gemcitabine 
effectiveness through molecular competition (Shukla et al., 2017) 
 
 
1.6 Mammalian 5’-nucleotidases  
Mammalian 5’-nucleotidases are involved in gemcitabine inactivation and are consequently 
interesting targets to study in regards to chemotherapeutic resistance. They build a class of 
enzymes that catalyze the dephosphorylation of non-cyclic nucleoside monophosphates to 
nucleosides and inorganic phosphates. Thus, these enzymes are also named nucleoside 
monophosphate phosphohydrolases (Bianchi & Spychala, 2003).  
Seven members of this enzyme family have been characterized so far, explicitly 
ecto-5’-nucleotidase, cytosolic 5’-nucleotidase IA, cytosolic 5’-nucleotidase IB, cytosolic 
5’-nucleotidase II,  cytosolic 5’-nucleotidase III, cytosolic 5’ (3’)-deoxyribonucleotidase, and 
mitochondrial 5’ (3’)-deoxyribonucleotidase (Hunsucker et al., 2005). They can be 
distinguished by their subcellular localization, their substrate specificity, and their 
tissue-specific expression (Hunsucker et al., 2005). For instance, cytosolic 
5’-nucleotidase 1 and 3 have tissue-specific expression compared to the other ubiquitously 
expressed 5’-nucleotidases. Typical for all 5’-nucleotidases is a broad substrate specificity 
and the dependency on magnesium (Bianchi & Spychala, 2003).    
A common catalytic mechanism among intracellular 5’-nucleotidases is assumed due to the 
presence of common motifs. The formation of a phosphoenzyme intermediate is assumed 
for all 5’-nucleotidases (Bianchi & Spychala, 2003; Hunsucker et al., 2005).  
 
1.6.1 Cytosolic 5’-nucleotidase 1A 
The cytosolic 5’-nucleotidase 1A (NT5C1A) has tissue-specific expression with the highest 
expression in skeletal and heart muscle (Bianchi & Spychala, 2003). The gene is located 
on chromosome 1 p33-p34.3, consists of 6 exons, and has a length of 1107 bp (Hunsucker 
et al., 2001). The purified enzyme has a subunit size of 41 kDa and is a tetramer. NT5C1A 
has a broad substrate-specificity with a preference for adenosine monophosphate (AMP) 
and pyrimidine deoxyribonucleotides (Hunsucker et al., 2005). Physiologically, NT5C1A is 
responsible for the formation of adenosine under ischemic and hypoxic conditions 
(Hunsucker et al., 2005). Due to its catalytic mechanism and a low Km value for 
deoxyribonucleoside monophosphates, NT5C1A may play an important role in the 
regulation of pyrimidine deoxynucleotide pools (Bianchi & Spychala, 2003; Hunsucker et 
al., 2005).  
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Furthermore, this high affinity for deoxynucleoside monophosphates suggests a high affinity 
for deoxynucleoside analogues as well. Thus, NT5C1A might reduce the pharmacological 
activity of deoxynucleoside analogues by reversing the initial activation step and 
consequently, decreasing intracellular dFdCTP formation (Bianchi & Spychala, 2003; 
Dumontet et al., 1999; Hunsucker et al., 2005; Hunsucker et al., 2001; Saliba et al., 2016). 
This dephosphorylation of deoxynucleoside monophosphates and potentially also its 
analogues render NT5C1A an interesting target for detailed investigation regarding its 
potential in mediating chemotherapeutic resistance.        
 
 
1.7 Aims of the study 
Pancreatic cancer is characterized by a dense and hypovascular tumor stroma and exerts 
strong resistance towards chemotherapeutic agents. The tumor stroma components were 
described to act as a biophysical barrier to chemotherapeutic drug delivery. This barrier was 
defined by pronounced vessel compression and high interstitial fluid pressure, being the 
result of excess collagen and hyaluronan content (Jacobetz et al., 2013; Olive et al., 2009; 
Provenzano et al., 2012). Especially CAFs, as the predominant source of ECM proteins 
(Apte et al., 2004; Bachem et al., 2005), play a central role in the desmoplastic reaction. 
Consequently, several studies proposed stroma depletion as novel strategy to enhance 
drug responses (Jacobetz et al., 2013; Olive et al., 2009; Provenzano et al., 2012).  
Strikingly, tumors from GEMMs with depleted stroma were observed to have a more 
undifferentiated phenotype and were reported to be more aggressive (Oezdemir et al., 
2014; Rhim et al., 2014), thus indicating also tumor restraining properties of stromal 
components. As a result, stromal reprogramming rather than depletion seems to be a more 
promising way for improved drug efficacy. Given the intensive cross-talk between stromal 
components and pancreatic cancer cells, discovering potential biomarkers or therapeutic 
targets is challenging.  
In my thesis, I sought to deepen our understanding about stromal and epithelial cell-driven 
drug resistance in PDAC. We revisited the drug metabolism of gemcitabine to unravel how 
differential stromal and epithelial expression of gemcitabine inactivating enzymes contribute 
to drug resistance. In particular, we set the focus on NT5C1A, a gemcitabine-inactivating 
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This was achieved by investigating the following: 
1. Analysis of drug metabolites in KPC bulk tissues, matched liver tissues, liver metastases, 
and also fibroblast and tumor cell lines.  
2. Elucidation of the expression pattern of gemcitabine metabolizing enzymes in the 
epithelial and stromal compartments. 
3. Evaluation of NT5C1A for its function in cell-autonomous and non-cell-autonomous 
resistance to gemcitabine.  
 
My hypotheses are based on the initial finding that highest levels of gemcitabine prodrug 
and of the cytotoxic metabolite dFdCTP accumulate in primary tumor tissue of KPC mice.   
Consequently, hypothesis 1 is: The tumor stroma is actively involved in drug metabolism 
in pancreatic cancer by providing a biochemical treatment barrier.  
Consequently, we studied differences in the expression of gemcitabine metabolizing 
enzymes between epithelial cells and stromal cells. In this context, NT5C1A was of utmost 
interest, as it is a previously unrecognized gemcitabine inactivating enzyme in pancreatic 
cancer. Thus, the aim was to characterize NT5C1A as mediator of epithelial and stromal 
driven gemcitabine resistance and to determine its potential as predictive biomarker for 
improved patient stratification.   
Hypothesis 2 is therefore: Pronounced NT5C1A expression in the epithelial compartment 
and low expression levels in the tumor stroma mediate gemcitabine resistance in pancreatic 
cancer.  
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2. Material and Methods  
2.1 Material  
2.1.1 Lab equipment 
Table 1: Lab equipment. 
Equipment Company 
Analog rotator – RS-RD 5 Phoenix Instrument GmbH, Garbsen, 
Germany 
Analytical lab balance – MC1 AC210P  Sartorius AG, Göttingen, Germany 
Anesthetic vaporizer – Sigma delta Penlon Ltd., Abingdon, UK 
Aspirator – Grant-bio FTA-1 Grant Instruments, Cambridge, UK 
Autoclave – FVA2/A1 Fedegari group ibs/ tecnomara GmbH, Fernwald, 
Germany 
Autoclave - Laboklav SHP Steriltechnik AG, Detzel 
Schloss/Satuelle, Germany 
AutoClip® system  Fine Science Tools GmbH, Heidelberg, 
Germany 
Beaker/ Erlenmeyer flask – Schott 
DURAN® 
DWK Life Sciences GmbH, 
Wertheim/Main, Germany 
Benchtop Orbital Shaker - MaxQ™ 4450 Thermo Fisher Scientific, Waltham, MA, 
USA 
Biological safety cabinet, class II – Thermo 
Scientific™ Safe 2020 
Thermo Electron LED GmbH, 
Langenselbold, Germany 
Cell Counter – Cellometer® Auto 1000, 
with single use cell counting chambers 
Nexcelom Bioscience LLC., Lawrence, 
MA, USA 
Centrifuge – Heraeus Megafuge 16/ 
Multifuge X1R 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Centrifuge – Universal 320R Andreas Hettich GmbH & Co. KG, 
Tuttlingen, Germany 
CO2 incubator - HERAcell® 240i Thermo Fisher Scientific, Waltham, MA, 
USA 
Cryo boxes with grid inserts - Labsolute® Th. Geyer GmbH & Co. KG, Renningen, 
Germany 
Dewar flask for liquid nitrogen – KGW-
Isotherm 
Karlsruher Glastechnisches Werk - 
Schieder GmbH, Karlsruhe, Germany 
Digital camera – Cyber-shot DSC-RX100 Sony Europe Limited, Surrey, UK 
Dry bath incubator – BSH 5002-E Benchmark Scientific, Inc., Edison, NJ, 
USA 
Fluid aspiration system - BVC control Vacuubrand GmbH & Co. KG, Wertheim, 
Germany 
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Fluorescence microscope - DMi8 
automated 
Leica Microsystems CMS GmbH, Wetzlar, 
Germany 
Forceps and dissecting scissors Karl Hammacher GmbH, Solingen, 
Germany 
Freezer – Mediline/ Fridge - Profi line/ 
Fridge and freezer - glass line 
Liebherr-International Deutschland GmbH, 
Biberach an der Riß, Germany 
Glass bottles 100 ml, 250 ml, 500 ml, 1 l – 
Schott DURAN® 
DWK Life Sciences GmbH, 
Wertheim/Main, Germany 
Graduated cylinders - SILBERBRAND 
ETERNA - 100 ml, 500 ml, 1 l 
BRAND GmbH + Co. KG, Wertheim, 
Germany 
Heated Paraffin Embedding Module - 
EG1150 H with cold plate - HistoCore 
Arcadia C 
Leica Biosystems Nussloch GmbH, 
Nussloch, Germany 
High resolution ultrasound system - Visual 
Sonics Vevo2100, including imaging 
stage, anesthesia line, and micro scan 
transducer (MS-550-D, 22-55 MHz)  
FUJIFILM VisualSonics Inc., Toronto, 
Canada 
Horizontal gel electrophoresis system –  
41-2025 
PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
Hot plate – 062 Labotect Labor-Technik-Göttingen GmbH, 
Rosdorf, Germany 
Ice bath – 1-6030 neoLab Migge GmbH, Heidelberg, 
Germany 
Ice machine - Scotsman® AF80 Scotsman Ice Srl, Milano, Italy 
Imaging system – ChemiDoc™ XRS+ Bio-Rad Laboratories GmbH, Munich, 
Germany 
Immunostaining slide rack and slides - 
Thermo Scientific™ Shandon Sequenza™  
Thermo Shandon Limited, Subsidiary of 
Thermo Fisher Scientific, Runcorn, UK 
Incubator – UF260/ UN55pa Memmert GmbH & Co. KG, Schwabach, 
Germany 
INTAS UV system Intas Science Imaging Instruments GmbH, 
Göttingen, Germany 
Lab balance – PCB 2000-1 Kern & Sohn GmbH, Balingen, Germany 
Lab balance – PT210/ universal PRO11 Sartorius AG, Göttingen, Germany 
Liquid nitrogen cell storage canister –  
Bio-cane™ 47 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Magnetic stirrer - RH basic IKA®-Werke GmbH & Co. KG, Staufen, 
Germany 
Microcentrifuge – PerfectSpin 24 Plus/ 
PerfectSpin 24R, refrigerated 
PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
Microplate reader – PHOmo  Autobio Labtec Instruments Co. Ltd., 
Zhengzhou, China 
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Microscope – Axiovert 25 Carl Zeiss AG, Oberkochen, Germany  
Microscope – BX43F/ CKX53 Olympus Corporation, Tokyo, Japan 
Microwave – NN-E209W 
 
Panasonic Marketing Europe GmbH, 
Hamburg, Germany 
Microwave heatpad for animals - 
snuggleSafe® 
SnuggleSafe Lenric C21, West Sussex, 
UK 
Mini centrifuge - sprout™ Heathrow Scientific, Vernon Hills, IL, USA 
Mini gel tank – Invitrogen, for Western blot 
analysis with mini blot module – B1000 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Multi-functional orbital shaker – Grant-bio 
PSU-20i 
Grant Instruments, Cambridge, UK 
Nano Photometer - P330 Intas Science Imaging Instruments GmbH, 
Göttingen, Germany 
Oxygen generator – Aeroplus 5 Kroeber Medizintechnik GmbH, Dieblich, 
Germany 
pH meter – FiveEasy Plus  METTLER TOLEDO AG, Schwerzenbach, 
Switzerland 
Pipette filler - pipetus® akku Hirschmann Laborgeräte GmbH & Co. KG, 
Eberstadt, Germany 
Pipettes - Research plus (10 µl, 20 µl, 
100 µl, 200 µl, 1000 µl), Multipette® plus 
Eppendorf AG, Hamburg, Germany 
Plate spinner – PerfectSpin P PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
PowerPac™ HC for gelelectrophoresis 
and Western blot analysis 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
Real-time PCR system – Applied 
Biosystems StepOnePlus™ 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Residual gas filter - CONTRAfluranTM ZeoSys GmbH, Berlin, Germany 
Rotary Microtome - RM2265 with flattening 
table for histopathology – HI 1220 
Leica Biosystems Nussloch GmbH, 
Nussloch, Germany 
Shaker - Duomax 1030 Heidolph Instruments GmbH & CO. KG, 
Schwabach, Germany 
Shaver – ER-PA10 Panasonic Corporation, Osaka, Japan 
Spectrophotometer – DS-11+ DeNovix Inc., Wilmington, DE, USA 
Staining jar/ Staining rack, glass Th. Geyer GmbH & Co. KG, Renningen, 
Germany 
Test tube shaker - Lab dancer  IKA®-Werke GmbH & CO. KG, Staufen, 
Germany 
Thermal cycler – T100™ Bio-Rad Laboratories GmbH, Munich, 
Germany 
Thermal cycler – T30 Analytik Jena AG, Jena, Germany 
ThermoMixer® compact  Eppendorf AG, Hamburg, Germany 
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Timer – WB-388 Oregon Scientific, Gennevilliers, France 
Tissue float bath – 1052 Gesellschaft für Labortechnik mbH, 
Burgwedel, Germany 
Tissue lyser – Qiagen with stainless steel 
beads, 5 mm 
RETSCH GmbH, Haan, Germany 
Tissue processor – TP1020 Leica Biosystems Nussloch GmbH, 
Nussloch, Germany 
Ultra-low freezer – Sanyo VIP™ series, 
MDF-454V 
EWALD Innovationstechnik GmbH, 
Rodenberg, Germany 
Ultrapure water system - arium® pro Sartorius AG, Göttingen, Germany 
Ultrasonic homogenizer – Sonopuls HD70 BANDELIN Electronic GmbH & Co. KG, 
Berlin, Germany 
Universal small shaker - MS3 basic IKA®-Werke GmbH & Co. KG, Staufen, 
Germany 
Vortex mixer – REAX2000 Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany 




Table 2: Consumables. 
Consumable Catalogue number  Supplier 
Adhesion slides for IHC - 
SuperFrost® Plus  
J1800AMNZ Gerhard Menzel B.V. & Co. KG, 
Braunschweig, Germany 
Blood collection system –  
S-Monovette® 1.2 ml, Z 
06.1663.001 Sarstedt AG & Co., Nuembrecht, 
Germany 
Cell culture multiwell plate, 
24 well/ 96 well, F-bottom 
662160/ 655180 Greiner Bio-One GmbH, 
Frickenhausen, Germany 
Cell scraper 25 cm 83.1830 Sarstedt, Inc., Newton, NC, USA 
Chamber slide™ system – 
Lab-Tek®, 8 well, 
Permanox® slides 
177445 Thermo Fisher Scientific, 
Rochester, NY, USA 
Chromatography paper - 
Whatman™, 3 mm 
3030917 Merck KGaA, Darmstadt, 
Germany 
Combitips - advanced® 
0.5 ml, 1 ml, 2.5 ml, 5 ml/ 
BIOPUR 1 ml, 5 ml 
0030 089.421/ 430/ 
448/ 456/ 642/ 669   
Eppendorf AG, Hamburg, 
Germany 
CryoPure tube 1.6 ml red 72.380.002 Sarstedt AG & Co., Nuembrecht, 
Germany 
Desinfectant - Desomed 
rapid AF 
DT-311-010 DESOMED Dr. Trippen GmbH, 
Freiburg, Germany 
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9160844 Th. Geyer GmbH & Co. KG, 
Renningen, Germany 
Eye and nose ointment - 
Bepanthen® 
6029009.00.00 Bayer Vital GmbH, Leverkusen, 
Germany 
Filter tips - TipOne® 




GmbH, Hamburg, Germany 
Folded filters, 185 mm  311647 Schleicher & Schuell BioScience 
GmbH, Dassel, Germany 
Gloves – latex/ nitrile - 
Starguard®  
SG-T-M/ SG-C-S STARLAB International GmbH, 
Hamburg, Germany 
Hair removal cream – Veet 8319533 RB Healthcare UK, Hull, UK 
Insulin syringes 30G – BD 
Micro-Fine™ + Demi 
324826 Becton, Dickinson and Company, 
Franklin Lakes, NJ, USA 
Micro Amp® fast optical 96-
well reaction plate (0.1 ml) – 
Applied biosystems® 
4346906 Life Technologies Corporation, 
Carlsbad, CA, USA 
Microscope coverslips 
24 x 32 mm 
7695 028 Th. Geyer GmbH & Co. KG, 
Renningen, Germany 
Microtest plate 96 well, F 2021-08 Sarstedt AG & Co., Nuembrecht, 
Germany 
Microtome blade - Feather® 
S35 
207500000 pfm medical AG, Cologne, 
Germany 




Sarstedt AG & Co., Nuembrecht, 
Germany 
Needle Sterican® - 
20 G x 2‘, 26 G x 1‘‘  
466 7093/ 465 7683 B. Braun Melsungen AG, 
Melsungen, Germany 
Nitrocellulose blotting 
membrane 0.45 µm - 
Amersham™ Protran™ 
10600002 GE Healthcare Europe GmbH, 
Freiburg, Germany 
NuPAGE 4-12% Bis-Tris 
Gel 1,5mm x 15 well – 
novex®, Invitrogen 
NP0336BOX Life Technologies Corporation, 
Carlsbad, CA, USA 
Optical adhesive covers – 
applied biosystems® 
4360954 Life Technologies Holdings Pte. 
Ltd., Singapore 
Parafilm® PM-996 Pechiney Plastic Packiging, Inc., 
Menasha, WI, USA 
PCR tubes 200 µl - 
Multiply® µStrip Pro  
72.990.002 
 
Sarstedt AG & Co., Nuembrecht, 
Germany 
Pipette tips - TipOne® 10 µl, 
200 µl, 1000 µl 
S1111-3000/ S1113-
1006/ S1111-6001 
STARLAB International GmbH, 
Hamburg, Germany 
Precision Plus Protein™ 
Dual color standards  
161-0374 Bio-Rad Laboratories GmbH, 
Munich, Germany 
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Razor blades – Apollo 
ever-shape blades 
9156110 Th. Geyer GmbH & Co. KG, 
Renningen, Germany 
Rolled rim bottles 
55x27 mm 
9400240 Th. Geyer GmbH & Co. KG, 
Renningen, Germany 
Scalpel 02.001.30.021 Feather Safety Razor Co., LTD, 
Osaka, Japan 
Screw vials – ND8, 1.5 ml, 
with lid - LABSOLUTE® 
7 615 163, 7 612 
928 (lid) 
Th. Geyer GmbH & Co. KG, 
Renningen, Germany 
Serological pipette 2 ml, 




Sarstedt AG & Co., Nuembrecht, 
Germany 
Serological pipette 5 ml, 
10 ml 
606180/ 607180 Greiner Bio-One GmbH, 
Frickenhausen, Germany 
Sterilium® classic pure  975512 BODE Chemie GmbH, Hamburg, 
Germany 
Surgical suture material - 
Ethicon® Vicryl™ 
Polyglactin 910 
V497 Johnson & Johnson Medical 
GmbH, Norderstedt, Germany 
Syringe 1 ml – BD 
Plastipak™ 
303172 Becton Dickinson S.A., Madrid, 
Spain 
Syringe 5 ml, 10 ml - Injekt® 4606710V / 
4606728V  
B. Braun Melsungen AG, 
Melsungen, Germany 
TC dish 100/ TC plate 
6 well 
83.3902/ 83.3920 Sarstedt AG & Co., Nuembrecht, 
Germany 
TC flask T25, T75, T175 83.3910.002/ 
83.3911.302/ 
83.3912.002 
Sarstedt AG & Co., Nuembrecht, 
Germany 
Tube 5 ml, 15 ml, 50 ml 60.558.001/ 
62.554.502/ 
62.547.254 
Sarstedt AG & Co., Nuembrecht, 
Germany 
Ultrasonic gel ASUSG1 Asmuth GmbH Medizintechnik, 
Minden, Germany 
Weighing boats 9.900 786 Lab Logistics Group GmbH, 
Meckenheim, Germany 
Wound clips – Reflex 9 
 
201-1000 CellPoint Scientific, Inc., 
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2.1.3 Chemicals and reagents 
Table 3: Chemicals and reagents.  
Chemical / Reagent Catalogue 
number  
Supplier 
2-propanol 33539 Sigma-Aldrich, Co., St. Louis, 
MO, USA 
Acetic acid, glacial 3788.4 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
AEC+ High Sensitivity  
Substrate Chromogen 
K3469 Dako Denmark A/S, Glostrup, 
Denmark 
Agarose  AG 02 Nippon Genetics Europe 
GmbH, Düren, Germany 
Albumin Bovine Fraction V, 
pH 7.0  
11930.03 SERVA Electrophoresis GmbH, 
Heidelberg, Germany 
Albumin standards (BSA), 
2 mg/ml 
23209 Thermo Fisher Scientific Inc., 
Rockford, IL, USA 
Ampicillin K029.2 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Aqua/ Aqua ad iniectabilia 75/12604052/1212/ 
6724123.00.00 
B. Braun Melsungen AG, 
Melsungen, Germany 
Bromphenol blue indicator 
pH 3.0-4.6, ACS  
1.08122.005 Merck KGaA, Darmstadt, 
Germany 
Chemiluminescence reagent 
Western Lightning® Plus/ Ultra 
NEL105001EA/  
NEL112001EA 
Perkin Elmer, Inc., Waltham, 
MA, USA 
Chloroform p. a.  1.02442.1000 Merck KGaA, Darmstadt, 
Germany 
Citric acid monohydrate p. a.  3958.1 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Coomassie blue G-250 based 
protein assay reagent 
1856209 Thermo Fisher Scientific Inc., 
Rockford, IL, USA 
Crystal violet  T123.1 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) D8418-100ML Sigma-Aldrich, Co., St. Louis, 
MO, USA 
DNA ladder – Gene ruler plus 
1 kb 
SM0311 Thermo Fisher Scientific, 
Waltham, MA, USA 
DNA ladder - Quick-load® 
100 bp 
N0467S New England Biolabs GmbH, 
Frankfurt am Main, Germany 
dNTP set 100 mM 10297-018 Invitrogen Corp., Carlsbad, CA, 
USA 
Dulbecco’s Phosphate Buffered 
Saline - gibco® 
14190-094 Life Technologies Corporation, 
Paisley, UK 
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Embedding wax (Paraffin) 17932A Engelbrecht GmbH, 
Edermünde/ Besse, Germany 
Eosin Y solution aqueous HT110232-1L Sigma-Aldrich, Co., St. Louis, 
MO, USA 
Ethanol - CHEMSOLUTE® 




Th. Geyer GmbH & Co. KG, 
Renningen, Germany 
Ethylene glycol-bis(2-amino-
ethylether)-N, N, N’, N’-tetra-
acetic acid (EGTA) 
E4378-100G Sigma-Aldrich, Co., St. Louis, 
MO, USA 
Ethylenediaminetetraacetic 
acid, disodium salt dihydrate 
(EDTA) 
147850010 Acros Organics N.V., Fair 
Lawn, NJ, USA 
Formaldehyde solution 4 %, 
buffered, pH 6.9 
1.00496.5000 Merck KGaA, Darmstadt, 
Germany 
Glycerin Rotipuran >99.5% 3783.2 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Goat serum (normal)  X0907 Dako Denmark A/S, Glostrup, 
Denmark 
Hematoxylin solution according 
to Mayer 
51275-1L Sigma-Aldrich, Co., St. Louis, 
MO, USA 
HEPES - PUFFERAN®, buffer 
grade 
HN78.2 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Hydrochloric acid 2 N/ 37 % T134.1/ 9277.1 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Hydrogen Peroxide 30 % - 
ROTIPURAN® p.a. 
8070.2 Carl Roth GmbH & Co. KG, 
Karlsruhe, Germany 
Isotonic saline solution - 0.9 % 6697366.00.00 B. Braun Melsungen AG, 
Melsungen, Germany 
LB Broth (Miller) – powder, 
microbiological growth medium 
L3522 Sigma-Aldrich, Co., St. Louis, 
MO, USA 
Lithium chloride 27026 Sigma-Aldrich, Co., St. Louis, 
MO, USA 
Matrigel® growth factor reduced 
basement membrane matrix, 
phenol red-free - Corning® 
356231 VWR International GmbH, 
Darmstadt, Germany 
Methanol 8388.5 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Midori green advance DNA 
stain 
MG04 Nippon Genetics Europe 
GmbH, Dueren, Germany 
Mountant for microscopy - 
Roti®-Mount  
HP68.2 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
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Mounting medium for 
fluorescence with DAPI - 
VECTASHIELD® 
H-1200 Vector Laboratories, Inc., 
Burlingame, CA, USA 
Non-woven wipes - Desco 
wipes 
00-915-RD7003-01 Dr. Schumacher GmbH, 
Malsfeld, Germany 
NuPAGE® LDS sample buffer 
(4x), Invitrogen, novex® 
NP0007 Life Technologies Corporation, 
Carlsbad, CA, USA 
NuPAGE® novex® MOPS SDS 
Running Buffer/ Transfer buffer 
NP0001/ NP0006 Life Technologies Corporation, 
Carlsbad, CA, USA 








78830-56 Sigma-Aldrich, Co., St. Louis, 
MO, USA 
Ponceau S solution P7170-1L Sigma-Aldrich, Co., St. Louis, 
MO, USA 
Powdered milk  T145.4 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Pro Taqs II Antigen-Enhancer 401602192 Biocyc GmbH & Co. KG, 
Potsdam-Golm, Germany 
Protease inhibitor cocktail 
tablets - cOmplete™ mini 
11 836 170 001 Roche Diagnostics GmbH, 
Mannheim, Germany 
RNAlater® RNA stabilization 
reagent 
1018087 Qiagen GmbH, Hilden, 
Germany 
RNase-free water – peqGOLD 12-RWATER-88 VWR International BVBA, 
Leuven, Belgium 
Roticlear® for histology A538.2 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
Sodium chloride - Fluka™ 
 
31434 Honeywell International Inc., 
Morristown, NJ, USA 
Sodium fluoride S1504 Sigma-Aldrich, Co., St. Louis, 
MO, USA 
Sodium hydroxide solution 5587.2500 Merck KGaA, Darmstadt, 
Germany 




221368 Sigma-Aldrich, Co., St. Louis, 
MO, USA 
TaqMan® universal PCR master 
mix - Applied Biosystems  
4324018 Life Technologies LTD, 
Warrington, UK 
Thiazolyl blue tetrazolium 
bromide 
M5655 Sigma-Aldrich, Co., St. Louis, 
MO, USA 
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Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
TritonX®-100 3051.4  Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
TRIzol® reagent - ambion® 15596018 Life Technologies Corp., 
Carlsbad, CA, USA 




R0531 Thermo Fisher Scientific, 
Waltham, MA, USA 
Tween® 20 - PanReac A4974 AppliChem GmbH, Darmstadt 
Xylene – J.T. Baker® 8118 Avantor Performance Materials 
Poland S.A., Gliwice, Poland 
β-mercaptoethanol 4227.3 Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany 
 
Table 4: Enzymes. 
Enzyme Catalogue number  Supplier 




Fast digest HindIII FD0504 
Fast digest Nhe1 FD0974 
Fast digest Not1 FD0594 
Fast digest SpeI (BcuI) – Fermentas FD1254 
Jumpstart Taq DNA Polymerase 
2.5 units/µl 
D9307 Sigma-Aldrich, Co., 
St. Louis, MO, USA 
M-MLV reverse transcriptase 
(200U/µl), 
28025-013 Invitrogen Corp., 
Carlsbad, CA, USA 
Phusion high-fidelity DNA 





T4 DNA ligase EL0011 
VspI (AseI) ER0911 
 
Table 5: Inhibitors. 
Inhibitor Catalogue number  Supplier 
RNasin® Ribonuclease 
Inhibitor 
N2511 Promega Corporation, 
Madison, WI, USA 
Tetrahydrouridine - 
Calbiochem 
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2.1.4 Buffers  
Citrate buffer 10x stock solution, pH 6.0: 
100 mM citric acid monohydrate 
→ Ad 1000 ml with ultrapure water, sodium hydroxide for pH adjustment    
 
TE buffer 10x stock solution, pH 9.0: 
10 mM EDTA 
100mM TRIS 
→ Ad 1000 ml with ultrapure water   
 
TBE buffer 10x stock solution, pH 8.0: 
0.9 M TRIS 
0.9 M Boric acid 
25 mM EDTA 
→ Ad 1000 ml with ultrapure water, hydrochloric acid for pH adjustment   
 
TAE buffer 50x stock solution, pH 8.3 (protocol from (BioInfoWeb.com, n.d.)): 
2 M TRIS 
0.05 M EDTA  
1 M acetic acid glacial 
→ Ad 250 ml with ultrapure water 
 
TBS 10x stock solution, pH 7.5 (protocol from (Stromiedel & Wittmann, n.d.)): 
165 mM Tris-HCl 
35 mM Tris base 
5 M sodium chloride 
→ Ad 1000 ml with ultrapure water, pH adjustment not required  
 
➔ 1x buffer solutions were prepared by diluting stock solutions with ultrapure water  
 
PBS without Ca2+ and Mg2+: 
9.55 g/l PBS powder 
→ Ad 1000 ml with ultrapure water, autoclaved for use in cell culture 
 
PBS-T 0.1 %: 
1000 ml PBS buffer 
1 ml Tween® 20 
TBS-T 0.1 %: 
1000 ml TBS buffer 
1 ml Tween® 20
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Protein lysis buffer: 
50 mM HEPES (pH 7.5-7.9) 150 mM Sodium chloride 
1 mM EGTA 10 % Glycerin 
1 % TritonX®-100 100 mM Sodium fluoride 
10 mM Sodiumpyrophosphate decahydrate 
→ immediately before use add to 1 ml of lysis buffer: 
10 µl of 100 mM PMSF 40 µl of 25x cOmplete™ 
10 µl of 100 mM sodium orthovanadate 10 µl of 100 mM sodium fluoride  
 
2.1.5 Kits 
Table 6: Kits. 
Kit Catalogue number  Supplier 
DAB peroxidase substrate 
kit - ImmPACT™ 
SK-4105 Vector Laboratories, Inc., 
Burlingame, CA, USA 
HistoGreen substrate kit for 
peroxidase - Histoprime® 
E109 LINARIS Biologische Produkte 
GmbH, Dossenheim, Germany 
ImmPress reagent kit 
anti-rabbit IgG 
MP-7401 Vector Laboratories, Inc., 
Burlingame, CA, USA 
Midi prep kit - NucleoBond® 
Xtra plasmid purification kit 
740410.100 MACHEREY-NAGEL GmbH & 
Co. KG, Dueren, Germany 
Mini prep kit – innuPREP 
plasmid mini kit plus 
845-KS-5240250 Analytik Jena AG, Jena, Germany 
Mouse on mouse 
(M.O.M.™) basic kit  
BMK-2202 Vector Laboratories, Inc., 
Burlingame, CA, USA 
Mycoplasma PCR detection 
kit - LookOut®  
MP0035 Sigma-Aldrich, Co., St. Louis, 
MO, USA 
NucleoSpin® gel and PCR 
clean-up kit 
740609.10 MACHEREY-NAGEL GmbH & 
Co. KG, Dueren, Germany 
peqGold total RNA kit  12-6834-02 VWR International BVBA, 
Leuven, Belgium 
Peroxidase rabbit/ mouse 
IgG - Vectastain® ABC Kit 
PK-4001/ PK-4002 Vector Laboratories, Inc., 
Burlingame, CA, USA 
RNeasy® mini kit 74104 Qiagen GmbH, Hilden, Germany 
 
2.1.6 Drugs  
Table 7: Therapeutic drugs. 
Drug Catalogue number  Supplier 
5-fluorouracil 03738 
Sigma-Aldrich, Co., St. 
Louis, MO, USA 
Gemcitabine hydrochloride G6423 
Paclitaxel T7191 
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Table 8: Anesthetics and analgesics.  
Drug Approval number  Supplier 
Carprieve (carprofen) 401182.00.00 Norbrook Laboratories Limited, 
Newry, UK 
Forene® 100 % (V/V) 2594.00.00 AbbVie Deutschland GmbH & Co. 
KG, Ludwigshafen, Germany 
Temgesic (buprenorphine) 345928 Indivior Eu Ltd., Berkshire, UK 
 
2.1.7 Antibodies 
Table 9: Primary antibodies for Western blot, IHC, and ICC. 
Antibodies Catalogue 
number 
Supplier  Dilution 
Cytidine deaminase 
(Cda) 
ab82346 Abcam plc, Cambridge, UK 1:300 IHC (mouse) 
Cytidine deaminase 
(Cda) 
LS-B10533 LifeSpan Biosciences Inc., 
Seattle, WA, USA  
1:50 IHC (human) 
Cleaved Caspase-3 
(Asp175) (5A1E) 
9664 Cell Signaling Technology, 
Inc., Danvers, MA, USA 




Ab96599 Abcam plc, Cambridge, UK 1:100 IHC (mouse) 
Deoxycytidine 
kinase (dCK) 
LS-B10837 LifeSpan Biosciences Inc., 
Seattle, WA, USA 
1:100 IHC (human) 
DCMP deaminase 
(DCTD) 
EPP12174 Elabscience Biotechnology, 
Inc., Houston, TX, USA  
1:300 IHC (mouse 
+ human) 
HA-Tag (C29F4) 3724 
Cell Signaling Technology, 
Inc., Danvers, MA, USA 
1:1000 (WB)/ 
1:200 (ICC)/ 1:300 
(IHC)  
HSP90 (E289) 4875 1:1000 (WB) 
Ki-67 (SP6) RM9106-S0 Thermo Fisher Scientific, 
Waltham, MA, USA 
1:200 IHC/  
Co-IF 
NT5C1A  ab199632 Abcam plc, Cambridge, UK 1:1000 (WB) 
NT5C1A  C15296 Assay Biotechnology 
Company Inc., Sunnyvale, 
CA, USA 
1:100 (IHC, ICC) 




actin, Clone 1A4 
M0851 Dako Denmark A/S, 
Glostrup, Denmark 
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Table 10: Secondary antibodies.  
Antibodies Catalogue number Supplier  Dilution 
Donkey anti-rabbit IgG - 
Alexa Fluor® 555/ 568 




Goat anti-mouse IgG - 
Alexa Fluor® 488 
A21131 Invitrogen, Eugene, 
OR, USA 
1:1000 (Co-IF) 
Secondary antibody - 









Secondary antibody - 
swine anti-rabbit/ goat 
anti-mouse IgG/ HRP 






Table 11: Primers.  
Primer name Sequence (5'-3') Source 
mNt5c1A insert check CCTACAGCTCCTGGGCA
ACG 
Sigma-Aldrich, Co., St. 









Eurofins Genomics GmbH, 
Ebersberg, Germany 
Primer p(dT)15 for cDNA 
synthesis, 8 nmol 
Catalogue number: 
10814270001 
Roche Diagnostics GmbH, 
Mannheim, Germany 
 
Table 12: TaqMan® reagents used for qRT-PCR. 
TaqMan® reagent Catalogue number Supplier  
Human NT5C1A  Hs00261369_m1 
Thermo Fisher Scientific, 
Waltham, MA, USA 
Human β-actin Hs99999903_m1 
Murine dCK Mm00432794_m1 
Murine NT5C1A  Mm01192248_m1 
Murine NT5C3 Mm0046604_m1 
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2.1.9 Cell culture  
Table 13: Cell culture components.  
Component Catalogue number Company 
Dulbecco’s Modified Eagle 
Medium (DMEM) - gibco® 
41965-039 Life Technologies Corp., 
Paisley, UK 
Fetal bovine serum (FBS) - 
gibco® 
10270-106 Life Technologies Corp., 
Paisley, UK 
Hygromycin B Gold ant-hg-5 InvivoGen Europe, Toulouse, 
France 
L-glutamine 200 mM - gibco® 25030-024 
Life Technologies Corp., 
Paisley, UK 
Minimum Essential Medium 
(MEM) - gibco® 
51200-046 
MEM Non-Essential Amino 
Acids (NEAA) - gibco® 
11140-035 
Opti-MEM™ I Reduced 




P0781 Sigma-Aldrich, Co., St. Louis, 
MO, USA 
Trypsin-EDTA 0.5 % (10x) - 
gibco®  
15400-054 Life Technologies Corp., 
Paisley, UK 
 
Table 14: Cells. 
Cell type Source 
DH5α competent E.coli Department of Developmental Biochemistry, 
Extracellular Signaling Lab, UMG 
KPC tumor cells 
Department of Gastroenterology and 
Gastrointestinal Oncology, UMG 
KPC tumor cells from metastatic foci 
L3.6pl cells 
Myoblasts, undifferentiated (RNA) Isolated by the group of Prof. Dr. Jens 
Schmidt, Department of Neurology, UMG 
PSCs, immortalized 
 
Department of Gastroenterology and 
Gastrointestinal Oncology, UMG 
 
2.1.10 Software and tools 
Table 15: Software and tools.  
Software/ Tool Source 
Leica LAS X - Application 
Suite X  
Leica Microsystems CMC GmbH, Wetzlar, Germany 
Microsoft office 2010 Microsoft Corporation, Redmond, WA, USA 
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Nucleotide BLAST National Center for Biotechnology Information/ U.S. 
National Library of Medicine, Bethesda, MD, USA 
ImageJ 1.50b/ Fiji Wayne Rasband, National Institute of Health, USA 
(Schindelin et al., 2012) 
Image Lab 5.2.1 build 11 Bio-Rad Laboratories GmbH, Munich, Germany 
PVC Viewer v1.5.3.1 Intas Science Imaging Instruments GmbH, Göttingen, 
Germany 
StepOne v2.3 Life Technologies Corp., Carlsbad, CA, USA 
GraphPad Prism 6.05/ 7.03 GraphPad Software Inc., La Jolla, CA, USA 
AUTOsoft 2.6 Autobio Labtec Instruments Co. Ltd., Zhengzhou, China 
CellSens Entry 1.12 Olympus Corporation, Tokyo, Japan 
Statistica 12 (for Q-Q-plots) StatSoft Europe, Hamburg, Germany 
GIMP 2.8.16 Spencer Kimball, Peter Mattis and GIMP team 
 
2.1.11 Animals 
• C57BL/6-J mice: Charles River Laboratories, Inc., Wilmington, MA, USA 
• LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mice: archived tissue was used 
for the present study  
 
 
2.2 Methods  
2.2.1 Animal studies  
2.2.1.1 KPC mice 
The study was conducted with KPC mice (Hingorani et al., 2005). Archived tissues from 
previous preclinical studies were used (Cook et al., 2012; Neesse et al., 2013). Tumor 
development in these animals had been observed by small animal high-resolution 
ultrasound from eight weeks of age, and mice had been randomly enrolled into the studies 
at tumor volumes of 6-9 mm, as previously described (Neesse et al., 2013).  
 
2.2.1.2 Syngeneic orthotopic mouse model 
Orthotopic transplantation studies were conducted in C57BL/6-J mice. Surgery was 
performed at the age of eight weeks and mice were randomly separated into four groups 
before transplantation (n = 7 per group). Stably transfected syngeneic KPC-BL6 cells 
(+NT5C1A) and respective control cells (+vector) were used for this preclinical study. Before 
transplantation, cells were trypsinized and counted (1:1-mixture of cell suspension and 
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0.2 % trypan blue solution in PBS). A total number of 150,000 viable cells were used per 
mouse. Cell suspensions in culture medium were mixed with equal volumes of Matrigel and 
kept on ice until transplantation.   
 
2.2.1.3 Housing conditions  
Mice were housed at a 12 h light and 12 h dark cycle and all animal procedures were 
conducted in accordance with institutional and national regulations. Animals were kept in 
groups of up to five mice per cage and were separated according to treatments.  
 
2.2.1.4 Orthotopic transplantation procedure  
Animals were intraperitoneally (i.p.) treated with buprenorphine (0.1 mg/kg body weight) 
approximately 30 min. prior to surgery. Mice were then anesthetized with isoflurane (2-3 %) 
for hair removal and the surgical tumor cell implantation. Mice were kept on a warming plate 
for the duration of the surgical procedure. Carprieve (5 mg/kg body weight) was 
administered subcutaneously (s.c.) prior to transplantation, which was performed based on 
a published protocol (Feldmann et al., 2007). Following disinfection of the mouse abdomen, 
the peritoneum was opened up with a small incision and 40 µl of the resuspended cell 
suspension were injected into the tail of the pancreas. The peritoneum was closed with a 
single stich suture and the skin wound was closed using wound clips (removed seven days 
after surgery). Mice were transferred into a pre-warmed recovery cage. Mashed food was 
provided and mice were observed carefully following surgery. Mice were weighed at least 
three times per week and checked for general behavior every day during the whole study.  
 
2.2.1.5 Sonography  
Performance of small animal high-resolution ultrasound for tumor detection was previously 
described by our group (Goetze et al., 2018). Briefly, mice were anesthetized with 2 % 
isoflurane and hairs were removed from the abdomen. Sonography was then performed 
using a Visual Sonics Vevo 2100 High Resolution Ultrasound System.  
 
2.2.1.6 Gemcitabine treatment 
Orthotopically transplanted C57BL/6-J mice were treated with gemcitabine-hydrochloride or 
saline, starting seven days after surgery. Intraperitoneal injections with gemcitabine-
hydrochloride were administered with 100 mg/kg body weight on day 0, 3, 7, 10, and 13. 
Control animals were injected with comparable volumes of isotonic saline.  
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KPC mice were treated as stated in the method descriptions of the corresponding preclinical 
studies (Cook et al., 2012; Hessmann & Patzak et al., 2018; Neesse et al., 2013).  
Archived samples from KPC mice were used for this study. These animals had been dosed 
with gemcitabine at 100 mg/kg body weight by i.p. injections (gemcitabine powder, 48 % 
preparation of dFdC, provided by Addenbrooke’s Hospital Pharmacy, Cambridge, UK) 
(Cook et al., 2012; Hessmann & Patzak et al., 2018; Neesse et al., 2013). All mice received 
the last gemcitabine dose 2 h prior sacrifice.   
 
2.2.1.7 Endpoint criteria  
For all studies the endpoint criteria were defined as 20 % body weight loss, general 
morbidity, lack of social interaction and lethargy, as well as the development of ascites.  
 
2.2.1.8 Tissue harvesting 
Animals were sacrificed by cervical dislocation following administration of high doses of 
isoflurane. The peritoneum was opened up and mice were checked for metastases and 
other abnormalities. Tumor samples, liver tissue, and liver metastases were isolated and 
snap frozen. Samples were kept at -80 °C for subsequent LC-MS/MS analysis and protein 
isolation. Further pieces of tumor and liver tissue were incubated in 1 ml RNAlater® per tube 
for 24 h at 4 °C. The stabilizing solution was removed prior to storage at -80 °C. The 
remaining tumor parts, the pancreas, and liver tissue were fixed in 10 % neutral buffered 
formalin overnight and were further processed for paraffin embedding.      
 
2.2.1.9 Serum isolation 
Blood was collected at study endpoint. For animals that received gemcitabine, 10 µl of 1 mM 
tetrahydrouridine (THU) were added to the blood to inhibit ex vivo gemcitabine inactivation 
by CDA. Vials were incubated at room temperature for up to ten minutes and were 
subsequently put on ice. Samples were centrifuged (4000 g, 4 °C, 10 min.) and serum was 
transferred to new tubes for storage at -20 °C.   
 
2.2.1.10 Tissue preparation for paraffin-embedding 
Formalin-fixed tissues were further processed using a Leica Biosystems tissue processer 
for dehydration overnight. The following protocol was used: Formalin (75 min.), ethanol 
(EtOH) 55 % (30 min.), EtOH 85 % (45 min.), EtOH 96 % (60 min.), EtOH 99 % (75 min.), 
EtOH 99 % (70 min.), EtOH 99 % (90 min.), xylol (20 min.), xylol (30 min.), xylol (70 min.), 
paraffin (30 min.), paraffin (45 min.), paraffin (90 min.).  
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Tissues were subsequently embedded in paraffin and 4 µm-sections were prepared for 
H&E and immunohistochemistry stainings.   
 
2.2.1.11 Hematoxylin and eosin (H&E) staining 
Tissue slides were incubated in Roticlear solution for 2x 10 min. Tissues were rehydrated 
in a graded alcohol series (99 %, 99 %, 96 %, 80 %, 70 %, 50 %) for 3 min. each. Following 
three washing steps using tap water, the slides were stained for 7 min. in hematoxylin, 
washed again and kept in tap water for 5 min. until the color turned blue. Staining with eosin 
for 30 sec. and further three washing steps followed. Finally, slides were incubated in 
solutions with increasing alcohol concentrations for dehydration (3 min. each) and further 
incubated in Roticlear for 4x 10 min. Cover glasses were added using Roti®-Mount mounting 
medium.  
       
2.2.1.12 Immunohistochemistry (IHC)  
Tissue sections were processed according to standard procedures (Lang, 2013; Luttmann 
et al., 2014). Deparaffinization and tissue rehydration was achieved by incubation in 
Roticlear and in a graded alcohol series as described for H&E staining. Heat-induced 
epitope retrieval was performed in citrate buffer pH 6.0 or TE buffer pH 9.0 by boiling the 
tissue slides for 4-10 min. (according to primary antibody) in a microwave, keeping them 
inside the microwave for further 10 min., and a subsequent cooling step on ice for 20 min. 
Slides were washed three times in tap water and treated with freshly prepared 3 % hydrogen 
peroxide solution for 15 min. in order to block endogenous peroxidases and thus, to reduce 
background staining. Following three washing steps in tap water, the slides were aligned 
into the Shandon Sequenza™ racks using TBS-T. Slides were washed three times with 
TBS-T, non-specific antibody binding was blocked by incubation in 200 µl blocking reagent 
per slide for 1 h at room temperature. 200 µl of diluted primary antibody solution were added 
per slide and incubated overnight at 4 °C. Slides were washed three times before adding 
200 µl of a 1:200-dilution of the secondary antibody per slide for 1 h at 37 °C, followed by 
another three washing steps. Vectastain® ABC kits and DAB peroxidase substrate solution 
were used for target detection. AB complex formation required 30 min. preincubation before 
200 µl of the solution were added per tissue slide for 1 h at room temperature. All slides 
were disassembled from the staining system and washed three times in tap water. Tissues 
were directly exposed to 100-150 µl of DAB chromogen for few minutes (depending on 
primary antibody) and reaction was stopped with water. Counterstaining with hematoxylin 
was performed (4 min., three washing steps in tap water) with subsequent incubation for 
5 min. Rehydration steps and mounting was done as described for H&E stainings.  
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Negative controls without primary antibody or without secondary antibody, respectively, 
were included in the staining process. Primary antibodies are listed in Table 9. Image 
acquisition was conducted using an Olympus DP27 camera with 20x or 40x magnification, 
respectively.    
 
2.2.1.12.1 IHC using primary antibodies from mouse origin  
The Vector lab mouse on mouse (M.O.M.™) kit was used according to the manufacturer’s 
instructions for IHC stainings with primary antibodies from mouse origin. 200 µl of the 
required solutions were added per slide. Following the blocking step of unspecific binding 
sites, slides were preincubated with M.O.M™ diluent for 5 min. at room temperature, 
incubated with primary antibody for 30 min. at room temperature, secondary antibody 
incubation at 37 °C for 10 min., and AB complex incubation for 30 min. at room temperature.  
 
2.2.1.12.2 Co-IHC and Co-immunofluorescence  
The standard IHC-protocol was followed and pre-treatment with the second buffer was 
performed following DAB chromogen addition. Blocking of endogenous peroxidases and 
immunostaining were carried out as mentioned before and slides were developed for 
10 min. using HistoGreen solution according to the manufacturer’s recommendations. 
Slides were washed for 2 min. in TBS and briefly rinsed under tap water. Counterstaining 
was achieved by 2 min. incubation in hematoxylin and three washing steps under tap water. 
The dehydration process was shortened to 30 sec. incubations in a graded alcohol series 
and in Roticlear. Slides were finally mounted with coverglasses using Roti®-Mount.   
Archived tissues from a previously published preclinical trial were used for 
co-immunofluorescence (Co-IF) (Neesse et al., 2013), which was performed similar to the 
IHC staining procedure. However, following epitope retrieval, the slides were directly 
aligned into the Shandon Sequenza™ racks, blocked using 5 % goat serum in TBS-T and 
incubated with both primary antibodies together. Incubation with secondary antibodies was 
performed in the dark (1:1000-dilution of both Alexa Fluor® antibodies in 10 % BSA/TBS-T), 
followed by five washing steps. DAPI-containing mounting solution was used and slides 
were kept at 4 °C in the dark until analysis. Images were acquired at a Leica DMi8 
microscope and ten high performance fields (HPF) at 40x-magnification were counted per 
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2.2.2 Cell culture 
2.2.2.1 Cell culture conditions for adherent cells 
Archived KPC cells, cells from metastatic foci, and CAF and PSC cell lines were used for 
these studies. Furthermore, the human L3.6pl (pancreas to liver) tumor cell line (Bruns et 
al., 1999) was included. A comprehensive description of the establishment of these primary 
murine KPC cell lines and cell lines from metastatic foci (liver, spleen, ascites) was given in 
the publication by Hingorani et al. (2005). Moreover, the isolation of CAFs from LSL-
KrasG12D/+;Ptf1a-Cre (KC) mice by serial trypsinization as well as PSC purification by density 
gradient centrifugation with subsequent immortalization using the SV40 large T antigen, 
was previously described by Hessmann & Patzak et al. (2018).  
Cells were incubated at 37 °C with 5 % carbon dioxide supply. High glucose DMEM with 
phenol red was used for KPC, CAF, and PSC cell lines. Media were supplemented with 
10 % fetal bovine serum (FBS) and in case of KPC and CAF cells also with 
1 % non-essential amino acids. L3.6pl cells were cultured in MEM without phenol red, 
supplemented with 10 % FBS and 1 % L-glutamine. Cells were passaged at 80-95 % of 
confluency by standard trypsinization (Schmitz, 2011). For functional assays, cell 
suspensions were centrifuged at 1200 rpm for 3 min., resuspended and counted using the 
Nexcelom cell counter (20 µl of cell suspension in single-use counting chambers).  
Cell stocks were prepared using 90 % FBS and 10 % dimethyl sulfoxide (DMSO) (1 ml 
aliquots). A slow freezing process was ensured by the use of an isolating styrofoam box. 
Frozen cells were either stored at -80 °C or transferred into liquid nitrogen cell tanks for 
long-term storage. For thawing of cells, the stocks were quickly defrosted, mixed with 
culture medium, centrifuged, resuspended, and transferred into cell culture flasks. Cells 
were passaged at least once before performing functional assays.  
 
2.2.2.2 Mycoplasma test 
Mycoplasma tests of mammalian cells were conducted using a PCR detection kit according 
to manufacturer’s instructions. Cells were at 80-100 % confluency and medium was not 
older than two days. In brief, cell culture supernatants were incubated for 5 min. at 95 °C 
and briefly centrifuged. JumpStart™ Taq DNA polymerase and rehydration buffer from the 
kit were mixed and added to the samples and the controls. Samples were analyzed on an 
1.2 % agarose gel with Midori green DNA stain. 7 µl of a 100 bp DNA ladder and 12 µl of 
each sample (in duplicates) were used, gel electrophoresis performed, and bands 
visualized at the ChemiDoc XRS+ system.   
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The cell lines were tested for mycoplasma contamination prior to orthotopic transplantations 
(KPC-BL6 cells), prior to LC-MS/MS experiments (L3.6pl cells), and following stable 
transfections (PSC1 and PSC2 cell lines).  
 
2.2.2.3 Gemcitabine and 5-FU treatments 
Gemcitabine-hydrochloride powder and 5-FU powder were used for in vitro studies. Stock 
solutions with a concentration of 100 mM were prepared in sterile water (gemcitabine) or 
DMSO (5-FU), respectively, and kept at -20 °C. For LC-MS/MS analysis, cells were seeded 
at a density of 700,000 cells per well in 6-well plates and allowed to attach for 24 h. Cells 
were exposed to 1 µM gemcitabine-hydrochloride or water as control for 2 h at 37 °C. 
Supernatants (1 ml) were immediately stored at -80 °C. Cell pellets were harvested by 
washing twice with PBS, trypsinization, and subsequent incubation at 37 °C for few min. 
Culture medium was added, cell suspensions centrifuged at 1200 rpm for 3 min., and 
subsequently cells were resuspended in 2 ml of fresh medium per sample. Cells were 
counted and 1*106 or 5*105 cells per sample, respectively, were transferred into cryovials. 
Cells were centrifuged at 1500 rpm for 4 min. and washed twice with cold PBS. The 
supernatant was removed carefully and the cell pellets were stored at -80 °C.  
 
2.2.2.4 Establishment of cell lines stably expressing NT5C1A  
A pSG5-vector (a kind gift of Prof. Johnsen, University Medical Center Göttingen) containing 
a hemagglutinin tag (HA-tag) upstream of a multiple cloning site (MCS), a P2A-sequence, 
and a hygromycin resistance gene (pSG5-HA-MCS-P2A-Hygro), was used. Derivatives of 
the pSG5-vector containing the coding sequence of murine NT5C1A and a control plasmid 
without the NT5C1A insert were generated following the protocol as described by Kari et al. 
(2016).  
The 1.1 kb coding region of Mus musculus 5'-nucleotidase, cytosolic IA (NM_001085502.1) 
was amplified from undiluted KPC-PDA cell cDNA (RNA extraction from cells was 
performed with the RNeasy® mini kit from Qiagen according to the manufacturer’s 
instructions) using Phusion High-Fidelity DNA Polymerase.  
Forward (mNt5c1a_Cl_NotI_For) and reverse primers (mNt5c1a_Cl_NheI_Rev) were 
dissolved in water to a working concentration of 5 pmol/µl. The PCR reaction mixture (50 µl, 
triplicates) is shown in Table 16 and the PCR thermoprofile in Table 17. The triplicate 
samples were pooled, mixed with an according amount of 6x DNA loading dye (10 mM 
TRIS-HCl pH 7.4, 0.2 % bromophenol blue indicator, 60 mM EDTA pH 8.0, 60 % glycerol, 
in water), and gel purified using a 1.4 % agarose gel (30 min. at 80 V and 30 min. at 125 V). 
The appropriate band was marked under UV-light at a wavelength of 312 nm, cut out, and 
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the weight of the gel part determined. The Nucleo Spin® gel and PCR clean-up kit was used 
according to the manufacturer’s instructions for purification. 200 µl of binding buffer were 
added per 100 mg of gel, which was then dissolved at 50 °C in a heating block (1300 rpm, 
15 min.). The purified product was eluted with 15 µl of elution buffer and DNA concentration 
was measured at a nanophotometer.   
 
Component Volume per tube 
Phusion DNA Polymerase 0.5 µl 
Undiluted cDNA 10 µl 
5x Phusion HF buffer 10 µl 
20 mM dNTPs 0.5 µl 
mNt5c1a_Cl_NotI_For 5 µl  
mNt5c1a_Cl_NheI_Rev 5 µl 
Water (Aqua B.Braun) 19 µl 
Table 16: Reaction mixture for cloning of NT5C1A-insert.  
 
Number of cycles Temperature (°C) Duration (min.) 
1 98  3 
2 98 72 0.5 4 
2 98 70 72 0.5 0.5 4 
2 98 68 72 0.5 0.5 4 
2 98 66 72 0.5 0.5 4 
2 98 64 72 0.5 0.5 4 
2 98 62 72 0.5 0.5 4 
28 98 60 72 0.5 0.5 4 
1 72 10 
1 4 Infinite hold 
Table 17: Thermoprofile for plasmid amplification.  
 
Restriction digestion was accomplished with appropriate fast digest enzymes for 15 min. at 
37 °C and 300 rpm with subsequent heat inactivation of enzymes for 5 min. at 65 °C and 
450 rpm. The pSG5-vector was incubated with NotI and SpeI and the NT5C1A-insert with 
NotI and NheI (SpeI and NheI create compatible sticky ends). The product was loaded on 
a 1.3 % agarose gel (20 min., 200 V), cut out and gel purified as described above. The 
vector-plasmid, the insert, and T4 DNA ligase were mixed with 10x buffer and water for 
ligation and incubated at 22 °C for 20 min. with slight agitation at 300 rpm. 
 
Material and Methods 
 
Page | 42  
 
For transformation, DH5α competent E.coli (100 µl) were added to the reaction tube and 
incubated 5 min. on ice with subsequent heat shock at 42 °C for 3 min. The mixture was 
given on ampicillin-containing LB-plates (the pSG5-vector contains an ampicillin resistance 
site) and incubated at 37 °C overnight. Four clones were picked and incubated in 
LB-medium with 100 µg/ml of ampicillin overnight (37 °C, 180 rpm). Plasmid DNA was 
extracted using the innuPREP plasmid mini kit plus according to the manufacturer’s protocol 
(40 µl elution buffer).    
The plasmids were mixed with water and the 5’-CCTACAGCTCCTGGGCAACG primer 
(2 µM, Sigma) and subsequently sent to SeqLab Göttingen for sequencing to check for the 
correct insert sequence. Correct plasmids were amplified using DH5α competent E.coli. 
Ampicillin (100 µg/ml) was added to overnight cultures in LB-medium (37 °C, 180 rpm) for 
selection. Plasmids were purified using the NucleBond® Xtra plasmid purification kit 
according to the manufacturer’s protocol (DNA reconstituted in 200 µl water). The plasmids 
were amplified, purified, and DNA concentrations determined.  
The control vector without NT5C1A-insert was incubated with SpeI and NheI to obtain 
compatible sticky ends (HindIII and BglII were added to the digestions to inactivate an 
ERT2-site, which was present in the original vector). T4 DNA ligase was added, incubated, 
and the product directly purified using the PCR clean up kit (1:3-dilution of binding buffer, 
30 µl elution volume). The control vector plasmid was amplified and sequenced as 
previously described.     
To achieve better transfection efficiency, the plasmids were linearized using AseI restriction 
enzyme with 20 µg of plasmid. The mixtures were incubated at 37 °C overnight under slight 
agitation with 300 rpm with subsequent phenol-chloroform purification. Here, 100 µl of water 
were added to 100 µl of the reaction mixture and an equal volume of phenol/ chloroform/ 
isoamylalcohol (25:24:1) was added. The mixtures were vortexed briefly and centrifuged at 
12000 rpm at room temperature for 5 min. The aqueous top phase was transferred into a 
new reaction tube and mixed with 8 M lithium chloride (1/10 of the volume). An equal volume 
of isopropanol was added, incubated for 5 min. at room temperature, and centrifuged for 
20 min. at 12000 rpm at 4 °C. The precipitates were washed in 200 µl 70 % ethanol, 
centrifuged again for 10 min. and subsequently EtOH was discarded, the pellets dried at 
room temperature, and dissolved in 20 µl water.   
The constructs were transfected into murine PSC and KPC cells and into human L3.6pl 
cells, as recently described by our group (Hessmann & Patzak et al., 2018). For this 
purpose, 6 μg of linearized plasmids and 20 µl of TurboFect transfection reagent were 
separately preincubated with each 625 µl OptiMEM medium for 5 min. Both components 
were mixed and further incubated for 20 min. at room temperature. Cells were washed using 
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PBS and 4 ml of DMEM, respectively MEM, without supplements were added per 10 cm-
dish. Cells were kept at 37 °C following dropwise addition of the transfection mixture.  
Medium was changed 8 h after transfection and penicillin-streptomycin was added to the 
medium for two days. The vector plasmid without the NT5C1A insert was utilized to obtain 
control cells.  
Successfully transfected cells were selected 48 h after transfection by treatment with 
hygromycin B Gold with the following concentrations: PSC1 and PSC2: 250 µg/ml, KPC1: 
500 µg/ml, KPC2: 900 µg/ml, and L3.6pl: 500 µg/ml. The most suitable concentrations to 
avoid growth of untransfected cells were determined in advance of the transfection 
procedure by incubation of untransfected cells with increasing hygromycin concentrations 
for one week. Only half of the mentioned concentrations were added to the culture media 
for maintenance, but hygromycin was not added during the performance of functional 
assays. Successful generation of stably transfected cell lines was confirmed by Western 
blot, immunocytochemistry, and qRT-PCR.  
 
2.2.2.5 Crystal violet cell proliferation assay 
Crystal violet staining was used according to standard procedures to determine cell viability 
(Feoktistova et al., 2016). Transfected cell lines were seeded at a density of 2000 cells 
(KPC, PSC cell lines) or 7500 cells (L3.6pl cell lines), respectively, in 24-well plates. Cells 
were allowed to attach for 24 h and were then treated with increasing concentrations of 
gemcitabine or paclitaxel, respectively. Treatment media were renewed every other day for 
a total treatment time of six days. Subsequently, cells were washed once with PBS, fixed 
with methanol for 15 min. at room temperature, and incubated with crystal violet solution 
(0.1 % in 20 % EtOH). Finally, excess staining solution was removed under tap water.   
Crystal violet staining intensity was determined using spectrophotometric analysis. 500 µl 
of 10 % acetic acid were added per well to dissolve the crystal violet stain. The plates were 
incubated for 20 min. under slight agitation. Samples were diluted with water and 
subsequently absorbance measured at 595 nm (Elangovan et al., 2008).  
 
2.2.2.6 Co-culture studies with conditioned medium 
As recently published (Hessmann & Patzak et al., 2018), 1*106 cells of primary murine 
fibroblasts were seeded per 10 cm dish, allowed to attach for 24 h, and then treated with 
30 nM of gemcitabine-hydrochloride or water for 24 h. Conditioned medium (CM) was 
collected and centrifuged at 1200 rpm for 3 min. Supernatants were then used in MTT cell 
viability assays. Confluency of CAFs was not less than 80 % at this stage. Conditioned 
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media of transfected PSC cells were prepared accordingly following treatment with 25 nM 
of gemcitabine-hydrochloride (confluency > 70 %).    
 
2.2.2.7 MTT cell viability assays 
KPC tumor cells were seeded at a density of 5000 cells per well in 96-well plates as 
technical triplicates and allowed to attach for 24 h.  
Previously prepared conditioned media were used for cell treatment. Regarding the CAF 
cells, the control-CM without gemcitabine was mixed with 30 nM fresh gemcitabine-
hydrochloride. For transfected PSCs, CM was used directly after centrifugation. The cells 
were cultured under this treatment for 72 h with subsequent performance of the MTT cell 
viability assay (Mosmann, 1983). In brief, MTT reagent (thiazolyl blue tetrazolium bromide) 
was added to the culture media to a final concentration of 0.5 mg/ml. Media were carefully 
removed following 2 h incubation at 37 °C. Precipitates were dissolved under gentle 
agitation for 15 min. in 100 μl of acidified isopropanol (80 ml 2-propanol, 10 ml 1 M 
hydrochloric acid, 10 ml TritonX®-100). Finally, absorption values were determined at 
595 nm without reference wavelength and cell viability is expressed relative to controls. 
 
2.2.2.8 Immunocytochemistry 
For immunocytochemistry (ICC) (Junqueira & Carneiro, 2005; Luttmann et al., 2014), the 
cells were seeded at a density of 5000 cells per well in chamber slides and allowed to attach 
overnight. The cells were washed once with PBS and fixed with ice cold methanol for 
20 min. at -20 °C, with subsequent three washing steps with PBS. Permeabilization was 
achieved by 30 sec. incubation at room temperature in a PBS-TritonX®-100 solution 
(0.1 %). Cells were washed four times with PBS and unspecific binding sites were blocked 
using 10 % goat serum in PBS for 1 h at room temperature and cells were then washed 
twice for 5 min. each. Primary antibody solution (200 µl) was added and incubated for 1 h 
at 37 °C and further at 4 °C overnight. Cells were washed again in PBS (2x) for 5 min. each. 
Alexa Fluor®-conjugated secondary antibodies were added to the cells for detection in a 
1:500-dilution in 10 % goat serum in PBS and incubated in the dark for 1 h at room 
temperature. Subsequently, cells were washed 3x 5 min. with PBS. The chambers were 
removed carefully from the slides and cells were mounted with DAPI-containing mounting 
solution (Vectashield®) and stored at 4 °C in the dark until analysis. Antibodies are listed in 




Material and Methods 
 
Page | 45  
 
2.2.3 Molecular biology techniques 
2.2.3.1 RNA extraction from cells  
The PeqLab Gold Total RNA kit was used according to the manufacturer’s instructions to 
extract RNA from cell samples. RNA was eluted from the provided columns using 40 µl of 
RNase-free water and RNA concentrations were determined.  
 
2.2.3.2 RNA extraction from tissue  
RNA extraction was achieved using the single step method (Mülhardt, 2013b). 1 ml of Trizol 
reagent was added per tissue piece and one stainless steel bead per tube to process the 
tissues using the Qiagen tissue lyser at a frequency of 30/sec. for 2 min. Chloroform (200 µl) 
was added to the samples, mixed, incubated 5 min. at room temperature, and subsequently 
centrifuged at 13500 rpm for 15 min. at 4 °C. The top phase was mixed with 500 µl of 
isopropanol, incubated 10 min. at room temperature, and centrifuged at the same 
conditions. The supernatants were discarded, the pellets washed with 75 % EtOH, and 
centrifuged (5 min., 13000 rpm, 4 °C). The supernatants were removed and the 
RNA-containing pellets were dissolved in 50 µl of water. RNA concentrations were 
determined at the INTAS nanophotometer.     
 
2.2.3.3 cDNA preparation  
RNA samples were diluted using RNase-free water to obtain 1 µg of RNA and incubated 
with recombinant RNasin® ribonuclease inhibitor (10 min, 65 °C). Samples were briefly 
centrifuged and cooled on ice before adding reverse transcription buffer (8 µl), poly(dT)15 
oligo primers (8 µl), 2 mM dNTP’s (8 µl), 0.1 M DTT (4 µl) and M-MLV reverse transcriptase 
(2 µl). Samples were mixed carefully, centrifuged briefly, and incubated for 1 h at 38 °C and 
subsequently for 10 min at 72 °C (Mülhardt, 2013b). Samples were put on ice and 120 µl of 
water were added to obtain the working concentration for qRT-PCR.  
Myoblast-mRNA (kindly provided by Prof. J. Schmidt, University Medical Center Göttingen) 
and murine muscle RNA served as positive controls for human and murine NT5C1A 
expression, respectively.  
 
2.2.3.4 qRT-PCR 
Quantitative PCR (Mülhardt, 2013a) was performed using TaqMan® probes. Universal PCR 
mastermix (5 µl/ sample), TaqMan® probes (0.5 µl/ sample), and water were mixed (3.5 µl/ 
sample) and added to the according wells of a 96-well PCR plate. 1 µl of cDNA was added 
to each well and technical duplicates of samples were analyzed. 1 µl of water was used for 
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negative control wells. The PCR plate was closed using appropriate cover foils and 
centrifuged briefly. The thermoprofile shown in Table 18 was run at an Applied Biosystems 
real-time PCR system with the StepOne software for analysis. A list of TaqMan® probes is 
provided in Table 12.  
 
Number of cycles Temperature Duration 
1 50 °C 2 min. 
1 95 °C 10 min.  
40 95 °C 15 sec. 
60 °C 1 min.  
Table 18: Thermoprofile for standard qRT-PCR.  
 
2.2.4 Protein biochemistry  
2.2.4.1 Protein isolation from cells 
Cultured cells were washed twice with PBS and 40 µl of lysis buffer were added per well to 
obtain whole cell lysates. Two wells of a 6-well plate were pooled for protein isolation. Cells 
were removed from the plates using cell scrapper, treated with three short sonication 
impulses, and incubated on ice for at least 20 min. Subsequently, lysates were centrifuged 
for 15 min (4 °C, 13500 rpm) and supernatants were stored at -80 °C.   
 
2.2.4.2 Protein isolation from tissue 
Dependent on the tissue size, 300-400 µl of protein lysis buffer were added to each tissue 
piece. Tissues were disrupted using stainless steel beads with the Qiagen Tissue lyser with 
a frequency of 30/sec. for 2 min. Lysates were immediately transferred back on ice and 
incubated for 30 min. Samples were centrifuged and supernatants kept at -80 °C.     
 
2.2.4.3 Bradford protein assay 
Protein concentration was determined with the Bradford method (Bradford, 1976; Rehm & 
Letzel, 2016) using bovine serum albumin (BSA) standards. Protein samples were diluted 
with water to be in the range of the standard curve. All samples were measured in duplicates 
on a clear 96-well plate with flat bottom. Samples were incubated with the Coomassie Blue 
G-250 Protein Assay Reagent for 5-10 min. and absorption was subsequently measured at 
the PHOMO plate reader at 595 nm.  
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2.2.4.4 Western blot analysis 
Common polyacrylamide gel electrophoresis was performed (Rehm & Letzel, 2016) using 
35 µg of protein. Lysates were prepared with 4x NuPAGE loading buffer and 
β-mercaptoethanol (to reduce the disulfide bonds of the proteins). Samples were denatured 
for 5 min. at 95 °C, cooled on ice, and centrifuged briefly. 
Western bolt (WB) analyses were done by loading the prepared protein samples on precast 
4-12 % Bis-Tris protein gels. Electrophoresis was conducted at 160 V for 1 h using 
NuPAGE™ MOPS SDS running buffer and proteins were subsequently transferred on 
0.45 µm nitrocellulose membranes (15 V, 90 min.) using NuPAGE™ transfer buffer with 
addition of 10 % methanol. Protein bands were visualized with Ponceau S solution and 
subsequently cut at appropriate positions. Membrane parts were then washed in PBS-T. 
Dependent on the primary antibodies’ recommendations and in-house testing, 5 % milk in 
PBS-T or 5 % BSA in TBS-T were used for blocking of unspecific binding sites (incubation 
for at least 1 h at room temperature on an orbital shaker). Membranes were incubated with 
primary antibody solutions overnight at 4 °C on an orbital shaker. Subsequently, 
membranes were washed with PBS-T or TBS-T (3x 10 min.), respectively, and incubated 
with horseradish peroxidase (HRP)-coupled secondary antibodies for 1 h at room 
temperature. Primary and secondary antibodies are listed in Table 9 and 10. Following 
another three washing steps, chemiluminescence substrate Plus-ECL or Ultra-ECL (for 
CC3-detection) were added to the membranes and protein bands were detected using the 
ChemiDoc™ XRS+ imaging system with Image Lab software. 3 µg of murine muscle lysate 
were loaded as positive control for NT5C1A expression.  
Quantification of Western blot analyses was performed using the rectangle volume tool of 
the Image Lab software. Each band was exactly marked by a rectangle form and 
background areas were marked as well. The values obtained for the volumes and the 
number of pixels per rectangle were utilized for further calculations. Values were normalized 
to the loading control.   
 
2.2.5 Tissue microarray analysis 
Images of the gemcitabine-metabolizing enzyme IHC-stainings were obtained from human 
TMAs from Oslo University Hospital, Norway (Hessmann & Patzak et al., 2018).  
TMAs for NT5C1A analysis were obtained from postoperative PDAC patients from the 
Department of Pathology, University Medical Center Göttingen (TMA-1, n = 77 patients) 
and the Department of Pathology, University Medical Center Erlangen (TMA-2, n = 337 
patients) in accordance with ethical requirements. Written consent from every patient was 
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received prior to tissue collection and analysis. Patient samples of the TMA-1 originate from 
patients of the University Medical Center Göttingen.  
TMA-2 PDAC tumor samples were collected in Dresden (Institute of Pathology, University 
Hospital Dresden), Regensburg (Institute of Pathology, University Hospital Regensburg) 
and Jena (Institute of Pathology, University Hospital Jena) from 1993 to 2015. 65 % of these 
patients did not undergo adjuvant chemotherapy, the remaining 35 % of patients were 
chiefly treated with 5-FU or gemcitabine-based regimens.  
Standard IHC protocols were followed to stain for NT5C1A with hematoxylin 
counterstaining. Citrate buffer pH 6.0, NT5C1A antibody (Assay Biotech, 1:100), and the 
Vectastain® ABC Rabbit Kit with ImmPACT DAB Peroxidase Substrate Kit were used for 
TMA-1 staining. Reagents for NT5C1A staining of TMA-2 were the Pro Taqs II Antigen 
Enhancer pH 9.5, NT5C1A antibody (Atlas Antibodies AB, 1:100) and the ImmPress 
Reagent Kit Anti-Rabbit IgG with AEC-Plus Substrate-Chromogen.  
The maximal NT5C1A expression was analyzed for each tumor sample by experienced 
pathologists from Göttingen and Erlangen. Mean values of replicate samples were used for 
data analysis and a semi-quantitative scoring system was applied, reaching from score 0 
(no expression) to score 3 (strong expression).  
 
2.2.6 Liquid chromatography tandem mass-spectrometry 
LC-MS/MS analysis of the gemcitabine metabolites dFdC, dFdU, and dFdCTP, and of 5-FU 
was performed as previously described (Hessmann & Patzak et al., 2018).  
For in vitro studies, cell culture supernatants and cell pellets that were exposed to 1 µM of 
gemcitabine-hydrochloride or 100 µM of 5-FU for 2 h were analyzed. Mouse tissue and 
blood samples that had been taken 2 h after administering the last dose of gemcitabine 
were used. Snap frozen tumor samples, frozen serum samples, as well as cell pellets and 
cell culture supernatants were processed and analyzed according to a published protocol 
(Bapiro et al., 2014; 2016).   
 
2.2.7 Statistical analysis 
Statistical analysis was performed using Graph Pad Prism (version 6.05 in chapter I and 
7.03 in chapter II). Data are presented as mean ± SEM. Statistical significance was 
considered for p < 0.05 with * p < 0.05, ** p < 0.01, and *** p < 0.001. If not stated otherwise 
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3. Results 
3.1 Intratumoral gemcitabine accumulation in murine PDAC 
results from fibroblast drug scavenging  
 
The content of this chapter is part of the following publication and the descriptions refer to 
this publication. Further citations are only included in this chapter for additional data and for 
the presented figures.  
 
Hessmann, E.*, Patzak, M.S.*, Klein, L., Chen, N., Kari, V., Ramu, I., Bapiro, T.E., 
Frese, K.K., Gopinathan, A., Richards, F.M., Jodrell, D.I., Verbeke, C., Li, X., Heuchel, R., 
Löhr, J.M., Johnsen, S.A., Gress, T.M., Ellenrieder, V., and Neesse, A. (2018). Fibroblast 
drug scavenging increases intratumoural gemcitabine accumulation in murine 
pancreas cancer. Gut, 67(3), 497-507. https://doi.org/10.1136/gutjnl-2016-311954  
(*Co-first authors) 1 
 
In this project, I was mainly involved in the conception and design of experiments, in the 
analysis of results and in the preparation of the figures, as well as in reviewing the 
manuscript. Furthermore, I performed cell culture experiments, including establishment, 
analysis, and treatment of NT5C1A overexpressing cell lines, Co-ICC, CM assays, and 
histology stainings (mouse samples were obtained from previous preclinical trials with KPC 
mice), (Figures 11 A, B, C; 13 murine tissues (NT5C1A, CDA, DCTD), 14 A, B, C, D; 32 of 
my thesis). Colleagues supported this project by performing ICC of fibroblasts, gemcitabine 
and 5-FU treatments for LC-MS/MS analysis, qRT-PCR of gemcitabine metabolizing 
enzymes, and IHC stainings of human tissues. LC-MS/MS measurements were carried out 
at the Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, 








1 https://gut.bmj.com/content/67/3/497; published as an Open Access article (Creative Commons 
Attribution license CC BY 4.0; https://creativecommons.org/licenses/by/4.0/) 
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3.1.1 Gemcitabine treatment and the tumor stroma in pancreatic cancer  
The pronounced TME and the hypovascular nature of pancreatic tumors were intensively 
discussed in recent literature to exert a biophysical treatment barrier and to impair drug 
delivery to the tumor (Jacobetz et al., 2013; Olive et al., 2009; Provenzano et al., 2012). 
However, several studies showed that stromal ablation is not the method of choice to 
improve treatment effectiveness as tumors became even more aggressive (Oezdemir et al., 
2014; Rhim et al., 2014).   
Initially, to elucidate the impact of the tumor stroma and its different components on 
gemcitabine drug delivery, metabolism, and thus treatment response, we performed 
LC-MS/MS analysis of gemcitabine metabolites in KPC mouse tissue. Our group 
re-analyzed KPC mouse tumor tissues from a previously published preclinical trial (Neesse 
et al., 2013) to study whether a correlation between intratumoral gemcitabine 
concentrations and overall survival could be described, as it would be expected in case of 
a biophysical treatment barrier. Interestingly, no correlation between the intratumoral 
concentration of the active, cytotoxic gemcitabine metabolite dFdCTP and overall survival 
could be shown in the ten analyzed mice (Hessmann & Patzak et al., 2018). Therefore, it 
was concluded that intratumoral dFdCTP concentrations in KPC bulk tumor tissue might not 
be a suitable marker for treatment response towards gemcitabine.  
 
3.1.2 Increased gemcitabine accumulation in primary KPC tumors 
compared with liver metastases and normal liver  
Consequently, we performed a detailed analysis of gemcitabine metabolites in KPC bulk 
tumor tissues, tissues from liver metastases, and well-perfused tissue from adjacent normal 
liver. It was already described that peak concentrations in the tumors are reached 2 h after 
i.p. injection (Neesse et al., 2013). Thus, KPC mice with detected tumors (Figure 6A and 
6B) had been dosed with 100 mg/kg gemcitabine intraperitoneally and sacrificed exactly 
2 h after injection. Using an established protocol for LC-MS/MS analysis of gemcitabine 
metabolites (Bapiro et al., 2014; 2016), the concentrations of native gemcitabine dFdC, the 
active metabolite dFdCTP, and the inactive metabolite of gemcitabine dFdU were 
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Figure 6: The KPC mouse model. A) Macroscopic view of a tumor-bearing KPC mouse at necropsy. 
The tumor in the pancreas is marked by the dotted blue circle and liver metastases are indicated by 
orange arrows. Adapted from (Hessmann & Patzak et al., 2018). B) Microscopic H&E images of a 
KPC mouse pancreatic tumor with matched liver metastasis (LM) and normal liver (NL). Scale bars 
50 µm. Own illustration, based on (Hessmann & Patzak et al., 2018).  
 
Surprisingly, the highest concentrations of gemcitabine prodrug were found in the primary 
tumor tissues and were significantly higher than in liver metastases (8.1 ng/mg vs. 
4.6 ng/mg; p = 0.04) and normal liver tissue (8.1 ng/mg vs. 4.0 ng/mg; p = 0.01). 
Concentrations in the liver metastases and in normal liver tissue were comparable 
(Figure 7A). Significant differences in the concentrations of the inactive gemcitabine 
metabolite between the three tissue types were not found (Figure 7B). The difference in 
the mean concentrations of the active metabolite dFdCTP between primary tumor tissues 
and liver metastases was also not significant (4.5 ng/mg vs. 2.3 ng/mg; ns). Yet, 
significantly elevated dFdCTP concentrations were found in the primary tumor samples 





Legend to Figure 7:  
Pharmacokinetic distribution of gemcitabine metabolites in murine pancreatic cancer tissue. 
Pharmacokinetic profile of gemcitabine metabolites in KPC bulk tumor tissue, corresponding liver 
metastases, and normal liver samples. KPC mice with confirmed tumor growth were intraperitoneally 
treated with one dose of gemcitabine for 2 h with 100 mg/kg body weight. Tissue samples were 
subsequently processed using LC-MS/MS to analyze the main gemcitabine metabolites. A) The 
concentration of native gemcitabine (dFdC) was significantly elevated in primary pancreatic tumor 
tissue compared to liver metastases (p = 0.04) and normal liver tissue (p = 0.01) (n = 15). B) No 
differences between the three groups were observed for the inactive metabolite dFdU (n = 15). C) 
Significantly higher concentrations of the active triphosphorylated gemcitabine metabolite dFdCTP 
were found in the primary tumor samples when compared to normal liver samples (p = 0.002) 
(n = 15). Mann-Whitney test was performed for all three metabolites. Graphs show mean ± SEM. 
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Figure 7: Pharmacokinetic distribution of gemcitabine metabolites in murine pancreatic 
cancer tissue. For legend, see bottom of previous page.  
 
3.1.3 Higher stromal content in primary pancreatic tumors than in liver 
metastases 
The finding that gemcitabine accumulates in the primary tumors was unexpected and in 
contrast to the hypothesis of a biophysical treatment barrier. Therefore, we hypothesized 
that either the stromal composition or the vascularization might be the reason for the 
significantly higher gemcitabine concentrations in the primary bulk tumor tissue.  
For this purpose, our group determined the differences between the analyzed tissue types. 
IHC stainings for the fibroblast marker α-SMA, collagen, and SPARC clearly indicated 
reduced desmoplasia, especially lower fibroblast density, in matched liver metastases 
compared to primary tumor tissues (Hessmann & Patzak et al., 2018). As expected, very 
low amounts of activated fibroblasts and ECM components were present in normal liver 
tissue (Hessmann & Patzak et al., 2018). Moreover, mean vessel density did not differ 

























































































Primary tumor n = 15
Liver metastases n = 15
Normal liver n = 15
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3.1.4 Fibroblast drug scavenging increases intratumoral gemcitabine 
accumulation  
3.1.4.1 CAFs and PSCs accumulate significant amounts of gemcitabine 
in vitro  
The results regarding stromal content of primary tumor tissue and matched liver metastases 
suggested that the tumor stroma rather promotes gemcitabine accumulation in bulk tumor 
tissue than to impair drug delivery. Consequently, we hypothesized that the cellular 
components of the TME might be actively involved in drug accumulation. In order to 
understand the impact of the tumor stroma and the underlying mechanisms for gemcitabine 
ineffectiveness in pancreatic cancer, we determined gemcitabine metabolites in different 
cell types. We used four primary cell lines from pancreatic tumors (n = 4) and four cell lines 
from metastatic foci (n = 4) from KPC mice. Furthermore, primary CAF lines (n = 2) from 
primary pancreatic tumors and immortalized PSCs (n = 2) from healthy C57BL/6 mice were 
used for the study and will be referred to as “fibroblasts” in the following analyses. All 
fibroblast cell lines showed typical spindle-like morphology along with strong expression of 
α-SMA (Figure 8A), as well as fibronectin and SPARC (Hessmann & Patzak et al., 2018). 
Moreover, the concentrations of intracellular dFdCTP were comparable between CAFs and 
PSCs (Figure 8B).  
 
Figure 8: Characterization of CAFs and PSCs. A) Typical morphology of CAFs demonstrated by 
α-SMA ICC (α-SMA: green, DAPI nuclear staining: blue). B) LC-MS/MS analysis of cytotoxic dFdCTP 
in CAFs (n = 2) and PSCs (n = 2). Intracellular concentrations did not differ significantly. Graph 
shows mean ± SEM of two different cell lines. Concentrations were determined from technical 
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To determine the pharmacokinetic profile of gemcitabine metabolites in the three different 
cell types, we treated the cells with 1 µM gemcitabine-hydrochloride for 2 h and harvested 
cell pellets as well as cell culture supernatants. Samples were subsequently subjected to 
LC-MS/MS analysis. Tumor cell lines derived from primary pancreatic tumors or from 
metastatic foci did not show significant differences in dFdCTP concentrations (Figure 9A). 
Yet strikingly, the dFdCTP concentrations in fibroblasts were significantly elevated 
compared to neoplastic cells (three- to fivefold increase, both p = 0.03, n = 4) (Figure 9A). 
Following the standardized treatment, intracellular native gemcitabine and dFdU 
concentrations were below the level of quantification in all tested cell lines. However, 
concentrations of inactive dFdU in the supernatants from cultured fibroblasts were reduced 
by factor five compared to neoplastic cells (Figure 9B) (2.6 ng/ml vs. 12 ng/ml for primary 
tumor cells and 13.4 ng/ml for metastatic tumor cells; both p = 0.03, n = 4). Excess amounts 
of native dFdC were measured in cell culture supernatants of all cell types (each cell type 
n = 4), with all concentrations being above 570 nM (150 ng/ml) (Figure 9C). Therefore, the 
initial dFdC concentration was unlikely to be the limiting factor for gemcitabine uptake and 
activation.      
 
Moreover, our group demonstrated that the accumulation of gemcitabine in stromal cells is 
not a general effect of chemotherapeutic drugs in pancreatic cancer. The three different cell 
types were treated, as described for gemcitabine, with 100 µM 5-FU, another antinucleoside 
chemotherapeutic drug. A higher concentration of 5-FU was required to reach detectable 
intracellular drug levels. The intracellular concentration of 5-FU was lowest in fibroblasts 
and did not differ significantly between neoplastic cell lines and fibroblasts (p = 0.06) 
(Figure 10A). Additionally, no differences were found in 5-FU concentrations in cell culture 
supernatants of all three cell types (Figure 10B). We therefore concluded that not the drug 
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Figure 9: Accumulation and decreased inactivation of gemcitabine in CAFs. A)-C) 
Pharmacokinetic profile of gemcitabine metabolites in primary murine pancreatic tumor cells, tumor 
cells from metastatic foci, and fibroblasts. Cells were treated with 1 µM of gemcitabine-hydrochloride 
for 2 h. Cell pellet homogenates and cell culture supernatants were subsequently subjected to 
LC-MS/MS analysis. A) The activated gemcitabine metabolite dFdCTP was found in significantly 
increased concentrations in fibroblasts (CAFs: n = 2, PSCs: n = 2) compared to tumor cells derived 
from the primary tumors and from metastatic foci (both p = 0.03). B) Compared with tumor cells and 
cells from metastatic foci, the inactivated metabolite dFdU was significantly reduced in cell culture 
supernatants from fibroblasts (both p = 0.03). C) No differences were observed between primary 
tumor cells, tumor cells from metastases, and fibroblasts regarding native gemcitabine 
concentrations in cell culture supernatants. All statistics were performed using the Mann-Whitney 
test with n = 4 for the three different cell categories (technical triplicates per cell line). Graphs show 
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Figure 10: Pharmacokinetic analysis of 5-FU. A) LC-MS/MS analysis of intracellular 5-FU 
concentrations in tumor cell lines derived from primary KPC tumors and from metastatic sites and in 
fibroblasts. Cells were treated with 100 µM 5-FU (13000 ng/ml) for 2 h. Lowest concentrations were 
found in fibroblasts. No significant differences were observed between the cell types (primary tumor 
cells vs. fibroblasts: p = 0.06, Mann-Whitney test). Concentrations were below the limit of 
quantification in two metastatic tumor cell lines and in three of the fibroblast cell lines. Thus, 
0.4 ng/106 cells as the limit of quantification were used for statistics. B) 5-FU concentrations in cell 
culture supernatants analyzed from the same cell lines. No difference of statistical significance was 
observed between the cell lines. Graphs show mean ± SEM of four cell lines per cell type and three 
technical replicates per sample. Adapted from (Hessmann & Patzak et al., 2018). 
 
Following intracellular phosphorylation of dFdC to dFdCTP, the active gemcitabine 
metabolite is unable to pass the cell membrane and is thus entrapped in fibroblasts. 
Entrapped dFdCTP could be unavailable for tumor cell treatment. Therefore, I addressed 
the question whether this effect could reduce the therapeutic response by performing 
conditioned medium assays. Two KPC tumor cell lines were treated for 72 h with CM of two 
CAF cell lines that were pretreated for 24 h with therapeutically relevant doses of 
gemcitabine (approximate GI50 concentration of tumor cell lines) (Figure 11A). Indeed, the 
viability of tumor cells significantly increased by 41 % to 82 % compared to treatment with 
CM with fresh gemcitabine, suggesting a drug scavenging effect of CAFs in vitro 
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Figure 11: Fibroblasts increase murine pancreatic tumor cell survival in vitro by scavenging 
gemcitabine. A) Schematic illustration of the conditioned medium assay. Murine CAFs were 
pre-incubated for 24 h with 30 nM of gemcitabine-hydrochloride to produce CM (upper panel). 
Control medium was taken from CAFs that were cultured for 24 h without gemcitabine and 30 nM 
gemcitabine were added prior to tumor cell treatment (lower panel). B) and C) 72 h MTT cell viability 
assay of two murine tumor cell lines treated with CM of CAFs. KPC1 tumor cells showed 41 % to 
50 % increase in viability after treatment with CM of CAF1 or CAF2, respectively (GI50: 32 nM) (B). 
Cell viability was significantly increased (65 % to 82 %) in the KPC2 tumor cell line following 
treatment with CM of CAF1 and CAF2 cells (GI50: 25 nM) (C). Statistical results are KPC1-CAF1: 
p = 0.002; KPC1-CAF2: p = 0.04; KPC2-CAF1: p = 0.006; KPC2-CAF2: p = 0.03. Graphs show 
mean ± SEM of three biological replicates. Figures 11B and 11C adapted from (Hessmann & Patzak 
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3.1.4.2 Low expression of gemcitabine-inactivating genes in stromal cells 
in vitro and in vivo 
Many different enzymes and specific transporters are involved in gemcitabine activation 
and inactivation (Figure 5). The reduction of dFdU levels in supernatants of fibroblasts 
indicate that less inactivation occurs in these cells compared to tumor cells. Moreover, the 
elevated amounts of cytotoxic dFdCTP in fibroblast cell pellets point towards increased 
gemcitabine activation. To understand the molecular basis behind the drug scavenging of 
CAFs, we assessed the mRNA expression profile of different gemcitabine-metabolizing 
genes in primary tumor cells, metastatic tumor cells, and fibroblasts (Hessmann & Patzak 
et al., 2018). Interestingly, the NT5C1A and cytosolic 5’-nucleotidase 3 (NT5C3) genes were 
significantly downregulated in CAFs and PSCs compared to neoplastic cell lines 
(Figure 12A and 12B). NT5C genes code for cytosolic 5’-nucleotidases that reverse the 
initial phosphorylation step of nucleotides (Bianchi & Spychala, 2003). Accordingly, the low 
expression of these enzymes would increase the pool of dFdCMP in fibroblasts, finally 
resulting in elevated amounts of dFdCTP in these cells. The mRNA expression of the main 
activating kinase dCK did not differ significantly between the cell types (Figure 12C).  
To determine the expression levels in vivo, archived KPC mouse tissue (Figure 13, upper 
panel) and tissue from pancreatic cancer patients (Figure 13, lower panel) were examined 
immunohistochemically. KPC mice had been screened for tumors by small animal high-
resolution ultrasound and were subsequently enrolled in a survival study. Gemcitabine had 
been administered at 100 mg/kg 3-4 times per week until endpoint (Hessmann & Patzak et 
al., 2018). IHC revealed strong protein expression of NT5C1A in epithelial cells, yet, very 
low expression in the stromal compartment (Figure 13), which is in line with the prior mRNA 
analysis of tumor cells and fibroblasts. Further gemcitabine-inactivating enzymes like CDA 
and DCTD were not differentially expressed on mRNA level (Hessmann & Patzak et al., 
2018), however, strong protein expression was found in KPC mice and human pancreatic 
cancer tissues. The TME was mainly devoid of immunoreactivity for both enzymes 
(Figure 13). Markedly, the main activating kinase dCK was expressed at comparable levels 
in the neoplastic and the stromal compartment of KPC mice and in tumors of pancreatic 
cancer patients (Figure 13).  
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Figure 12: Low expression of gemcitabine-inactivating genes in stromal cells in vitro. RNA 
was isolated from murine CAFs (n = 2) and PSCs (n = 2), as well as from primary KPC tumor cells 
(n = 4) and cells from metastatic foci (n = 4). Quantitative RT-PCR revealed that the gemcitabine-
inactivating genes NT5C1A (A, both p = 0.03) and NT5C3 (B, both p = 0.03) were significantly 
downregulated in fibroblasts compared to tumor cells. Differences in gene expression for the main 
activating kinase dCK between tumor cells, cells from metastatic foci, and fibroblasts were not 
significant (C). Mann-Whitney test was performed. The median is shown with the minimum and 
maximum values. Four cell lines per cell type with each two technical replicates were analyzed. 
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Figure 13: Gemcitabine-inactivating enzymes are hardly expressed in the pancreatic cancer 
stroma. Representative IHC images from gemcitabine-treated tumor bearing KPC mice and from 
human pancreatic cancer tissues demonstrate robust NT5C1A, CDA, and DCTD expression in the 
tumor cells. Stromal cells are mainly devoid of immunoreactivity. dCK is robustly expressed in tumor 
and stromal cells. Scale bars 50 µm. Figure adapted from (Hessmann & Patzak et al., 2018). 
 
3.1.4.3 CAFs are intrinsically resistant to gemcitabine treatment  
It was shown that CAFs scavenge gemcitabine, which is then not available anymore for 
tumor cells. To address the question whether altered gemcitabine metabolism in these cells 
might result in increased sensitivity of fibroblasts towards gemcitabine treatment, I carefully 
analyzed proliferation and apoptosis rates in α-SMA-positive fibroblasts. Archived tissue 
from gemcitabine-treated KPC mice from a previous preclinical trial was used. These mice 
had been treated intraperitoneally with gemcitabine (n = 6) or vehicle (n = 6) for 9 days 
(Neesse et al., 2013). A proliferation rate of 2 % to 5 % was demonstrated in α-SMA-positive 
cells in control KPC tumors using Co-ICC. Gemcitabine treatment did not significantly 
change the proliferation rate (Figure 14A and 14B). Additionally, Co-IHC for CC3, 
indicating apoptotic cells, and for α-SMA revealed a low number of double-positive cells in 
vehicle- and gemcitabine-treated KPC mice without significant differences between both 
groups (Figure 14C and 14D). These findings point towards intrinsic resistance of CAFs to 
treatment with gemcitabine. It is quite likely that the low proliferation rate of fibroblasts 
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Figure 14: CAFs are intrinsically resistant to gemcitabine treatment. Archived tissues from 
tumor-bearing KPC mice were evaluated retrospectively for proliferating and apoptotic fibroblasts. 
Mice had been treated with gemcitabine (100 mg/kg) or control every 3-4 days for a total treatment 
period of 9 days. The last dose had been administered 2 h prior to sacrifice. A) and B) Co-IF for 
α-SMA (green) and Ki67 (red; DAPI: blue) did not show significant differences in the proliferation rate 
in α-SMA-positive cells (p = 0.5, n = 6). Scale bar 50 µm. C) and D) Co-IHC for α-SMA (green) and 
CC3 (brown) did not reveal significantly different percentages of apoptotic fibroblasts in gemcitabine-
treated KPC tissues compared to control tissues (p = 0.2, n = 6). Scale bar 50 µm, arrow indicates 
apoptotic fibroblast. Image J software was used for manual cell counting. Adapted from (Hessmann 
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3.2 Cytosolic 5‘-nucleotidase 1A is overexpressed in pancreatic 
cancer and mediates gemcitabine resistance by reducing 
intracellular gemcitabine metabolites 
 
The content of this chapter is included in a manuscript, which was in revision at the time of 
thesis submission. The title, results, and figures of this chapter were directly taken from this 
manuscript with minor adaptions, mainly to the figure legends. Additionally, section 3.2.6, 
Figure 32, and Figure 37 are shown in this chapter of my thesis.  
 
Patzak, M.S., Kari, V., Patil, S., Hamdan, F.H., Goetze, R.G., Brunner, M., Gaedcke, J., 
Kitz, J., Jodrell, D.I., Richards, F.M., Pilarsky, C., Gruetzmann, R., Rümmele, P., Knösel, T., 
Hessmann, E., Ellenrieder, V., Johnsen, S.A., and Neesse, A. Cytosolic 
5‘-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine 
resistance by reducing intracellular gemcitabine metabolites. (in revision at the time of 
thesis submission); please refer to page 123 for the citation of the accepted manuscript. 
 
For this manuscript, I chiefly conceived and designed the experiments, performed data 
analysis, assembled the data and wrote the manuscript. Moreover, I designed and 
performed cell culture and animal experiments and did histology stainings (Figures 15A, C; 
17B; 18A, B; 19A, B, C, D; 20A, B, C; 21A, B; 22A, B; 23A, B; 24A, B; 25A, B; 26A, B, C; 
28A, B, C, D; 29A, B; 30; 31A, B; 33; 34; 35; 36A, B; 37; 38; 39; 40 of my thesis). Orthotopic 
transplantations, intraperitoneal injections of mice, staining of the Erlangen TMA cohort, 
scoring of TMA slides, collection of clinical data, and LC-MS/MS measurements were 
performed by lab colleagues and collaborators.  
 
 
3.2.1 NT5C1A is strongly expressed in murine and human PDAC and is 
not associated with overall survival 
Comprehensive expression data of NT5C1A in PDAC are not available so far. To address 
this question, we employed two independent TMAs of resected PDAC specimens. A 
semi-quantitative scoring system ranging between score 0 (no expression) to score 3 
(strong expression) was utilized. A relevant subgroup of patients expressed NT5C1A at high 
levels (score 2 and 3). 56 % of all patients showed moderate expression (score 2) of 
NT5C1A in the epithelial compartment of the tumors and 8 % expressed NT5C1A at high 
levels (score 3) in TMA-1 with 77 samples (Figure 15A).  
Results – Chapter II 
 
Page | 63  
 
A larger TMA dataset with 337 samples confirmed these findings with 44 % scored with 2, 
and 26 % of all patient samples had score 3 (Figure 15B). Furthermore, only 13.0 % 
(TMA-1) and 4.5 % (TMA-2) of all tumors did not show immunoreactivity against NT5C1A 
(Figure 15A-C). 
  
Figure 15: Expression of NT5C1A in resected PDAC patients. Tissue microarrays from A) 
Göttingen (TMA-1, n = 77) and B) Erlangen (TMA-2, n = 337). Score 0 = no NT5C1A expression, 
score 3 indicates strong intratumoral expression of NT5C1A. C) Representative images of TMA-1 for 
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Tumor score 2 Tumor score 3 
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Interestingly, NT5C1A expression did not correlate with overall survival in either TMA, 
comparing low NT5C1A expression (score 0 and 1) with high expression levels of NT5C1A 
(score 2 and 3). Median survival was 18.5 vs. 15 months in TMA-1 (p = 0.5), and 17 vs. 
16.4 months in TMA-2 (p = 0.3) (Figure 16A and 16B). Moreover, KPC pancreatic tumors 
were analyzed for NT5C1A expression and robust expression could be confirmed by IHC 
staining in the majority of samples, and was already present in early stages of pancreatic 
cancer (Figure 17A). The expression was confirmed by qRT-PCR to determine mRNA 
levels for NT5C1A in KPC bulk tissue. As expected, no expression was found in healthy 
control pancreata (Figure 17B).  
 
Figure 16: NT5C1A is not prognostic for the survival of PDAC patients. A) and B) Survival 
analysis of patients from the Göttingen TMA cohort (A) and the Erlangen TMA cohort (B). Median 
survival of TMA-1 with low NT5C1A expression = 18.5 months (n = 27) and high NT5C1A expression 
= 15 months (n = 38; p = 0.5, log-rank test) and of TMA-2 with low NT5C1A expression = 17 months 
(n = 101) and high NT5C1A expression = 16.4 months (n = 235; p = 0.3, log-rank test). Low 
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Figure 17: Expression of NT5C1A in the KPC mouse model. A) Representative images of 
NT5C1A-IHC in KPC mice with PanINs (left image) and invasive carcinoma (right image). Scale bars 
20 µm. B) NT5C1A-mRNA expression in KPC bulk tissue (n = 3 mice) and control normal pancreas 
(n = 2 mice). Mean ± SEM of two technical replicates is shown for each mouse. Murine muscle was 
used as positive control and values were normalized to the housekeeping gene β-actin.   
 
3.2.2 NT5C1A expression in murine and human PDAC cell lines  
In analogy to our published data about gemcitabine drug scavenging of stromal cells 
(Hessmann & Patzak et al., 2018), we hypothesized that high levels of NT5C1A within the 
tumor cells might be involved in chemoresistance in PDAC, in particular gemcitabine 
resistance. To this end, NT5C1A may affect gemcitabine metabolism by reversing the initial 
phosphorylation step of dFdC to dFdCMP, resulting in decreased levels of cytotoxic 
dFdCTP. To test this hypothesis, NT5C1A expression was investigated in murine and 
human pancreatic cancer cell lines. Interestingly, murine and human pancreatic cancer cells 
revealed only low levels of NT5C1A expression in vitro compared to robust expression 
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Figure 18: Reduced expression of NT5C1A in murine and human pancreatic cancer cell lines 
in vitro. A) Western blot analysis showing protein expression of untransfected KPC1 and KPC2 cells, 
as well as of human L3.6pl cells. HSP90 was used as loading control and murine muscle as positive 
control. B) mRNA-expression of NT5C1A in KPC1, KPC2, and L3.6pl cells. Values were normalized 
to the housekeeping gene β-actin. Murine muscle extract and human myoblasts were added as 
positive controls for NT5C1A-expression. 
 
Therefore, NT5C1A was stably expressed in murine KPC cell lines (KPC1 and KPC2 
= KPC-BL6) and in the human L3.6pl cell line. Stable cell lines were established using a 
pSG5-vector derivative with subsequent hygromycin selection. NT5C1A expression in 
stable cell lines was validated by Western blot analysis, ICC, and qRT-PCR analysis 
(Figure 19A-D). NT5C1A and the integrated HA-tag were robustly expressed in transfected 
cells. Control cells that were transfected with an empty vector, were shown to express 
endogenous NT5C1A at low levels and did not show HA-tag expression by ICC 
(Figure 19A and 19B). Additionally, qRT-PCR analysis was employed to confirm mRNA 
expression of NT5C1A, and Western blot analysis was used to determine NT5C1A protein 
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Figure 19: Recombinant expression of NT5C1A in human and murine pancreatic cancer cell 
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Legend to Figure 19:  
Recombinant expression of NT5C1A in human and murine pancreatic cancer cell lines. A) and 
B) Representative images of two biological replicates of ICC staining for NT5C1A and HA-tag. 
Robust staining is shown for HA-tag (A, lower panel) and NT5C1A (B, lower panel) in transfected 
KPC-BL6 (= KPC2) cells. No staining of HA-tag (A, upper panel) and low endogenous NT5C1A 
expression (B, upper panel) were detected in vector control cells (n = 2), scale bars 50 µm. C) 
Quantitative RT-PCR analysis confirmed overexpression of NT5C1A in transfected cells. Diagram 
indicates mean ± SEM of three biological replicates. Murine muscle sample was used as positive 
control and values were normalized to the housekeeping gene β-actin. D) Western blot analysis 
confirmed NT5C1A protein expression in transfected tumor cells with hardly any expression in vector 
control cells. Robust expression of HA-tag is shown in all +NT5C1A cell lines. Representative image 




3.2.3 Pharmacokinetics of gemcitabine upon recombinant NT5C1A 
expression 
NT5C1A dephosphorylates gemcitabine monophosphate (dFdCMP) to the prodrug dFdC, 
thus potentially limiting the cytotoxicity of gemcitabine by increasing the pool of dFdC and 
decreasing the amount of cytotoxic dFdCTP. To test the implication of NT5C1A on 
gemcitabine metabolism in pancreatic cancer, we analyzed gemcitabine metabolites in cell 
pellets upon gemcitabine treatment using LC-MS/MS. The concentrations of the native form 
of gemcitabine dFdC as well as the triphosphate, the active metabolite of gemcitabine 
(dFdCTP), were measured using a previously established protocol (Bapiro et al., 2014; 
2016). Following NT5C1A overexpression in the murine KPC-BL6 cell line, upon 2 h of 
gemcitabine treatment, the dFdCTP concentration was significantly reduced compared to 
control cells (27.3 vs. 9.4 pM per 1*106 cells, p = 0.0008) (Figure 20A). Equivalent results 
were seen for the human L3.6pl cell line (67.3 vs. 30.8 pM per 1*106 cells, p = 0.021) 
(Figure 20B). Interestingly, intracellular dFdC levels were only detectable in the NT5C1A-
overexpressing KPC-BL6 cells, all values in the vector control cells were below the limit of 
quantification (Figure 20C). Thus, our findings suggest a significant contribution of NT5C1A 
towards the availability of active gemcitabine metabolites in PDAC, and possibly 
gemcitabine resistance. 
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Figure 20: NT5C1A overexpression decreases dFdCTP accumulation in pancreatic cancer cell 
lines. A) Pharmacokinetic analysis of gemcitabine metabolites in murine PDAC cells. Murine 
KPC-BL6 cells (A) and human L3.6pl cells (B) (+NT5C1A) and respective control cells (+vector) were 
simultaneously treated with 1 µM gemcitabine-hydrochloride for 2 h. The concentration of the active 
gemcitabine metabolite dFdCTP (KPC-BL6: 27.3 vs. 9.4 pM per 1*106 cells, p = 0.0008 and L3.6pl: 
67.3 vs. 30.8 pM per 1*106 cells, p = 0.021) and of native gemcitabine dFdC (C) were determined in 
homogenates of cell pellets using LC-MS/MS-analysis. Three biological replicates and the mean 
value are shown. Each dot represents the mean of three (KPC-BL6) or two (L3.6pl) technical 
replicates, respectively. All dFdC measurements of KPC-BL6 control cells were below the level of 
quantification, thus the values were set to zero. 
 
3.2.4 NT5C1A overexpression confers chemotherapeutic resistance 
towards gemcitabine in vitro  
We showed that NT5C1A decreases the concentration of dFdCTP in vitro, and thus, 
hypothesized that NT5C1A may be an important candidate in mediating gemcitabine 
resistance. Using crystal violet cytotoxicity assays for two murine KPC cell lines as well as 
the human L3.6pl pancreatic cancer cell line, we found that NT5C1A expression reverts 
chemosensitivity in a concentration-dependent manner in all cell lines (Figure 21A and 
21B, Figure 22A and 22B). In contrast, all cell lines were still sensitive to treatment with 
paclitaxel, which is another important chemotherapeutic agent for the treatment of 
pancreatic cancer patients (Figure 23A and 23B). 
C 
A B 
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Figure 21: High levels of NT5C1A increase chemotherapeutic resistance towards gemcitabine 
in pancreatic cancer cells. A) Murine and human pancreatic cancer cell lines were incubated with 
different concentrations of gemcitabine for six days. Crystal violet staining was more pronounced in 
cell lines with high NT5C1A expression. Three independent experiments, with each two technical 
replicates, were performed for all cell lines shown. B) Quantification of crystal violet assays for KPC1 
cells using 10 % acetic acid to solubilize crystal violet stain and photometric measurements at 
595 nm. Results were normalized to untreated control cells. Two-way ANOVA with Sidak’s multiple 
comparisons test was performed (12 nM: p = 0.0007, 20 nM: p < 0.0001). Graph shows mean 
± SEM.   
Figure 22: High levels of NT5C1A reduce chemotherapeutic response to gemcitabine in 
pancreatic cancer cells. A) and B) Crystal violet assay of murine KPC-BL6 cells and human L3.6pl 
cells. Crystal violet staining was performed following six days of gemcitabine treatment. Crystal violet 
staining intensity was more pronounced in NT5C1A overexpressing cell lines. Three independent 
experiments were performed, with each two technical replicates. Quantification of crystal violet assay 
was performed and results were normalized to untreated control cells. Graphs present mean ± SEM, 
two-way ANOVA with Sidak’s multiple comparisons test was performed (KPC-BL6: 7 nM: p < 0.0001, 
12 nM: p < 0.0001, 20 nM: p = 0.007; L3.6pl: 3 nM: p < 0.0001, 5 nM: p < 0.0001, 7 nM: p = 0.015). 
A B 
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Figure 23: Pancreatic cancer cell lines expressing high levels of NT5C1A are still sensitive to 
paclitaxel treatment. A) Crystal violet assay was performed with murine KPC cells and human 
L3.6pl cells that have been treated with increasing concentrations of paclitaxel for six days. The 
staining intensity was comparable between control cells and cells overexpressing NT5C1A. Two 
independent experiments were performed, with each two technical replicates. B) Quantification of 
crystal violet assay was performed. Diagram shows the quantification of murine KPC-BL6 cells. The 
results were normalized to untreated control cells. Graph presents mean ± SEM, two-way ANOVA 
with Sidak’s multiple comparisons test was performed (ns).  
 
To confirm and further clarify the involvement of NT5C1A in gemcitabine resistance, we 
performed Western blot analysis for CC3 protein levels upon gemcitabine treatment. 
Gemcitabine-induced CC3-levels were reduced by factor 4 following recombinant NT5C1A 
expression in KPC1 cells (Figure 24A and 24B). Similar results were obtained for the 
KPC-BL6 cell line (factor 2, Figure 25A and 25B). These results confirmed the impact of 
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Figure 24: Reduced apoptosis in murine pancreatic cancer cells overexpressing NT5C1A. A) 
Western blot analysis revealed reduced CC3 protein levels in NT5C1A-expressing cells following 
gemcitabine treatment for 24 h. Strong NT5C1A and HA-tag expression was demonstrated in the 
+NT5C1A-cell line. Three independent experiments were performed. B) Quantification of CC3 
protein expression in these three Western blot analyses. Two-way ANOVA with Sidak’s multiple 
comparisons test was performed (30 nM: p = 0.249, 50 nM: p = 0.002). Graph shows mean ± SEM.  
 
Figure 25: NT5C1A overexpression decreases CC3-levels in vitro. A) Western blot analysis of 
murine KPC-BL6 cells showed reduced protein levels of CC3 in NT5C1A-expressing cells following 
gemcitabine treatment for 24 h. NT5C1A and HA-tag expressions were confirmed in the 
+NT5C1A-cell line. Three independent experiments were performed. HSP90 was used as loading 
control and murine muscle as positive control for NT5C1A. B) Quantification of CC3 protein 
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3.2.5 NT5C1A expression and function in the tumor stroma  
With the objective to obtain a more comprehensive picture of the clinical situation regarding 
NT5C1A, we analyzed both TMAs for stromal NT5C1A expression. The same scoring 
system was employed with score 0 indicating no stromal expression of NT5C1A and score 3 
indicating strong expression of NT5C1A. The proportion of PDAC patients without stromal 
NT5C1A expression was between 87.7 % in TMA-1 (n = 77) and 47.3 % in TMA-2 
(n = 330). Low expression was detected in 11.0 % (TMA-1) and 33.3 % (TMA-2) of these 
patients. Interestingly, high scores (2 and 3) of stromal NT5C1A was only given to the 
samples of 1.4 % (TMA-1) or 19.4 % (TMA-2) of all patients (Figure 26A-C).   
 
 
Figure 26: NT5C1A expression and function in PDAC stroma in vivo. A) and B) TMA analysis 
for NT5C1A expression revealed very low expression in the tumor stroma of resected PDAC patients. 
A semi-quantitative scoring system indicated no stromal expression with score 0 and strong stromal 
expression with score 3. TMA-1 from Göttingen (A) with n = 77 patients (none scored with 3) and 
TMA-2 from Erlangen (B) with n = 330 patient samples. C) Representative IHC of NT5C1A 
expression showing no NT5C1A expression (score 0), low expression (score 1), and robust stromal 
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Consistent with the tumor data, stromal NT5C1A expression was not a prognostic marker. 
The median post-surgical survival time was 15.2 months for patients that did not express 
NT5C1A (n = 156) in the tumor stroma and 17.3 months for all other patients (n = 173; 
p = 0.3, TMA-2) (Figure 27). Due to the lack of treatment details, it remains to be answered 
whether stromal NT5C1A might be a predictive marker for gemcitabine response in PDAC 
patients. 
Figure 27: Stromal NT5C1A expression does not correlate with overall survival in resected 
pancreatic cancer patients. Survival analysis of the Erlangen TMA-2 cohort comparing no NT5C1A 
expression with any intensity of NT5C1A expression. Median survival was 15.2 months (n = 156) for 
no NT5C1A expression and 17.3 months (n = 173) with stromal expression of NT5C1A (p = 0.3, 
log-rank test).   
       
As shown by our group previously, NT5C1A is expressed at very low levels in CAFs and 
PSCs (Hessmann & Patzak et al., 2018). Furthermore, PSCs do not differ significantly 
regarding intracellular dFdCTP accumulation compared to CAFs (Hessmann & Patzak et 
al., 2018). Therefore, two PSC cell lines were stably transfected and +NT5C1A cells and 
vector control cells were analyzed by Western blot as previously shown (Hessmann & 
Patzak et al., 2018), and also by ICC and qPCR. HA-tag expression and robust expression 
of NT5C1A was confirmed in the +NT5C1A-cells (Figure 28A-D). Crystal violet staining 
showed increased resistance of NT5C1A expressing PSCs to gemcitabine treatment 
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Figure 28: NT5C1A overexpression in stably transfected PSC cell lines. For legend, see top of 
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Legend to Figure 28: 
NT5C1A overexpression in stably transfected PSC cell lines. A) and B) Representative ICC 
pictures for NT5C1A and HA-tag expression in stably transfected PSCs (red; DAPI nuclear staining: 
blue). HA-tag expression was exclusively shown for +NT5C1A cells (A, lower panel), control cells 
were devoid of immunoreactivity (A, upper panel). Very low endogenous levels of NT5C1A were 
demonstrated in vector control cells (B, upper panel) compared to NT5C1A expression in the 
NT5C1A-overexpressing cells (B, lower panel). Two technical replicates were analyzed per cell line 
and antibody. Scale bars 50 µm. C) Strong NT5C1A mRNA expression was shown in both +NT5C1A 
murine pancreatic stellate cell lines, as analyzed by quantitative RT-PCR (PSC1: p = 0.003 and 
PSC2: p = 0.0001). NT5C1A expression was hardly detectable in vector control cells. Diagram 
indicates mean ± SEM of three biological replicates. Murine muscle sample served as positive 
control. Values were normalized to β-actin as housekeeping gene. D) Western blot analysis of 
transfected PSCs showing robust NT5C1A and HA-tag protein expression in cells expressing 
NT5C1A and no detectable expression in vector control cells. Representative image of three 
independent experiments is shown with murine muscle lysate as positive control for NT5C1A 




Figure 29: NT5C1A function in PDAC stroma. A) Murine PSCs were treated with increasing 
concentrations of gemcitabine for six days and crystal violet assays were performed. The staining 
was more pronounced in NT5C1A expressing cell lines. Representative images of two independent 
experiments, with each two technical replicates, are shown. B) Crystal violet stain intensity was 
quantified and results were normalized to untreated control cells. Graph indicates mean ± SEM, 
two-way ANOVA with Sidak’s multiple comparisons test was performed (7 nM: p < 0.035, 12 nM: 
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Figure 30: Stromal NT5C1A expression enhances gemcitabine resistance in vitro. 
Quantification of crystal violet assay for stably transfected PSC2 cells with and without NT5C1A 
expression. Two-way ANOVA with Sidak’s multiple comparisons test was performed (7 nM: 
p = 0.002, 12 nM: p < 0.0001).   
 
Considering our previously published findings that +NT5C1A-PSCs accumulate significant 
lower amounts of intracellular gemcitabine triphosphate (Hessmann & Patzak et al., 2018), 
we hypothesized that gemcitabine availability would be significantly increased in the 
supernatant of NT5C1A-PSCs. To test this, MTT assays with conditioned media (CM) of 
transfected PSCs were performed. PSCs were incubated with 25 nM of gemcitabine-
hydrochloride for 24 h and CM was then transferred to two KPC tumor cell lines 
(Figure 31A). Cell viability was determined 72 h later and demonstrated significantly 
decreased tumor cell viability with CM of +NT5C1A-PSCs, compared to vector control cells 
with only endogenous levels of NT5C1A. In the two KPC cell lines the viability decreased 
to 73 % and 75 %, respectively (KPCa: p = 0.003 and KPCb: p = 0.047) (Figure 31B).  
Figure 31: Stromal cells expressing NT5C1A increase available amounts of gemcitabine for 
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Legend to Figure 31:  
Stromal cells expressing NT5C1A increase available amounts of gemcitabine for tumor cells 
in vitro. A) and B) MTT cell viability assay for KPC cell lines treated with CM of NT5C1A expressing 
PSCs and control CM. A) Schematic experimental overview. CM from PSCs (+NT5C1A) and control 
PSCs (+vector) was obtained by preincubation with 25 nM gemcitabine-hydrochloride for 24 h. 
Subsequently, tumor cells were treated for 72 h with CM of PSCs and viability was assessed using 
MTT cell viability assay. B) Tumor cell viability of two different murine KPC cell lines was significantly 
decreased following treatment with CM of +NT5C1A-expressing PSCs (KPCa: 73 %; p = 0.003 and 
KPCb: 75 %; p = 0.047). Graphs indicate mean ± SEM of four biological replicates.  
 
 
3.2.6 Reduced accumulation of the cytotoxic gemcitabine metabolite 
dFdCTP in NT5C1A expressing stromal cells  
The transfected PSCs were incubated with gemcitabine for 2 h and subjected to 
LC-MS/MS-analysis to investigate the hypothesis that NT5C1A expression in stromal cells 
would decrease intracellular gemcitabine accumulation, as it was already shown for tumor 
cell lines. Indeed, the concentration of intracellular dFdCTP was significantly decreased in 
both NT5C1A re-expressing PSC lines (Figure 32) (Hessmann & Patzak et al., 2018). As 
a result, it could be assumed that the transfected cells would consequently increase the 
amount of available gemcitabine for tumor cells.  
Figure 32: Pharmacokinetic analysis of the gemcitabine metabolite dFdCTP in murine PSCs. 
Cells were treated with 1 µM of gemcitabine-hydrochloride for 2 h and cell pellets were harvested. 
Concentrations of the cytotoxic gemcitabine metabolite dFdCTP were determined using LC-MS/MS. 
Significantly lower amounts of dFdCTP were found in both transfected fibroblast cell lines (+NT5C1A) 
(compared to control cells (+vector) (PSC1: 166 vs. 71 ng/ 1x106 cells; p = 0.006 and PSC2: 228 vs. 
100 ng/ 1x106 cells; p = 0.0002). Graph shows mean ± SEM of three technical replicates. Adapted 
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3.2.7 NT5C1A expression mediates chemoresistance in vivo  
Finally, we aimed to investigate whether NT5C1A mediates chemoresistance in vivo. To 
this end, we employed a syngeneic, orthotopically transplanted mouse model using 
C57BL/6-J mice and stably transfected KPC-BL6 cells. Seven days after tumor cell 
transplantation, mice were treated with gemcitabine or saline for 14 days (Figure 33). 
High-resolution small animal ultrasound screening was performed on day 9 of the treatment 
to verify tumor growth upon transplantation (Figure 34). Intratumoral NT5C1A and HA-tag 
expression were confirmed by IHC and showed robust protein levels in tumors derived from 
stably transfected cells (Figure 35). 
 
Figure 33: Syngeneic orthotopic transplantation of modified KPC tumor cells. A) Schematic 
presentation of orthotopic transplantations in C57BL/6-J mice and subsequent treatment schedule. 
Mice were treated seven days after transplantation with gemcitabine 100 mg/kg or saline, 




Figure 34: Tumor detection by high-resolution ultrasound. Tumor detection was performed by 
small animal high-resolution sonography of orthotopically transplanted mice in all groups on day 9 of 
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Figure 35: NT5C1A is robustly expressed in tumors from mice with orthotopically 
transplanted NT5C1A overexpressing tumor cells. Representative IHC showing HA-tag (left) and 
NT5C1A (right) stainings in vector (upper panel) and +NT5C1A (lower panel) orthotopic tumors. 
Scale bars 20 µm.   
 
Tumor growth measured by absolute tumor weights was significantly increased following 
gemcitabine treatment in NT5C1A-overexpressing tumors compared to tumors derived from 
vector control cells (0.25 g vs. 0.37 g; p = 0.03) (Figure 36A and 36B). However, the overall 
number of apoptotic cells within the tumor was not significantly decreased upon NT5C1A 
overexpression (Figure 37). Moreover, serum levels of dFdU, the inactive gemcitabine 
metabolite, were significantly increased in mice bearing NT5C1A-overexpressing tumors 
with median concentrations of 14.1 vs. 17.6 µM dFdU (p = 0.009) (Figure 38). These data 
strongly support our hypothesis that high NT5C1A expression reduces sensitivity to 
gemcitabine. Accordingly, and in line with the patient data demonstrating NT5C1A not to be 
a prognostic marker (Figure 16A and 16B), we did not observe significant 
NT5C1A-dependent differences in tumor growth upon saline treatment of mice (0.82 g vs. 
0.99 g; p = 0.07) (Figure 39). Additionally, comparing gemcitabine treated tumors to saline 
treated tumors, we show that NT5C1A expression is not induced by gemcitabine treatment 
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Figure 36: NT5C1A expression mediates chemoresistance in vivo. A) Tumor weights upon 
necropsy are shown with significantly increased tumor weights upon NT5C1A overexpression in the 
gemcitabine treated cohort (n = 7 each; p = 0.03). Graph shows mean ± SEM. B) Necropsy pictures 
of orthotopically transplanted pancreatic tumors upon gemcitabine treatment with vector (left) and 
stable expression of NT5C1A (right).  
 
Figure 37: Apoptotic cell numbers were not changed upon NT5C1A expression in murine 
tumors. IHC for CC3-expression was performed to compare the overall numbers of apoptotic cells 
in NT5C1A expressing tumors and in control tumors of gemcitabine treated orthotopically 
transplanted mice. The overall numbers of CC3-positive cells were low and were comparable 
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Figure 38: Enhanced inactivation of gemcitabine in NT5C1A expressing orthotopic tumors.  
The inactive gemcitabine metabolite dFdU was measured in serum samples of gemcitabine treated 
mice. Significantly higher values were detected in mice with +NT5C1A tumors (median: 14.1 vs. 
17.6 µM, p = 0.009, Mann-Whitney test). Single values of n = 6 mice per group and the mean values 
are shown.    
Figure 39: Tumor growth was not altered in NT5C1A-expressing tumors following saline 
treatment. NT5C1A expression in saline treated control mice did not have a significant effect on 











Figure 40: Gemcitabine treatment does not alter NT5C1A expression using an orthotopic 
mouse model of PDAC. Comparison of NT5C1A expression in control tumors treated with saline or 
gemcitabine, respectively. NT5C1A expression was not induced by gemcitabine treatment. 
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4. Discussion 
4.1 Gemcitabine resistance and its association with the pancreatic 
cancer stroma  
Pancreatic cancer is one of the most aggressive solid tumors and effective treatment 
options are still missing. Increasing incidence and mortality rates in combination with very 
limited progress in the development of novel treatment strategies render pancreatic cancer 
a major challenge in industrial countries (Adamska et al., 2017; Gordon-Dseagu et al., 
2018). Consequently, many international research groups aim to unravel the underlying 
molecular mechanisms for PDAC progression and therapeutic resistance.    
In the present study, I aimed to elucidate the conundrum of gemcitabine effectiveness 
in vitro, in pancreatic cancer cells, but strong resistance in vivo in patients with PDAC. We 
also observed comparable treatment effectiveness of gemcitabine in primary tumor cells 
isolated from endogenous KPC tumors and metastatic liver lesions (Hessmann & Patzak et 
al., 2018). In contrast to in vitro observations, Burris et al. described the overall response 
rate for gemcitabine in pancreatic cancer patients with 5.4 % (Burris et al., 1997).  
As pancreatic cancer characteristics are hypovascularity and a strong desmoplastic 
reaction, it is plausible that the pancreatic cancer microenvironment plays a crucial role in 
therapeutic resistance. A biophysical barrier that impairs the delivery of chemotherapeutic 
agents to the tumor, especially based on vessel compression through high interstitial fluid 
pressure, was proposed by several groups (Jacobetz et al., 2013; Olive et al., 2009; 
Provenzano et al., 2012). The stromal components like PSCs, collagen, hyaluronic acid, 
and SPARC as key regulators of the desmoplastic reaction (Neesse et al., 2015) were 
examined for their contribution to drug resistance in PDAC by various groups.  
Consequently, stromal depletion approaches were conducted and promising results were 
obtained preclinically. In 2009, Olive et al. presented data from a preclinical trial where the 
authors inhibited the desmoplasia promoting sonic hedgehog signaling pathway in KPC 
mice by administration of the Smoothened (Smo) inhibitor IPI-926 (Olive et al., 2009). This 
inhibitor led to increased mean vessel density and decreased stromal content with markedly 
reduced levels of collagen I and reduced proliferation of α-SMA-positive stromal 
myofibroblasts. The delivery of gemcitabine and also doxorubicin to the primary tumors was 
improved in combination therapies with IPI-926. However, the effect on vascular content 
reversed over time, indicating adaption to the inhibitor treatment (Olive et al., 2009). Few 
years later, two studies were published regarding the influence of hyaluronan as central 
element of the stroma (Jacobetz et al., 2013; Provenzano et al., 2012). Provenzano et al. 
and Jacobetz et al. both investigated the influence of enzymatic depletion of hyaluronan on 
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drug delivery and effectiveness. Intravenous treatment with the hyaluronidase PEGPH20 in 
KPC mice resulted in a normalization of interstitial fluid pressure and thus, in increased 
vessel diameters (Provenzano et al., 2012), and was shown to be directly related to 
re-expansion of existing vessels as mean vessel density was not affected (Jacobetz et al., 
2013). Despite the slightly different preclinical trial design, the conclusions of these studies 
were similar. In both studies, median overall survival of mice was significantly increased 
following combination treatment of PEGPH20 and gemcitabine compared with gemcitabine 
monotherapy (Jacobetz et al., 2013; Provenzano et al., 2012). Moreover, Provenzano and 
colleagues described an intensive remodeling process of the tumor stroma following 
hyaluronidase treatment, with reduced numbers of PSCs and decreased collagen content 
(Provenzano et al., 2012). Regarding collagen content, the impact of angiotensin II should 
be emphasized. Angiotensin II enhanced DNA synthesis in PSCs, thereby promoted PSC 
proliferation (Hama et al., 2004). The angiotensin II type 1 receptor antagonist losartan was 
demonstrated to effectively inhibit collagen and hyaluronan production in murine orthotopic 
tumors derived from pancreatic tumor cells. Furthermore, this was associated with a 
reduction in CAF density and improved chemotherapeutic drug delivery (Chauhan et al., 
2013). PEGPH20 is currently one of the most promising targets for personalized antistroma 
therapies. In a randomized phase II study (NCT01839487), progression-free survival times 
were significantly improved in patients that received PEGPH20 with nab-paclitaxel plus 
gemcitabine versus those patients that only received the combination of nab-paclitaxel plus 
gemcitabine and were especially pronounced in patients with high hyaluronan levels 
(Hingorani et al., 2018). Consequently, patients are currently enrolled in a phase III study 
for previously untreated hyaluronan-high stage IV pancreatic cancer (NCT02715804) to 
compare the efficacy and safety profiles between PEGPH20 with nab-paclitaxel plus 
gemcitabine and placebo with nab-paclitaxel plus gemcitabine administration (Halozyme 
Therapeutics, n.d.).  
Altogether, these studies supported the assumption of a biophysical barrier that would be 
responsible for the low and disappointing response rate following gemcitabine 
administration in PDAC. As a result, stromal depletion was seen as method of choice to 
enhance chemotherapeutic efficacy in the treatment of pancreatic cancer.    
 
4.1.1 Gemcitabine accumulation in stroma-rich pancreatic tumors    
In our study, we addressed this hypothesis in more detail. We investigated dFdCTP 
concentrations in bulk tumor tissues from KPC mice and correlated our findings with overall 
survival times of these mice. However, and in contrast to the assumption of a biophysical 
treatment barrier, the intratumoral concentration of active gemcitabine was not a predictor 
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for treatment response as there was no correlation between intratumoral gemcitabine 
accumulation and survival (Hessmann & Patzak et al., 2018).  
Furthermore, we compared bulk tumor tissues, liver metastases, and liver tissues from 
gemcitabine-treated KPC mice for their amounts of gemcitabine metabolites. Strikingly, we 
have demonstrated highest levels of dFdCTP in bulk tumor tissues of KPC mice compared 
with matched liver metastases and adjacent normal liver tissues. In regards to the discussed 
biophysical treatment barrier we would have expected to observe the highest levels in liver 
tissue, as the liver is a well-perfused organ. We cannot exclude a potential involvement of 
vessel compression, high interstitial fluid pressure, and hypovascularity of pancreatic 
tumors in mediating drug resistance. However, our findings strongly question the hypothesis 
of impaired drug delivery in pancreatic tumors as the limiting factor for gemcitabine efficacy.  
Moreover, two recently published studies showed an association of stromal depletion with 
a more aggressive, highly undifferentiated, and invasive tumor phenotype (Oezdemir et al., 
2014; Rhim et al., 2014). These studies by Rhim et al. and Oezdemir et al. were both 
published in 2014 in the same issue of Cancer Cell and added another layer of complexity 
to this topic and challenged the stroma depletion approaches. Conditional depletion of sonic 
hedgehog (Shh) in a mouse model similar to the KPC model resulted in earlier tumor onset 
and significantly reduced survival times of these mice. Additionally, Shh depletion gave rise 
to poorly differentiated tumors with increased numbers of intratumoral blood vessels and 
resulted in a higher frequency of metastasis development (Rhim et al., 2014). Oezdemir 
and colleagues selectively depleted proliferating α-SMA-positive myofibroblasts, which 
resulted in a significant reduction in survival of these mice, which died from undifferentiated 
and aggressive tumors (Oezdemir et al., 2014). Moreover, the authors also showed that 
patients with low scores of α-SMA often have less differentiated tumors than the ones with 
higher α-SMA scores. The depletion of myofibroblasts reduced the amount of collagen I and 
the stiffness of the ECM. In spite of this, the depletion of CAFs did not improve the efficacy 
of gemcitabine therapy and survival was not prolonged in comparison to untreated mice 
(Oezdemir et al., 2014). This finding is in line with our data that gemcitabine anyhow reaches 
the primary tumors of KPC mice.  
In addition, the outcome of two clinical trials (NCT01195415, NCT01064622) was 
disappointing as the combination treatment of gemcitabine with the hedgehog pathway 
inhibitor Vismodegib failed to induce significantly increased response rates, progression-
free-survival, or median overall survival rates of patients with metastatic pancreatic cancer 
when compared with single agent gemcitabine administration (Catenacci et al., 2015; Kim 
et al., 2014). These studies were followed by the premature termination of a similar clinical 
trial conducted by Infinity Pharmaceuticals, Inc. The company reported that the group 
receiving gemcitabine plus the Smo inhibitor Saridegib showed higher progression rates 
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and the difference in survival favored the placebo plus gemcitabine group (Infinity 
Pharmaceuticals, n.d.). Taken these findings together, unselective depletion of the tumor 
stroma should be avoided as some stromal components might even have tumor restraining 
properties. Consequently, a more detailed picture about the exact function and interplay of 
the different stromal components is required.        
The fact that gemcitabine accumulates in stroma-rich primary tumors and lower levels were 
observed in stroma-poor metastases (Hessmann & Patzak et al., 2018) implicated that the 
stromal components are actively involved in drug metabolism. In line with this new 
hypothesis are the data presented by Neesse et al. from 2013. The authors demonstrated 
increased gemcitabine levels in plasma and tumor biopsies from KPC mice when 
gemcitabine therapy was combined with the CDA inhibitor THU, but did not observe 
significant changes of tumor volumes and of the number of apoptotic cells (Neesse et al., 
2013). Taken together, increased gemcitabine concentrations in the tumor bulk of mice 
were not sufficient to improve the response to this drug. Consequently, an active 
involvement of the stromal components in gemcitabine metabolism and subsequent 
availability for tumor cells was further investigated.  
 
4.1.2 The tumor microenvironment is actively involved in drug 
metabolism 
Interestingly, we were able to describe a drug scavenging effect of CAFs in vitro. The levels 
of the active gemcitabine metabolite dFdCTP were highest in CAFs and PSCs and the 
inactive metabolite dFdU was significantly decreased in these cells. As phosphorylated 
gemcitabine is unable to cross the cell membrane, it is entrapped within the fibroblasts and 
thus, becomes unavailable for tumor cells. Consequently, we concluded that the pancreatic 
cancer stroma rather exerts a biochemical barrier to gemcitabine treatment by actively 
metabolizing the drug. Thus, the issue is not the drug delivery to the tumors, but the 
intratumoral redistribution of gemcitabine in stroma-rich pancreatic tumors. Putting these 
findings in context with the observations published by Jacobetz et al., Provenzano et al., 
and Olive et al. (Jacobetz et al., 2013; Olive et al., 2009; Provenzano et al., 2012), we gave 
an alternative explanation why gemcitabine treatment was shown to be more efficient in 
mice with reduced amounts of PSCs or activated α-SMA-positive myofibroblasts. Increasing 
the mean vessel density by stromal depletion would consequently enhance gemcitabine 
drug scavenging by CAFs, instead of increasing effective concentrations in the tumor cells. 
Notably, in another study of our laboratory, higher levels of dFdC were observed in 
pancreatic tumors of SPARC-wildtype and SPARC-knockout KC mice compared with 
normal pancreatic tissue. This result was independent of SPARC and thus, unrelated to the 
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SPARC dependent amount of collagen. The differences in overall cellularity were assumed 
to be the underlying mechanism for this observation (Ramu et al., 2018). Taken our findings 
together, we suggest the number of CAFs in pancreatic tumors to be a predictable marker 
for the response to gemcitabine.  
Additionally, the effectiveness of gemcitabine and nab-paclitaxel on metastases in PDAC 
has been demonstrated in a preclinical study by Aiello et al. In this study, the metastases 
were characterized by their grade of desmoplasia, where smaller metastases presented 
reduced amounts of stromal components than larger metastases. The authors observed 
comparable chemotherapeutic effectiveness in metastases of all sizes (Aiello et al., 2016). 
This could be explained in part by our proposed drug scavenging effect, as the gemcitabine 
accumulation in fibroblasts would explain the effective killing of nano- and micro-metastases 
due to their lower number of fibroblasts, but not the effects on highly desmoplastic macro-
metastases. However, the authors based their finding on a single dose of gemcitabine with 
subsequent detection of CC3-positive tumor cells. The effect on the overall metastatic 
burden are in line with our findings as metastatic size was significantly reduced following 
long-term treatment, which suggests effective inhibition of progression of smaller 
metastases (Aiello et al., 2016).  
In our present work, we did not observe the drug scavenging for 5-FU, another nucleoside 
analogue. However, further chemotherapeutics were not included in our study of the tumor 
stroma. Consequently, further data are required to assess whether this mechanism impacts 
on several classes of chemotherapeutic agents or if it is selective for gemcitabine.  
Yet, we were not able to demonstrate the drug scavenging of fibroblasts in vivo as it was 
not possible, by the LC-MS/MS method that we used in our study, to distinguish between 
gemcitabine in stromal cells and in tumor cells of the bulk tumor tissue. Further data are 
required that explicitly show the tumor compartment specific distribution of gemcitabine. 
Labelling gemcitabine with a fluorescence marker could be a feasible approach to obtain 
these data.  
 
4.1.3 Stromal expression of gemcitabine-metabolizing enzymes and 
gemcitabine resistance  
Regarding the significantly lower intracellular dFdU levels in fibroblasts compared with 
tumor cells, we investigated whether drug influx, activation, or inactivation would be 
underlying mechanisms. No differences in the expression levels were found for dCK, which 
is considered to be the rate-limiting step in the activation of gemcitabine. Moreover, as 
dFdCTP levels had been significantly higher in fibroblasts, the transport of native prodrug 
into the cells was very unlikely to limit drug activation. Interestingly, gemcitabine inactivating 
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enzymes were shown to be hardly expressed in the tumor stroma of human and murine 
pancreatic cancer tissue. In contrast, the expression detected in the epithelial compartment 
was very robust. Therefore, we concluded that the low levels of dFdU are a consequence 
of downregulated gemcitabine inactivation in stromal cells. The main inactivating enzymes 
are CDA, DCTD, and NT5C1A. CDA leads to quick inactivation of the gemcitabine prodrug 
to dFdU, and DCTD deaminates the monophosphate metabolite, thus, preventing further 
phosphorylation of dFdCMP to the cytotoxic dFdCTP metabolite (De Sousa Cavalcante & 
Monteiro, 2014). NT5C1A was a previously unrecognized gemcitabine inactivating enzyme 
and to the best of our knowledge, we have been the first group to describe differential 
expression of NT5C1A between CAFs and pancreatic cancer cells. Mechanistically, 
NT5C1A reverses the initial phosphorylation step, which results in the production of 
gemcitabine prodrug (De Sousa Cavalcante & Monteiro, 2014). Consequently, we 
hypothesized that overexpression of NT5C1A in fibroblasts would be an opportunity to 
increase gemcitabine prodrug levels. Native gemcitabine would consequently be available 
for tumor cells. In a preliminary experiment, we were able to demonstrate decreased levels 
of intracellular dFdCTP in stably transfected PSCs that overexpress NT5C1A (Hessmann 
& Patzak et al., 2018). Thus, upregulation of NT5C1A expression levels in stromal cells 
seems to be a suitable approach to reprogram the tumor stroma. Taken together, the data 
propose stromal reprogramming as a more appealing way to deal with ineffective responses 
to chemotherapeutic administration than unselective stromal depletion.    
Additionally, it is important to understand how the expression of gemcitabine-metabolizing 
enzymes is regulated and which factors might affect protein expression. For instance, Frese 
et al. demonstrated that administration of nab-paclitaxel to KPC mice reduced CDA protein 
expression without changing its mRNA expression (Frese et al., 2012).  
 
4.1.4 Characteristics of CAFs  
In our study, we have used primary CAFs and immortalized PSCs as source of stromal 
cells. In general, quiescent PSCs are part of the normal pancreas and these cells become 
activated in response to tissue injury, thus, building the main source for CAFs in PDAC 
(Erkan, Adler, et al., 2012; Nielsen et al., 2016). In classical 2D cell culture, these cells 
develop the characteristic features of the activated state (Omary et al., 2007), like loss of 
vitamin D lipid droplets and acquisition of a myofibroblast-like phenotype with a 
spindle-shape morphology. Thus, standard 2D cell culture seems to activate PSCs. 
Furthermore, comparing the pharmacokinetic profiles of gemcitabine metabolites in these 
cells, we did not detect significant differences compared to CAF cells. Consequently, we 
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considered our PSCs to be suitable for using them together with primary CAF cell lines to 
study the impact of stromal cells on gemcitabine resistance.   
CAFs were described to be a heterogenous component of the tumor stroma. For instance, 
the myCAF and iCAF subgroups with differing marker expressions were identified by 
Öhlund et al. (2017). Consequently, it would be possible that these CAF subgroups also 
differ in their expression of drug metabolizing enzymes and consequently, contribute to 
gemcitabine drug scavenging to a different extent. Moreover, this study highlights that not 
only tumor heterogeneity is a central aspect in PDAC, but also the stromal heterogeneity.  
Another point to discuss is the significantly higher accumulation of active cytotoxic 
gemcitabine metabolites in CAFs and PSCs compared with tumor cells that we 
demonstrated in the present study. Using archived tissues from gemcitabine treated KPC 
mice and from vehicle treated mice, we determined if dFdCTP might affect viability of 
stromal cells itself. Interestingly, the number of apoptotic cells did not change following 
9 days of gemcitabine treatment. Gemcitabine acts by interfering with DNA synthesis and 
consequently only harms proliferating cells. Thus, the very low proliferation rate of 2 % to 
5 % of α-SMA-positive cells gives a plausible explanation.   
 
4.1.5 Gemcitabine drug scavenging by further stromal components 
We have demonstrated drug scavenging in CAFs, which represent the predominant cell 
type in the pancreatic cancer stroma. This drug scavenging mechanism had significant 
impact on tumor cells when cultured in vitro. It still needs to be clarified if the amount of 
gemcitabine that is scavenged is enough to impair gemcitabine efficiency in patients. One 
could hypothesize that other cell types are not present in significant numbers or amounts to 
really impair drug availability for tumor cells. However, the concentration of scavenged 
gemcitabine could be significantly higher compared with fibroblasts and thus, could 
compensate for the differences in cell numbers. Therefore, it is definitely worth to investigate 
other cell types, like immune cells if these cells are able to intensify drug scavenging. 
Indeed, in vitro experiments from another study of our group revealed that tumor-associated 
macrophages (TAMs) also scavenge significant amounts of gemcitabine, which had an 
impact on tumor cell viability in vitro (Buchholz et al., 2018). Complementing our finding that 
TAMs directly metabolize gemcitabine, Weizman and colleagues had already demonstrated 
a paracrine crosstalk between tumor cells and TAMs, which resulted in reduced 
gemcitabine efficacy (Weizman et al., 2014). In their study, they have shown a 75-fold 
upregulation of CDA expression on RNA level following treatment with gemcitabine and 
TAM conditioned medium. The authors confirmed their findings in vivo by macrophage 
depletion with clodronate in an orthotopic mouse model of pancreatic cancer (Weizman et 
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al., 2014). Thus, tumor-stroma crosstalk might influence the expression of gemcitabine-
metabolizing enzymes in general, which still requires further investigation. Additionally, 
acellular stromal components might directly or indirectly, through changes in the biophysical 
properties (e.g. hypoxia), alter the expression of relevant enzymes and consequently, 
modify the relevance of the described drug scavenging mechanism.  
It is important to mention that intratumoral bacteria were recently demonstrated to be 
involved in the failure of gemcitabine therapy (Geller et al., 2017), which consequently 
supports our hypothesis that the tumor stroma exerts a biochemical treatment barrier. Geller 
et al. incidentally found co-cultures of primary human dermal fibroblasts and colorectal as 
well as pancreatic cancer cells to be more resistant towards gemcitabine treatment 
compared with single cultures (Geller et al., 2017). The authors associated this observation 
with the presence of a Mycoplasma hyorhinis infection of the fibroblasts and were able to 
reverse the resistance by treatment with antibiotics. Conditioned medium of the fibroblast 
cultures were analyzed by high-performance LC-MS/MS and high levels of dFdU were 
observed (Geller et al., 2017). The authors used several in vitro and in vivo assays to 
determine the reason on a molecular basis and found the long isoform of bacterial CDA to 
be responsible for the intensified gemcitabine inactivation. Importantly, bacteria were 
detected in 86 of 113 human PDAC samples and were only present in 3 of 20 normal 
pancreas controls (Geller et al., 2017). With their study, Geller et al. suggested to further 
explore the potential clinical benefit of co-administration of antibiotics with gemcitabine for 
patients with PDAC. In general, the microbiome is a topic of growing interest in the field of 
chemotherapeutic resistance mechanisms and it remains to be clarified if standard drugs 
like antibiotics might help to improve the treatment outcome for PDAC patients.     
  
 
4.2 NT5C1A in gemcitabine resistance in PDAC 
To the best of our knowledge, we have been the first group linking NT5C1A expression to 
chemotherapeutic resistance in PDAC (Hessmann & Patzak et al., 2018). However, the 
idea that NT5C1A might be involved in mediating resistance towards gemcitabine is not 
new to the scientific community. For instance, Hunsucker et al. overexpressed human 
NT5C1A in HEK293 and in Jurkat cells. They observed a 22-fold increase of the IC50 value 
for dFdC in the HEK293 cells. However, the IC50 value did not change using Jurkat cells 
(Hunsucker et al., 2001). These findings propose cell type, organ, or disease specific impact 
of NT5C1A on gemcitabine inactivation. In pancreatic cancer, NT5C1A is a previously 
unrecognized enzyme in tumor cell-autonomous as well as non-cell-autonomous 
chemoresistance. Thus, intensive research on NT5C1A is required.  
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4.2.1 NT5C1A in inclusion body myositis and in malignancies  
Interestingly, relevant data on functional aspects of NT5C1A in cancer are still missing. The 
only studies available in the area of malignancies were published in 1993 and in 1999 
(Dumontet et al., 1999; Kawasaki et al., 1993). Kawasaki et al. investigated the expression 
and activity levels of cytoplasmic 5’-nucleotidase (5’-NT) in cell lines that were derived from 
2-chlorodeoxyadenosin-treated chronic lymphocytic leukemia and hairy cell leukemia 
patients. Nonresponders had higher levels of 5’-NT and furthermore, increased 5’-NT 
activity (Kawasaki et al., 1993). Dumontet et al. presented in vitro data linking acute 
myelogenous leukemia and NT5C1A overexpression with gemcitabine resistance. The 
authors observed a strong decrease in intracellular dFdCTP accumulation in 
chemotherapeutic resistant variants of the human erythroleukaemic cell line K562 following 
2 h of gemcitabine treatment. They explained their findings with the overexpression of 
NT5C1A in all of their resistant cell lines (Dumontet et al., 1999).  
Furthermore, NT5C1A is intensively discussed in inclusion body myositis (IBM) (Larman et 
al., 2013; Lilleker et al., 2017; Yeker et al., 2018), which is assumed to be autoimmune-
driven and leads to progressive muscle degeneration (Dalakas, 2006; Greenberg, 2011; 
Needham & Mastaglia, 2007). Larman et al. identified NT5C1A as an important muscle 
autoantigen, which is the target of circulating autoantibodies (Larman et al., 2013). 
Subgroup analysis of IBM patients presenting with anti-NT5C1A autoantibodies in their 
blood had a significantly reduced median survival of 17.6 years compared with 24.2 years 
in the antibody-negative subgroup (Lilleker et al., 2017). Furthermore, the presence of these 
autoantibodies against NT5C1A was associated with a more severe clinical phenotype in 
patients with juvenile myositis. For instance, these patients presented with more severe 
pulmonary symptoms and had a higher rate of hospitalizations (Yeker et al., 2018). 
Therefore, NT5C1A autoantibody status was suggested as biomarker for patient 
stratification (Lilleker et al., 2017).   
Altogether, the literature provides first evidence that NT5C1A might play a role in drug 
resistance and might have the potential to be predictive for gemcitabine therapy responses.   
 
4.2.2 Influence of stromal NT5C1A expression on non-cell-autonomous 
gemcitabine resistance in PDAC 
In the first part of our study, we have identified NT5C1A as an interesting target in 
gemcitabine resistance (Hessmann & Patzak et al., 2018). The analysis of two independent 
TMAs revealed that 50-90 % of the tumor tissues of resected PDAC patients were devoid 
of immunoreactivity for NT5C1A in the stromal compartment, thus, gemcitabine drug 
accumulation might be enhanced in the stromal cells of these patients. Therefore, the 
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absence of stromal NT5C1A expression might mediate non-cell-autonomous resistance to 
gemcitabine. We proposed NT5C1A as a suitable target for stromal reprogramming by 
hypothesizing that NT5C1A re-expression in stromal cells might reduce intracellular 
dFdCTP concentrations, and in turn might lead to increased extracellular concentrations of 
dFdC. Consequently, stromal re-expression could increase the available amount of 
gemcitabine for tumor cells and enhance chemosensitivity in pancreatic cancer. Examining 
NT5C1A overexpressing PSCs, we were able to demonstrate significantly reduced 
intracellular levels of dFdCTP (Hessmann & Patzak et al., 2018), significantly increased 
resistance of these cells towards gemcitabine, and reduced tumor cell viability when treated 
with conditioned media of gemcitabine treated NT5C1A overexpressing PSCs. However, 
in vivo data regarding gemcitabine metabolism are still required for stromal NT5C1A.   
 
4.2.3 NT5C1A expression in the epithelial compartment of PDAC is not 
a prognostic factor  
The impact of tumoral NT5C1A expression on gemcitabine efficacy and PDAC patient 
survival has not been defined yet. Therefore, we aimed to complement our study by focusing 
on tumor cell-autonomous resistance by exploration of the detailed function of NT5C1A in 
the epithelial compartment of PDAC. Given its role in gemcitabine metabolism, we 
hypothesized that NT5C1A has potential as predictive biomarker for PDAC patient 
stratification for improved treatment regimens. Using TMAs, we could confirm that there is 
no prognostic significance on overall survival associated with NT5C1A expression in the 
epithelial compartment of resected pancreatic cancer patients. Unexpectedly, a prognostic 
role for the gemcitabine transporter hENT1 was demonstrated by Kim et al. in surgically 
resected PDAC patients, based on mRNA expression data (Kim et al., 2011). One third of 
the patients did not receive adjuvant therapy and the other patients received various kinds 
of adjuvant treatment, mainly in combination with radiation (Kim et al., 2011). However, and 
in contrast to the data by Kim et al., Greenhalf et al. did not report a prognostic effect of 
hENT1 expression levels on survival of PDAC patients in the ESPAC-1 and ESPAC-3(v2)-
randomized trials, who underwent curative tumor resection (Greenhalf et al., 2014). In line 
with our experimental design, the results by Greenhalf et al. are also based on protein 
expression data obtained from IHC stainings (Greenhalf et al., 2014). Furthermore, mean 
DCTD and RRM1 protein expression levels were also not associated with overall survival 
of the observation groups of postoperative PDAC patients in the ESPAC-1 and 
ESPAC-3(v1) trials (Elander et al., 2018). Additionally, Thomas et al., Logan-Collins et al., 
and Tactacan et al. presented data on RON (recepteur d’origine nantais, also termed 
macrophage stimulating 1 receptor), a receptor tyrosine kinase that impacts on cellular 
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motility and cancer cell survival upon ligand binding, which was reported to be another 
relevant factor in mediating gemcitabine resistance in pancreatic cancer (Logan-Collins et 
al., 2010; Tactacan et al., 2012; Thomas et al., 2007). Using KC mice, increasing 
expression of RON in the epithelial compartment during pancreatic cancer progression and 
metastasis was described, and blocking or downregulation of RON in pancreatic cancer 
cells and in a xenograft mouse model resulted in sensitization towards gemcitabine 
treatment (Logan-Collins et al., 2010; Thomas et al., 2007). However, comparable to our 
findings, RON was not associated with prognosis in resected PDAC patients (Tactacan et 
al., 2012).  
 
4.2.4 Recombinant overexpression of NT5C1A in pancreatic cancer cells  
Unexpectedly, dramatically reduced NT5C1A expression was observed in pancreatic 
cancer cells in 2D cell culture. We had previously shown robust in vivo expression of 
NT5C1A in KPC tumors (Hessmann & Patzak et al., 2018), from which primary tumor cells 
were generated. Consequently, we speculate that signaling cues from the TME might be 
involved in the regulation of NT5C1A expression. These signals are absent during 2D cell 
culture. The multifaceted composition and dynamic changes of the tumor stroma in PDAC 
indicate a complex interplay with pancreatic cancer cells and therefore, could explain our 
observation. The lack of NT5C1A might explain why these cells respond well to gemcitabine 
treatment in vitro, but gemcitabine does not show notable anti-tumor effects in GEMMs of 
pancreatic cancer and in PDAC patients with strong desmoplasia.  
A possibility to further investigate this hypothesis would be the use of 3D cell culture based 
on Matrigel, which is a common growth support matrix used in 3D cultures (Boj et al., 2016). 
Recent studies suggest cancer cell organoids or patient derived organoids as promising 
tools for in-depth molecular tumor characterization by transcriptomic and proteomic 
analyses. Furthermore, therapeutic profiling can be used in these organoids to identify 
targets and biomarkers for tailored therapy approaches (Boj et al., 2016; Tiriac et al., 2018). 
In further studies, this technique could be helpful in identifying the factors leading to 
differential expression of NT5C1A in vitro and in vivo and consequently, this knowledge 
could then be employed in patient stratification for improved treatment. Moreover, Hou et al. 
demonstrated differential responses to gemcitabine treatment between 2D cell cultures and 
3D spheroid cultures of primary resected human pancreatic cancer cells as well as of the 
established cell line PANC1 (Hou et al., 2018).     
A study by Dangi-Garimella et al. demonstrated an active involvement of the 3D 
microenvironment in pancreatic cancer cell proliferation following cell exposure to 
gemcitabine (Dangi-Garimella et al., 2011). The authors observed significant differences in 
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proliferation following 24 h treatment with gemcitabine, when cells were grown as 
monolayers compared with cells grown in a 3D collagen I matrix (Dangi-Garimella et al., 
2011). This study supports our hypothesis that the pancreatic cancer stroma might be 
involved in the regulation of NT5C1A expression.  
 
4.2.5 NT5C1A as predictive marker for gemcitabine therapy response 
Patient stratification and personalized treatment approaches are urgently required to 
achieve better treatment responses in pancreatic cancer patients. Accordingly, precision 
oncology is gaining importance. Remarkable progress was already made within the last 
years on the molecular understanding of PDAC and in patient stratification (Bailey et al., 
2016; Collisson et al., 2011; Moffitt et al., 2015), however, the therapeutic strategies did not 
improve considerably. An example for encouraging results in patient stratification is the 
increasing evidence that patients with BRCA mutations, the most common genetic 
alterations of familial pancreatic cancer, respond better to platinum-based agents and also 
benefit from poly-ADP-ribose polymerase (PARP) inhibitors (Kowalewski et al., 2018).  
Beside this progress, the urgent need for novel biomarkers, either diagnostic, prognostic, 
or predictive, is demonstrated by the overwhelming amount of studies on this topic. In 2012, 
Fong et al. reported that the research community studied already 10 % of all coding genes 
in the human genome for their potential as pancreatic cancer biomarkers (Fong & Winter, 
2012). For diagnostic purposes, serum carbohydrate antigen 19-9 (CA-19-9) is approved 
by the Food and Drug Administration (FDA) as blood test for PDAC, as serum levels of 
CA-19-9 were observed to be elevated in patients with pancreatic cancer (Fong & Winter, 
2012). However, certain limitations such as lack of sensitivity and specificity do not allow 
CA-19-9 to be routinely used for patient screening. As a result, the restricted use in high-risk 
patients or for the diagnosis of recurrence following pancreatic tumor resection have been 
discussed as well, but was still not predictive enough for routine use (Fong & Winter, 2012). 
Yet, established biomarkers for the selection of the most effective therapy for pancreatic 
cancer patients do not exist so far in the clinical routine.  
In the present study, we aimed to identify the potential of NT5C1A as novel predictive 
biomarker for gemcitabine treatment response in PDAC. Several studies have suggested 
proteins that play important roles in gemcitabine transport and metabolism to be involved in 
gemcitabine resistance. These proteins might be suitable as predictive biomarkers for the 
selection of patients for gemcitabine therapy. For instance, an association of high hENT1 
and dCK protein levels have been observed with improved survival times for PDAC patients 
who received adjuvant gemcitabine (Bird et al., 2017; Greenhalf et al., 2014; Maréchal et 
al., 2012). On the contrary, DCTD and RRM1 were not associated with PDAC patient 
Discussion 
 
Page | 95  
 
outcome following gemcitabine therapy (Elander et al., 2018; Maréchal et al., 2012). 
Moreover, inactivating mutations of dCK were reported in vitro in gemcitabine-resistant 
cancer cell lines, including pancreatic cancer cell lines, compared to the gemcitabine-
sensitive parental cell lines (Saiki et al., 2012).   
In the present study, overexpression of the gemcitabine inactivating enzyme NT5C1A was 
demonstrated to reduce the response to gemcitabine in vitro and in vivo. Using LC-MS/MS 
analysis, the direct involvement of NT5C1A in the metabolization of gemcitabine in 
pancreatic cancer cell lines could be determined. Furthermore, reduced apoptosis levels 
were observed in these cells. The mechanism of NT5C1A-mediated gemcitabine resistance 
is summarized in Figure 41.  
 
Figure 41: Mechanism of NT5C1A-mediated gemcitabine resistance. NT5C1A activity enhances 
the dephosphorylation of dFdC-monophosphate to native gemcitabine (dFdC), which can then be 
inactivated to dFdU. We observed increased levels of dFdU in the serum of mice with NT5C1A-
overexpressing tumors. In consequence, the formation of cytotoxic triphosphate metabolites 
(dFdCTP) was reduced in cells overexpressing NT5C1A, as shown by LC-MS/MS analysis. Protein 
levels of CC3 were reduced in cells with strong expression of NT5C1A. Thus, gemcitabine response 
was decreased in the overexpressing cell lines.  
 
In our patient dataset with more than 400 samples, we showed NT5C1A overexpression in 
the majority of tumor cells. Additionally, in most cases, stromal cells lacked NT5C1A 
expression. Regarding the in vitro data of our PSCs, reduced levels of dFdCTP were 
observed upon NT5C1A re-expression, as measured by LC-MS/MS analysis (Hessmann & 
Patzak et al., 2018). Moreover, the re-expression of NT5C1A in PSCs improved the 
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This finding supports our hypothesis that high NT5C1A levels in pancreatic fibroblasts and 
low expression in pancreatic cancer cells, as demonstrated in vitro under 2D cell culture 
conditions, promote chemosensitivity to gemcitabine. Besides, the impact of NT5C1A on 
chemoresistance does not seem to be dependent on tumor stages, as strong epithelial 
NT5C1A expression was observed in invasive tumors, but also in PanIN lesions. Tumor 
weights were significantly increased in samples from mice that were orthotopically 
transplanted with NT5C1A overexpressing KPC cells and subsequently treated with 
gemcitabine for 14 days. This supports our hypothesis that NT5C1A might have the 
potential to serve as a predictive biomarker for gemcitabine therapy response. Moreover, 
increased levels of the inactive gemcitabine metabolite dFdU were found in the serum of 
these mice. This result seems to reflect the increased dephosphorylation of dFdUMP to 
dFdC, which in turn might be deaminated to dFdU by CDA. Interestingly, Hodge et al. 
observed dFdU to be a substrate of hENT and hCNT transporters in HeLa cells, thus, 
suggested dFdU as a competitive inhibitor of gemcitabine transporters (Hodge et al., 2011). 
Though, the effect on intracellular gemcitabine accumulation was contradictory, as 
gemcitabine accumulation increased following longer incubation with dFdU, which again 
suggests a complex interplay of gemcitabine transport and metabolism (Hodge et al., 2011). 
The hypothesis that dFdU might compete with dFdC for their transport into cancer cells is 
of interest for our study, as this would even increase the resistance of pancreatic cancer 
cells, which express high levels of NT5C1A, towards gemcitabine. Nevertheless, organ and 
disease specific effects, as demonstrated by Hunsucker et al. (2001), need to be 
investigated before conclusions can be made.     
Furthermore, the presence and measurement of NT5C1A autoantibodies in patient plasma 
and serum samples have been described in IBM and juvenile myositis and were associated 
with a more severe disease phenotype and worse prognosis (Larman et al., 2013; Lilleker 
et al., 2017; Yeker et al., 2018). Therefore, an exciting approach to study the involvement 
of NT5C1A in chemotherapeutic resistance in PDAC would be the non-invasive 
determination of NT5C1A autoantibodies in PDAC patient plasma samples. It would be 
interesting to examine whether these autoantibodies are also present in PDAC patients and 
if so, whether the antibody status would correlate with tumoral NT5C1A expression and 
would be predictive for gemcitabine treatment response.        
Altogether, it remains to be elucidated whether predictive effects for NT5C1A can be seen 
in PDAC patients following treatment with gemcitabine. Our TMAs were obtained from 
heterogenous cohorts of PDAC patients in regards to whether patients received adjuvant 
chemotherapy or not. Consequently, these clinical data were too limited to analyze potential 
predictive effects. For example, the samples from the ESPAC clinical trials would be a 
suitable option to further address this issue.   
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Moreover, it needs to be seen whether NT5C1A alone would be suitable as predictive 
biomarker for gemcitabine treatment in PDAC patients. Maybe a combination with hENT1 
expression levels might even be more beneficial to predict therapeutic response to 
gemcitabine. Further studies with PDAC patient samples are necessary to finally determine 
the impact of NT5C1A as potential predictive biomarker for gemcitabine-based treatment 
approaches in PDAC.  
 
4.2.6 Differential expression of NT5C1A fuels chemotherapeutic 
resistance 
Importantly, we have demonstrated NT5C1A as mediator of gemcitabine resistance 
resulting from strong epithelial expression of NT5C1A and low expression of stromal 
NT5C1A, which was detected in a large subgroup of post-operative PDAC patients. Each 
factor itself contributes to gemcitabine resistance in pancreatic cancer. Accordingly, the 
combination of both is assumed to exert the least response to gemcitabine treatment. 
Provided that this hypothesis is confirmed in patient samples, the best possibility to enhance 
gemcitabine efficacy for PDAC patients would be to increase NT5C1A expression in stromal 
cells and to decrease its expression in neoplastic cells (Figure 42). Even if selective 
reprogramming of stromal or epithelial NT5C1A expression would not be feasible, the 
potential for NT5C1A to become a predictive biomarker for personalized treatment 









Figure 42: Schematic illustration of NT5C1A expression in pancreatic cancer. In the clinical 
situation, NT5C1A was shown to be strongly expressed in neoplastic cells of post-operative PDAC 
patients. Hardly any expression was demonstrated in the tumor stroma (left panel). According to our 
findings, the optimal situation for effective chemotherapy with gemcitabine would be low expression 
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4.2.7 NT5C1A regulation in pancreatic cancer 
Taken our findings together, we have proposed NT5C1A as a novel mediator of 
cell-autonomous and non-cell-autonomous chemotherapeutic resistance towards 
gemcitabine in pancreatic cancer. As suggested, tumoral and stromal NT5C1A expression 
could possibly be involved in the decision whether defined patient subgroups would benefit 
from gemcitabine therapy or not. In case of stroma rich tumors, another chemotherapeutic 
agent might be more beneficial than gemcitabine due to fibroblast drug scavenging.  
Aiming at further clinical benefit from the present study, it would be of utmost importance to 
unravel how NT5C1A is regulated in pancreatic cancer. The prerequisite that NT5C1A could 
become a therapeutic target would require different regulatory mechanisms of NT5C1A 
expression between the tumor stroma and the epithelial compartment. Possible 
mechanisms that might affect NT5C1A expression or activity in pancreatic cancer are 
epigenetic mechanisms, signaling cues from immune cells of the tumor stroma, microRNAs, 
metabolic changes, post-translational modifications, and various other factors. In reference 
to this, altered enzyme activity was demonstrated by Saliba et al. by investigation of genetic 
variations of the NT5C1A gene in HEK293 cells (Saliba et al., 2016). The NT5C1A variants 
were associated with differing responses to the standard nucleoside analogs gemcitabine, 
5-FU, and cladribine (Saliba et al., 2016). Related to this study, enhanced nucleotidase 
activity was demonstrated in cells expressing NT5C2 mutant proteins, another member of 
the cytosolic 5’-nucleotidases, in the context of acute lymphoblastic leukemia (ALL), which 
resulted in increased resistance to standard chemotherapeutics for ALL treatment in vitro 
(Tzoneva et al., 2013).   
Firstly, the involvement of epigenetic mechanisms in the regulation of NT5C1A expression 
should be discussed. Epigenetic changes in response to stromal cues might alter NT5C1A 
expression levels in tumor cells. As shown by Sherman et al., the soluble factors of 
fibroblasts are able to induce such changes in pancreatic cancer cells by increasing H3K9 
and H3K27 histone acetylation (Sherman et al., 2017). It remains to be determined whether 
the resulting activation of promoters and enhancers alter NT5C1A expression and could 
consequently serve as important therapeutic targets. For instance, we found one study 
where NT5C1A was described to be part of a significantly downregulated gene set in histone 
deacetylase 7 (HDAC7)-overexpressing pancreatic beta cells (Daneshpajooh et al., 2017). 
Thus, we hypothesize that transcriptional repression through overexpression of HDACs in 
CAFs could lead to downregulation of NT5C1A in these cells. Consequently, treatment with 
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Secondly, metabolic pathways might be involved in the regulation of NT5C1A expression 
and activity. For instance, NT5C1A expression could be altered by AMP-activated protein 
kinase (AMPK). NT5C1A prefers AMP as its substrate, the latter in turn allosterically 
stimulates AMPK activity (Hardie, 2014; Hunsucker et al., 2005). Kulkarni et al. have shown 
that gene silencing of NT5C1A in mouse skeletal muscle increases AMPK phosphorylation 
by 60 % (Kulkarni et al., 2011). Furthermore, AMPK can be activated through metformin, 
which is a standard agent for the treatment of diabetes mellitus type 2 (Gong et al., 2014). 
We speculate that a negative feedback loop could exist, which might result in reduced 
NT5C1A activity when AMPK activity is high. In this case, treatment with metformin could 
be beneficial to reduce cell-autonomous gemcitabine resistance.     
Taken together, the knowledge about the regulation of NT5C1A expression and activity in 
pancreatic cancer is very limited and intensive research is required to determine the 
potential of NT5C1A to become a therapeutic target in PDAC treatment.   
 
4.2.8 Specificity of NT5C1A-driven chemoresistance towards 
gemcitabine  
A question raised by the previous data was whether the contribution of NT5C1A to 
chemotherapeutic resistance in PDAC would be specific for gemcitabine. To address this 
point, we used pharmacokinetic and pharmacodynamics approaches. First, we treated 
CAFs and PSCs with 5-FU and, using LC-MS/MS analysis, did not observe notable 
differences in intracellular 5-FU concentrations (Hessmann & Patzak et al., 2018).  
In regards to tumor cells, we treated murine KPC and human L3.6pl cells with paclitaxel, a 
standard chemotherapeutic drug that acts independently of intracellular phosphorylation. In 
contrast to gemcitabine, NT5C1A overexpressing pancreatic cancer cells were still sensitive 
to paclitaxel treatment. Consequently, drugs other than gemcitabine might still be suitable 
to induce relevant responses in pancreatic tumors with strong epithelial or low stromal 
NT5C1A expression, respectively. Therefore, NT5C1A might be suitable for patient 
stratification to different treatment options.  
Taken together, the contribution of NT5C1A on gemcitabine resistance in pancreatic cancer 
does not extend to other classes of chemotherapeutic agents and seems to be specific for 
gemcitabine. Therefore, according to the in vitro and in vivo data, patients with high 
NT5C1A expression might not sufficiently benefit from gemcitabine treatment compared to 
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4.3 Concluding remarks  
Despite intensive research and a much better understanding of the underlying molecular 
characteristics of PDAC, the 5-year relative survival rates are still staying below 10 % 
(Siegel et al., 2018). The response rates towards available treatments are extremely poor 
and limited progress has been made in the successful development of novel therapeutic 
strategies over the past decades (Rossi et al., 2014).  
In the present study, we have deepened the understanding of stroma-derived gemcitabine 
resistance mechanisms. Furthermore, a detailed characterization of NT5C1A and its role 
as mediator of cell-autonomous and non-cell-autonomous gemcitabine resistance in PDAC 
was performed.   
 
The most important findings of the study are the following:  
• The hypothesis of a biophysical drug delivery barrier in PDAC was challenged by 
demonstrating that the highest levels of gemcitabine accumulate in primary KPC 
tumors compared with liver metastases and well-perfused liver tissue 
o CAFs actively metabolize gemcitabine and may act as drug scavengers  
o Differential expression of gemcitabine inactivating enzymes in stromal and 
epithelial cells contribute to gemcitabine accumulation in the tumor stroma 
• Identification of NT5C1A as important mediator of gemcitabine resistance in PDAC 
and potential predictive biomarker for treatment response 
o NT5C1A is differentially expressed in the stromal and epithelial 
compartments of post-operative PDAC patients with strong expression in 
epithelial cells and low expression levels in the stroma 
o Low stromal expression of NT5C1A enhances gemcitabine drug scavenging 
in vitro 
o NT5C1A re-expression in PSCs enhanced gemcitabine availability for tumor 
cells in vitro by reducing gemcitabine accumulation in transfected PSCs 
o Strong expression of NT5C1A in pancreatic cancer cells reduced 
intracellular dFdCTP concentrations, reduced apoptosis levels, and 
increased the resistance of these cells towards gemcitabine treatment 
in vitro 
o In comparison to vector control cells, NT5C1A overexpression in murine 
KPC cells increased tumor weights of orthotopically transplanted C57BL/6-J 
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o Response rates to paclitaxel treatment were not affected in NT5C1A 
overexpressing pancreatic cancer cells, suggesting specificity to 
gemcitabine 
 
Taken the findings together, altered drug metabolism and not biophysical drug delivery to 
pancreatic tumors seems to determine the response to gemcitabine. Particularly, NT5C1A 
was demonstrated to play important roles as mediator of cell-autonomous and non-
cell-autonomous chemoresistance in PDAC. Consequently, NT5C1A might serve as 
predictive biomarker for the development of stratified treatment approaches for PDAC 
patients. Assuming that NT5C1A expression would be controlled by epigenetic 
mechanisms, NT5C1A might even be suitable as therapeutic target for the development of 
novel therapeutic strategies to treat PDAC patients more effectively.  
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